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PREFACE 
Cancer is the unrestrained proliferation of malignant cells. It is now generally 
thought that the basis of cancer is the damage of genetic material. This damage can 
have different causes like radiation and chemical agents. In many types of cancer 
damage of genetic material has been demonstrated in the form of aberrations of the 
chromosomes andjor DNA. These aberrations have been found to be specific for 
different tumor types and are in many cases of diagnostic significance. 
Investigations towards the unlimited growth potential of tumor cells in vitro 
revealed that these cells are independent of exogenous growth factors. This 
independence and the unrestrained proliferation of tumor cells in vivo suggested that 
growth factors and growth regulation of normal and malignant cells was next to the 
genetic studies an important characteristic to be approached in cancer research. 
Human malignant mesothelioma is a tumor that is most frequently found in the 
covering of the chest cavity, called the pleura. The incidence of malignant mesothelio-
ma is strongly associated with asbestos exposure. In the areas of Rotterdam and 
Vlissingen the incidence of malignant mesothelioma is increased compared to other 
parts of the Netherlands. This is caused by the extensive use of asbestos in the 
shipbuilding and repair industries in these areas in the past. Diagnosis of malignant 
mesothelioma on pleural effusion cells is diffieult since there are no morphologic criteria 
for differentiation between benign and malignant mesothelial cells and adenocarcinoma 
cells. Establishment of a definite diagnosis on pleural effusions is important as it 
prevents more invasive diagnostic procedures like the taking of a biopsy for 
histological examination. 
The purpose of this study was to improve the diagnosis of human malignant 
mesothelioma on the one hand and to investigate the growth regulation and 
transformation of normal and malignant mesothelial cells on the other hand. 
In this thesis improvement of diagnosis was approached by the search for 
specific tumor markers. Therefore malignant mesotheliomas were analysed for their 
chromosomal aberrations and the expression of specific membrane antigen markers. 
For the investigation of the growth regulation in normal and malignant mesothelial cells 
a panel of in vitro growing malignant mesothelioma cell lines was established. These 
cell lines were studied for expression of growth factors and their receptors, with 
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emphasis on the platelet-derived growth factor and its receptor. Evidence has been 
obtained that platelet-derived growth factor (PDGF) may play a role in the malignant 
transformation of mesothelial cells. 
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1.1 Epidemiology 
Malignant mesothelioma is a tumor derived from the mesodermal tissues of the 
coelomic cavities. Mesotheliomas occur in the pleura and less frequently the 
peritoneum, pericard and tunica vaginalis testis. In 1960 Wagner et al. described the 
occurrence of malignant mesotheliomas among workers in South-African asbestos 
mines. Other epidemiological reports confirmed the relationship between asbestos 
exposure and malignant mesothelioma (McDonalds et al., 1977). In approximately 85% 
of the malignant mesotheliomas exposure to asbestos could be traced. The latency 
period between asbestos exposure and the occurrence of a malignant mesothelioma 
ranges from 1 5 to over 40 years. Due to the occupational exposition approximately 
70% of the malignant mesothelioma patients are men. 
The incidence of malignant mesothelioma in the developed countries is still 
increasing. According to the use of asbestos in the past, the long latency period and 
the fact that control measures have been taken since the seventies only, it has to be 
expected that the incidence of malignant mesothelioma will increase at least until the 
year 2000. A recent projection for asbestos related malignant mesothelioma mortality 
in the United States for the period 1985 - 2009 was estimated to be 21 ,500 (Lilienfeld 
et al., 1988). In the Netherlands 200-300 cases are diagnosed yearly and an increase 
until 500 has to be expected for in the year 2000. 
1 .2 Asbestos and malignant mesothelioma 
Asbestos is a family of silicate minerals which includes chrysotile, crocidolite and 
amosite as the industrially most significant fibers. The thermal, chemical and physical 
properties of these fibers are the cause of their technological importance. Asbestos 
was and still is used in e.g. shipbuilding industries, flooring products, insulation, and 
brake lining. Inhalation of crushed asbestos fibers is the major health risk in these 
industries. The carcinogenic effect of asbestos fibers has been found to be dependent 
on the physical properties of the fibers .. Respirable fibers with a diameter less than 0.1 
tLm and a length over 5.0 tLm were found to be responsible for mesotheliomas, but 
other sizes are also mentioned (Lippmann, 1988). Asbestos also can cause benign 
pleural thickening and pleural plaques but these are not considered as premalignant 
lesions. In rats intrapleural injection of asbestos was demonstrated to produce 
mesotheliomas (Wagner et al., 1969), which could be transplanted subcutaneously in 
syngeneic rats (Wagner et al., 1982). 
Nonasbestos fibers with the same physical properties as asbestos have also 
been found to cause malignant mesothelioma. A high incidence of mesothelioma has 
been observed in an area of Turkey, where zeolite is naturally occurring in the 
environment (Baris et al., 1979). Potential occupational hazards were suggested for the 
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so called man-made mineral fibers (Wagner et al., 1986). It seems that any fiber of the 
appropriate diameter and length must be regarded as a potential health hazard. 
Although several hypotheses have been suggested (Frei, 1987), the mechanism of 
asbestos induced mesothelioma remains to be elucidated. One hypothesis is that 
asbestos causes an increased cell turnover of fibroblasts and mesothelial cells, which 
then become more susceptible for a carcinogenic event. Another hypothesis is that 
incomplete phagocytosis of asbestos fibers by macrophages causes leakage of 
lysosomal enzymes with a liberation of superoxide and free radicals, which are 
carcinogenic in experimental animals (Frei, 1987). 
1.3 Clinical presentation, diagnosis and treatment 
Most patients presenting with a malignant mesothelioma are men over 50 years 
old. Initially, these patients have nonspecific complaints like weight loss, dyspnoea or 
chest pain. Chest X-ray in patients with a pleural mesothelioma shows an unilateral 
pleural effusion and frequently pleural thickening. With progression of the malignancy, 
the tumor can grow through the thoracic wall, the mediastinum, the diaphragm and the 
lungs. Metastases may occur in lymph nodes, liver, brain and adrenal glands. 
To establish the diagnosis of a patient suspected of a malignant mesothelioma, 
first the pleural effusion is aspirated and used for cytological investigation. When this 
does not lead to a definite diagnosis, histological material will be obtained by closed 
needle biopsy, thoracoscopy or ultimately open chest surgery. 
Cytological diagnosis of malignant mesothelioma is limited by the difficulty of 
distinguishing by light microscopy malignant mesothelial cells from benign mesothelial 
cells and from adenocarcinoma cells (Whitaker et al., 1984). Additional techniques like 
immunocytochemistry and electron microscopy have been applied. As immunocyto-
chemical markers antibodies against carcinoembryonic (CEA) and epithelial membrane 
antigen (EMA) have been proven useful (Wang et al., 1979; To et al., 1982; Whitaker 
et al., 1984). Malignant mesothelioma cells are seldomly positive for CEA while 
adenocarcinoma cells express this antigen frequently. Another marker which is positive 
on most adenocarcinoma cells and seems to be negative on malignant mesothelioma 
cells is MOC-31 (De Ley et al., 1985). EMA positive cells are found in most pleural 
effusions of malignant mesothelioma patients while reactive benign mesothelial cells 
are negative. 
Ultrastructural investigations of malignant mesothelioma cells in effusions show 
typical mesothelial characteristics like long slender villi, glycogen granules and fat 
droplets in the cytoplasm. Although these features cannot establish a definite diagnosis 
of malignant mesothelioma, they are useful for the distinction from adenocarcinoma 
cells (Warhol et al., 1982). 
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In most cases of malignant mesothelioma histology can lead to a definite 
diagnosis. This, however, is dependent on the amount and quality of the material. 
Three different histological types of malignant mesothelioma can be distinguished: 
(1) The epithelial type, consisting of cuboidal epithelial cells with a tubular or 
papillary growth pattern. 
(2) The mesenchymal or sarcomatoid type consisting of spindle shaped 
fibroblastic cells which are arranged in fascicles. 
(3) The mixed type exhibiting epithelial as well as mesenchymal structures. 
In 50% of the malignant mesotheliomas an epithelial histology was found, in 34% a 
mixed type and in 16% of the cases a mesenchymal type (Hillerdal, 1983). Histochemi-
cal procedures used for identification of malignant mesothelioma are the periodic acid 
Schiff-diastase (PAS-D) and the hyaluronidase-alcian blue method. The PAS-O stains 
neutral mucopolysaccharides and is found negative in malignant mesotheliomas and 
in 50% of the adenocarcinomas positive. The hyaluronidase-alcian blue staining reveals 
hyaluronic acid in the tumor. Positivity for this staining excludes an adenocarcinoma, 
but only about 30% of the malignant mesotheliomas is positive. Although both 
' -·~ 
methods can be helpful, in individual cases they do not always lead to a definite 
diagnosis (Corson et al., 1987). 
Immunohistochemical staining with keratin antibodies has been considered 
useful in mesothelioma diagnosis but often leads to discordant results (Corson, 1987). 
Biochemical analysis of the cytoskeletal composition of mesothelioma cells has 
revealed that cytokeratin 5 could be a valuable marker for the discrimination between 
malignant mesothelioma and adenocarcinoma (Biobel et al., 1985). But specific 
antibodies against this keratin are not available yet. Coexpression of vimentin and 
keratin has been suggested to be useful for distinction between malignant mesothelio-
ma and adenocarcinoma (LaRocca, 1984), but this coexpression also occurs in other 
cancers (Ramaekers et al., 1984). Staining with CEA and EMA as mentioned above 
could also be helpful to establish the diagnosis. However, even after application of all 
the above mentioned techniques the definite diagnosis of malignant mesothelioma is 
frequently made at autopsy. 
Cytogenetic analysis of malignant mesothelioma cells seems to have new 
diagnostic prospects. Non-random chromosomal abnormalities have diagnostic and 
prognostic value in leukemias and malignant lymphomas (Yunis, 1983). Reports about 
cytogenetic analysis of malignant mesothelioma cells in pleural effusions and biopsy 
material are few (Mark, 1978; Gibas et al., 1986; Tiainen et al., 1988) and so far did not 
indicate towards a specific aberration. But standardization of the methods used and 
study of larger series of patients before treatment will hopefully indicate which chromo-
somes are primarily involved and which changes are secondary. 
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The median survival of malignant mesothelioma patients is approximately 12 
months {Adams et al., 1986). Although several forms of therapy like surgery, radiation 
and chemotherapy have been applied to malignant mesotheliomas, their effect is 
limited (in Antman and Aisner, 1987). 
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2.1 Growth factors 
Growth regulation during embryogenesis and the maintenance of organs and 
tissues have to be controlled tightly. Aberrations of the normal growth control were 
thought to lead to the abnormal cell growth observed in tumor cells. The mechanisms 
that control normal growth have to be selective for different cell types and responsive 
to e.g. physical, hormonal and metabolic changes in the organism. Data are 
accumulating about the involvement of growth factors in embryonic development and 
normal growth regulation. Growth factors, in contrast to steroid hormones, were found 
to act locally and to diffuse only over a short-range. Growth factors are polypeptides 
that stimulate cell proliferation through binding to specific high affinity receptors 
(Goustin et al., 1986). 
In vitro models are frequently used to study growth regulation in normal and 
malignant cells. Normal cells display in culture a restricted growth and an ordered 
growth pattern and require serum addition to the culture medium for their proliferation. 
These properties were thought to be related to the increased growth factor require-
ment of normal cells compared to their malignant counterparts, which show unlimited 
growth potential and disordently growth. 
The purification of different growth factors has led to the development of growth 
factor defined culture media. Different normal cell types have been found to proliferate 
optimally on different combinations of growth factors. Some growth factors are highly 
specific for only a few cell types, e.g. the hematopoietic growth factors, while others, 
like the epidermal growth factor (EGF), stimulate many cell types. 
Tumor cells were found to have decreased serum requirements in vitro (Temin, 
1966) and to loose density dependent regulation compared to normal cells. These 
properties were found to be due to an independency of exogenous growth factors 
(Kaplan et al., 1982). It was proposed that tumor cells produce their own growth 
factors that can bind to specific receptors on the cell. This process has been called 
autocrine secretion compared to the endocrine and paracrine secretion models (Fig. 
1). The hypothesis of autocrine secretion was supported by the first identification of a 
growth factor in the conditioned medium of sarcoma virus-transformed cells (Todaro 
and De Larco, 1978). This so-called sarcoma-derived growth factor (SGF) caused 
overgrowth and morphologic transformation of normal fibroblasts and stimulated 
anchorage independent growth. Subsequent biochemical purification of SGF showed 
that it consisted of two different polypeptides: transforming growth factor (TGF) a and 
f3 (Anzano et al., 1983). In recent years evidence has been found that many different 
tumor cells can produce growth factors. TGFa and TGF/3 expression has been found 
for instance in colon-, epidermoid-, cervical-, renal-, prostate and mammary carcinoma 
cell lines (Coffey et al., 1986; Derynck et al., 1987). Expression ofTGF/3 only has been 
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Schematic representation of endocrine (A), paracrine (B) and autocrine 
secretion (C). Adapted from Sporn and Todaro (1980). 
reported for Burkitt lymphoma and T lymphoblast cell lines (Derynck et al., 1987). 
Insulin-like growth factors I and/or II have been found in fibrosarcomas, osteosar-
comas and mammary carcinomas (Marquardt et al., 1980; Blatt et al., 1984; Huff et al., 
1986). 
2.2 Oncogenes 
Since 1970 cancer research has been more and more focussed on the genetic 
damage of tumor cells. Molecular genetic studies of tumors have led to the identifica-
tion of genes which are involved in malignant transformation. Investigation of acute 
RNA tumor viruses revealed that these viruses efficiently induced tumors in animals 
and were capable to transform cells in culture. In the genome of these viruses specific 
genes called viral oncogenes (v-onc) were found to be responsible for the observed 
oncogenicity. In 1976 it was discovered that the viral oncogenes had a strong 
homology with cellular sequences in the genome of vertebrate cells (Stehelin et al., 
1976). These cellular oncogenes or proto-oncogenes were found to be highly 
conserved during evolution, suggesting an essential function. It was assumed that 
these oncogenes played a role in the regulation of proliferation, and after activation at 
the wrong time or on the wrong place could lead to malignant transformation. The first 
evidence supporting this hypothesis was obtained from DNA-transfection experiments 
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(Murray et al., 1981; Krontiris and Cooper, 1981). DNA from a human bladder cancer 
cell line was found to transfer tumorigenicity to NIH-3T3 mouse fibroblasts. The gene 
responsible for this was found to be the cellular homologue of the ras oncogene, 
which was activated by a single amino acid substitution (rabin et al., 1982; Reddy et 
al., 1982; Taparowsky et al., 1982). Since then, over 40 cellular oncogenes have been 
identified and the list is still growing. Activation of these oncogenes can occur by 
proviral integration, DNA rearrangements andjor mutations. The effect of activation of 
a single oncogene is limited but it has been demonstrated that aCtivation of two 
oncogenes in concert can transform normal fibroblasts (Land et al., 1983). Moreover, 
multiple cellular oncogenes were found to be activated in human tumor cell lines 
(Murray et al., 1981). In vivo experiments with transgenic mice carrying congenitally 
acquired oncogenes also indicate that a single oncogene is unable to induce tumors 
in all the cells that express it (Stewart et al., 1984). These observations support the 
generally accepted model of multistep carcinogenesis. 
2.3 Relationship between growth factors and oncogenes 
The relationship between cellular oncogenes and growth factors was estab-
lished with the discovery of oncogenes that encode growth factors or growth factor 
receptors. The viral oncogene v-sis from the simian sarcoma virus (SSV) has been 
found to be nearly identical to the B-chain of the platelet-derived growth factor (PDGF) 
(Waterfield et al., 1983; Robbins et al., 1983; Deuel et al., 1983). Examples of 
oncogenes that encode growth factor receptors are v-erbB, neu and fms oncogenes. 
The protein product of the v-erbB oncogene was found to be a mutated EGF receptor 
(Downward et al., 1984). The neu oncogene, which is distantly related to erbB, 
encodes a growth factor receptor with an unknown ligand (Bargman et al., 1986), while 
the fms oncogene encodes a mutated form of the receptor for the mononuclear 
phagocyte growth factor CSF-1 (Sherr et al., 1985). Genetic aberrations (like mutations, 
amplification and translocations) can convert these proto-oncogenes to oncogenes 
and directly influence growth control. These observations resulted in an extension of 
the autocrine secretion model (Fig. 2). In this model oncogene-stimulated growth factor 
production can be caused by stimulation of the expression of growth factor encoding 
genes by oncogenes or by deregulation of a growth factor encoding oncogene (A). 
When the cell has the appropriate growth factor receptor a constitutive mitogenic 
signal will be produced so that the cell becomes independent of exogenous growth 
factors. Growth factor autonomy can also be obtained by receptor alteration (B) which 
leads to malfunctioning receptors. Finally, a change in the signal transduction from the 
membrane to the nucleus can lead to an aberrant signal (C). These three mechanisms 
can explain the observed growth factor autonomy in tumor cells. 
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Three possible mechanisms which can allow a cell to escape depen-
dence of exogenous growth factors: by autocrine secretion (A), by 
receptor alteration (B) and by transducer alteration (C). Adapted from 
Weinberg (1985). 
2.4 Platelet-derived growth factor (PDGF) 
In 1974 it was discovered that platelets release mitogens which can support 
growth of cells in serum-free medium which otherwise is strictly dependent on serum 
supplementation (Ross et al., 1974). In subsequent studies one of these mitogens was 
identified as platelet-derived growth factor (PDGF). Human plasma contains undetect-
able levels of PDGF and experiments with intravenous administration of PDGF into 
baboons established an half life of less than 2 minutes (Bowen-Pope et al., 1984). 
PDGF is thought to be locally synthesized and secreted (Ross et al., 1986). 
2.4.1 Biological effects and biochemical analysis of PDGF 
Several biological effects of PDGF purified from platelets have been detected 
in in vitro systems. PDGF was found to be a strong mitogen for connective tissue cells 
and glial cells (Ross et al., 1974; Heldin et al., 1985). In responsive cells PDGF has 
been found to stimulate protein and collagen synthesis and collagenase secretion 
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(Canalis, 1981; Owen et al., 1982; Chua et al., 1985). PDGF has also been found to 
be chemotactic for fibroblasts, smooth muscle cells, monocytes and neutrophils 
(Grotendorst et al., 1982; Seppa et al., 1982). In the latter two cell types, which do not 
exhibit a mitogenic response to PDGF, PDGF was found to stimulate the release of 
granular constituents (Tzeng et al., 1984; 1985). Vasoconstriction of arterial smooth 
muscle cells was observed after PDGF stimulation (Berk et al., 1986). The above 
mentioned biological effects of PDGF are thought to be important in embryogenesis, 
wound-healing and pathological conditions as arthritis and atherosclerosis (Rappolee 
et al., 1988; Lynch et al., 1987; Pierce et al., 1988; Rubin et al., 1988; Barrett et al., 
1988). 
Biochemical analysis of PDGF from human platelets revealed a molecular weight 
of 30 kD and a composition of two different disulphide-bound polypeptide chains, 
designated the A- and B-chain (Johnsson et al., 1982). The dimeric structure is 
essential for its function as the biological activity is lost after reduction. The PDGF B-
chain has been found to be nearly identical to the transforming protein of Simian 
sarcoma virus (SSV) p28sis (Waterfield et al., 1983; Doolittle et al., 1983). This 
homology was an indication for the involvement of a PDGF-Iike growth factor in 
transformation and led to the study of the mechanism of SSV-transformation. 
2.4.2 Simian sarcoma virus transformation, PDGF A-chain and PDGF B-chain genes 
SSV has been firstly isolated from a fibrosarcoma of a woolly monkey (Theilen 
et al., 1971; Wolfe et al., 1971) and was found to induce sarcomas and gliomas in vivo 
(Deinhard et al., 1980) and to transform cells with PDGF receptors in vitro. Inhibition 
of the binding of PDGF to its receptor by antibodies (Johnsson et al., 1985) or suramin 
in SSVtransformed cells reversed the transformed phenotype (Betsholtz et al., 1986a). 
These experiments suggest that autocrine stimulation is the basis of SSV transforma-
tion although immortalization has not been observed in SSV transformed cells 
(Johnsson et al., 1986). 
The human cellular homologue of the viral sis gene, the c-sis or PDGF B-chain 
gene has been cloned (Josephs et al., 1984; Johnsson et al., 1984) and was mapped 
to chromosome 22q13.1 (Swan et al., 1982; Dalla Favera et al., 1982). The human 
PDGF A-chain gene has been cloned and mapped to chromosome 7p21-7p22 
(Betsholtz et al., 1986b; Morton et al., 1987). These data are summarized in table 1. 
The expression of the PDGF A-chain specific mRNA of 2.8, 2.3 and 1.9 kb has been 
found to be independent from B-chain expression (Betsholtz et al., 1986a; Bonthron 
et al., 1988). The amino acid sequence homology of the PDGF A-chain with the PDGF 
B-chain has been found to be 60% (Johnsson et al., 1984; Josephs et al., 1984; 
Betsholtz et al., 1986b). In transfection experiments with PDGF A- and PDGF B-chain 
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TABLE 1 
Chromosomal localization of human PDGF chain and PDGF receptor genes 
gene chromosomal localization reference 
PDGF A-chain 7p21-7p22 Betsholtz et al., 1986a 
Morton et al., 1987 
PDGF 8-chain (c-sis) 22q13.1 Swan et al., 1982 
Dalla Favera et al., 1982 
PDGF A-type receptor 4q11-4q12 Matsui et al., 1989 
PDGF 8-type receptor 5q23-5q31 Varden et al., 1986 
gene constructs phenotypical transformation and focus formation were detected in B-
chain transfectants and not in A-chain transfectants (Bywater et al., 1988). 
2.4.3 PDGF A-chain and B-chain expression in normal cells 
Production of PDGF has been described for the following normal cell types: 
activated macrophages (Shimokado et al., 1985; Martinet et al., 1986), cytotropho-
blasts in human placenta (Goustin et al., 1985), endothelial cells (Dicorleto and Bowen-
Pope, 1983; Collins et al., 1985; 1987) and arterial smooth muscle cells (Seifert et al., 
1984; Nilsson et al., 1985). In activated macrophages expression of the PDGF B-chain 
has been found, while about A-chain expression no data are available. The other cell 
types mentioned were all found to express both A- and B-chains. For PDGF in cyto-
trophoblasts and smooth muscle cells an autocrine function was suggested as both 
cell types also respond to PDGF (Heldin et al., 1988a). In injured arterial smooth 
muscle cells elevated PDGF production and down regulation of PDGF receptors have 
been described (Walker et al., 1986), which is suggestive for a role of PDGF in wound 
healing. Endothelial cells and macrophages do not have PDGF receptors but 
indications for a paracrine function are accumulating (Walker et al., 1986; Martinet et 
al., 1987). 
2.4.4 PDGF A-chain and B-chain production in human tumor cell lines 
Expression of PDGF A- andjor B-chain mRNA has been found in different types 
of human sarcoma cell lines, glioma cell lines, mammary carcinoma cell lines, prostate 
carcinoma cell lines, melanoma cell lines, non-small cell lung carcinoma cell lines and 
malignant mesothelioma cell lines (Table 2). In several cell lines production of PDGF 
was detected according to its presence in the conditioned media (Betsholtz et al., 
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TABLE 2 
POGF A- andjor B-chain mRNA expression in human tumor cell lines as detected by Northern 
blot analysis 
tumor number of number of number of reference 
cell lines cell lines cell lines 
investigated with A-chain with B-chain 
expression expression 
sarcoma 6 NO 5 Eva et al., 1982 
8 7 3 Betsholtz et al., 1986a 
glioma 5 NO 3 Eva et al., 1982 
23 23 17 Nister et al., 1988b 
mammary carcinoma 9 8 9 Peres et al., 1987 
prostate carcinoma 2 2 2 Sitaras et al., 1988 
malignant mesothelioma 7 6 6 Gerwin et al., 1987 
melanoma 5 3 1 Westermark et al., 1986 
large cell carcinoma 3 3 3 Sooerdahl et al., 1988 
adenocarcinoma 2 2 Sooerdahl et al., 1988 
squamous carcinoma Sooerdahl et al., 1988 
NO, not done 
1983; 1984; Nister et al., 1984). In most cell lines expression of PDGF A-chain as well 
as PDGF B-chain mRNA was detected (Table 2). Whether the produced PDGF can 
function as an autocrine growth factor and play a role in the malignant transformation 
of these cell lines is dependent on the presence of PDGF receptors. In several glioma 
cell lines and a single osteosarcoma cell line PDGF receptors have been detected. In 
mammary and prostate carcinoma cell lines, which lack PDGF receptors, an autocrine 
function of the produced PDGF is not likely. However, a paracrine role in vivo has to 
be considered as in many tumors an increase of connective tissue growth has been 
observed (Seemayer et al., 1979; Kao et al., 1984). So far no data are available about 
the expression of PDGF receptors in the other cell lines mentioned above. Recently 
expression of the genes for the PDGF A-chain, the PDGF B-chain and the PDGF B-
type receptor, detected by Northern blot analysis and RNA in situ hybridization was 
found in three cases of glioblastoma multiforme (Hermansson et al., 1988). So far this 
is the only report about expression of PDGF chain- and PDGF receptor genes in fresh 
solid tumor material. 
25 
TABLE 3 
Identified dimeric forms of PDGF and their source 
dimeric form 
of PDGF source reference 
AB human platelets Hammacher et al., 1988 
BB porcine platelets Strooband and Waterfield, 1984 
BB SSV transformed cells Robbins et al., 1983 
AA human osteosarcoma cell line Heldin et al., 1986 
AA human melanoma cell line Westermark et al., 1986 
AA human glioma cell line Hammacher et al., 1988 
2.4.5 Functional analysis of different dimeric forms of PDGF 
Although PDGF A-chain and B-chain expression has been found in many cell 
types it is only recently that it became possible to investigate by reversed-phase 
chromatography and subsequent immunoprecipitation whether the produced chains 
are assembled as hetero- or homodimers (Hammacher et al., 1988a). Table 3 
summarizes these results and shows that all different dimeric combinations of PDGF 
chains have been identified. Functional analysis of different dim eric forms indicates that 
they have different activities. An AA homodimer, purified from the conditioned medium 
of a human glioma cell line, was found to have on human foreskin fibroblasts a low 
mitogenic activity, a low ability to induce actin reorganization and membrane ruffling 
and no chemotactic activity (Nister et al., 1988a), while in human fibroblasts platelet-
derived AB displayed substantial activity in these respects. (Mellstrom et al., 1983; 
Nister et al., 1988a). 
2.5 PDGF receptors 
PDGF binds to specific cell surface receptors which are transmembrane 
proteins. The internal domain has protein tyrosine kinase activity (Ek et al., 1982; 
Yarden et al., 1986), while the external domain is involved in ligand binding. Ligand 
binding induces activation of the tyrosine kinase domain. Although several cellular 
effects of PDGF stimulation have been reported, like increase of cytoplasmic free Ca2+ 
concentration (Moolenaar et al., 1984) and stimulation of protein kinase C (Rozengurt 
et al., 1983), the exact mechanism of signal transduction is still unknown. 
With the availability of recombinant dimeric AA and BB it has become possible 
to investigate the specificity of PDGF receptors for these different dimeric forms. 
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Figure 3. 
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BB 
PDGF-AB 
The PDGF receptor subunit model. a. The two types of PDGF receptor 
subunits that are found: a-subunits that can bind PDGF A- and 8-chains 
and {3-subunits that bind PDGF-8 chains. b. Receptor types that can be 
composed of the subunits: aa-receptors, a{3-receptors and {3{3-receptors. 
c. Receptor binding: PDGF-AA can only bind to PDGF aa-receptors, 
PDGF-A8 can bind to PDGF aa- or a{3-receptors and PDGF-88 can bind 
to all three receptors. Adapted from Seifert eta/. (1989). 
Binding experiments to cultured cells have revealed the already suggested (Nister et 
al., 1988a; Hart et al., 1988) existence of two different PDGF receptor types, the PDGF 
A-type and the PDGF B-type receptor (Heldin et al., 1988b; Hart et al., 1988). The A-
type receptor was found to bind AA, AB and BB, whereas the B-type receptor binds 
BB with high affinity, AB with lower affinity and AA not at all (Heldin et al., 1988b). 
A human PDGF receptor has been recently cloned (Gronwald et al., 1988; 
Claesson-Welsh et al., 1988). After expression in CHO cells this receptor was found 
to be the B-type receptor with a molecular weight of 170-185 kD, which was synthe-
sized after glycosylation from a 160 kD molecule (Hart et al., 1987; Keating and 
Williams, 1987; Claesson-Welsh et al., 1988). In recent experiments PDGF was found 
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to induce dimerization of two PDGF receptors and subsequent activation of the 
tyrosine kinase domain of the dimerized receptor (Heldin et al., 1989; Seifert et al., 
1989). According to these observations the so called 'PDGF receptor subunit model' 
was proposed (Seifert et al., 1989). In this model the PDGF A- and B-type receptors 
are called subunit a and /3, respectively. These subunits dimerize to form three distinct 
PDGF receptors that have different specificities for binding the three isoforms of PDGF 
(Fig. 3). The role of the detected dimerization in signal transduction remains to be 
elucidated. The PDGF A-type receptor has been recently cloned (Matsui et al., 1989; 
Claesson-Welsh et al., 1989b), and characterized by immunoprecipitation. It was found 
to be a molecule of 170 kD after glycosylation of a 140 kD molecule (Ciaesson-Welsh 
et al., 1989a). The mitogenic response after binding of PDGF-AA to the A-type receptor 
in human fibroblasts was found to be low compared to binding of PDGF-BB to the B-
type receptor (Heldin et al., 1988b). Therefore, the A-type receptor has possibly 
another function. 
The PDGF A- and B-type receptors have both an extracellular part of five 
immunoglobulin-like domains, a transmembrane domain and an intracellular protein 
tyrosine kinase domain. This protein tyrosine kinase domain is divided into two parts, 
TK1 and TK2, by an intervening sequence. The amino acid sequence identity between 
the two PDGF receptors is most conserved in the tyrosine kinase domains (85% and 
75%), while between the extracellular ligand binding domains of the two receptors only 
31% homology has been found. The PDGF A- and B-type receptor genes are localized 
on the chromosomes 4 and 5, respectively (table 1). 
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CHAPTER 3 
INTRODUCTION TO THE EXPERIMENTAL WORK 
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In this thesis the clinical, diagnostic and cell biological aspects of human 
malignant mesothelioma are studied. The purpose of this study was to improve the 
diagnosis of human malignant mesothelioma on the one hand and to investigate the 
growth regulation and transformation of normal and malignant mesothelial cells on the 
other hand. 
In order to investigate whether the epidemiology of the malignant mesothelioma 
patients in the areas of Rotterdam and Vlissingen is similar to other studied groups 
medical records of 124 malignant mesothelioma patients were studied. Chapter 4 
describes this analysis with respect to asbestos exposure, duration of exposure, 
survival, radiologic findings and histopathology. 
Diagnosis of malignant mesothelioma on effusions by routine cytology is 
hampered by the lack of specific morphological characteristics of malignant 
mesothelioma cells. Improvement of diagnosis was approached by the search for 
specific tumor markers. Initially we tried to produce monoclonal antibodies, which 
specifically recognize malignant mesothelioma cells. These attempts, however, were 
unsuccessful. Subsequently, we investigated whether epithelial membrane antigen 
(EMA) was useful for the identification of malignant mesothelioma cells. However, 
antibodies against EMA recognized malignant epithelial and mesothelial cells. Then we 
investigated whether the combination of EMA expression and ultrastructural features 
was of diagnostic significance for malignant mesothelioma (chaper 5.1). 
Secondly, we studied the cytogenetics of malignant mesothelioma in order to 
find out whether these cells have specific chromosomal aberrations. Cytogenetic 
analysis was performed on patient material of 40 malignant mesotheliomas. 
Furthermore, the usefulness of cytogenetics for the distinction between effusions of 
metastatic carcinoma, lung adenocarcinoma and non-malignant effusions was 
evaluated. 
Cell biological investigations of malignant mesothelioma could lead to more 
insight into the properties and growth regulation of malignant mesothelioma cells and 
ultimately to new diagnostic methods. 
As viable tumor tissues of malignant mesothelioma for cell biological studies are 
difficult to obtain a panel of in vitro growing human malignant mesothelioma cell lines 
was established. In chapter 6.1 the method used for the establishment of seventeen 
malignant mesothelioma cell lines has been described since such a large panel of 
malignant mesothelioma cell lines has not been reported so far. Three of these 
malignant mesothelioma cell lines were characterized with regard to their growth 
characteristics, cytogenetic aberrations and cytokeratin expression. 
In chapter 7.1 we show by Northern blot analysis that the PDGF A-chain and 8-
chain genes are expressed in ten malignant mesothelioma cell lines. To investigate 
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whether expression of the c-sis oncogene is detectable in freshly obtained tumor 
material Northern blot analysis of patient material of eight malignant mesotheliomas 
was performed (chapter 7.2). If the by malignant mesothelioma cell lines produced 
PDGF functions as an autocrine growth factor in these cell lines expression of the 
appropriate receptors is a prerequisite. In chapter 7.3 the expression of PDGF A- and 
B-type receptors in malignant mesothelioma cell lines was studied by Northern blot 
analysis and binding experiments. Furthermore, the presence of the PDGF B-type 
receptor was investigated by immunoprecipitation and immunoelectron microscopy. 
In chapter 8 the results of the experimental work are discussed in the context 
of the literature. 
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SUMMARY 
This report is the result of an analysis of the medical records of "124 patients 
presenting with a malignant pleural mesothelioma. Information about asbestos 
exposure was available in "104 of them, which appeared to be positive in 95 (91%). 
The median duration of exposure was 33.6 years. The median latent period was 4 "1.2 
years. The median survival was "1 "1 months while different ways of treatment could not 
prolong survival. The most common radiologic findings were pleural effusions, while 
in some patients contralateral effusions or pleural thickening was found. Pleural 
plaques or asbestosis were seen in a minority of the patients. In this series a relatively 
high percentage of mixed type mesotheliomas was found (56%). Large biopsies often 
showed both epithelial and connective tissue type elements. Concerning diagnostic 
procedures we recommend to start with cytology of pleural fluid, which can easily be 
obtained together with an Abrams biopsy. If this does not give a definite diagnosis, 
thoracoscopy or thoracotomy is indicated. 
INTRODUCTION 
Many studies have confirmed the relationship between asbestos exposure and 
the occurrence of malignant mesothelioma (I ,2). It is now clear that exposure to 
asbestos may lead to a number of pathologic conditions, including benign abnormal-
ities (3,4) and involvement of other sites than lung or pleura. A long latency period of 
up to 60 years between the first exposure to asbestos and the development of a 
malignant mesothelioma has been described. Incidence rates for pleural mesothelioma 
among men are increasing (5-7). The substantial increase of the frequency of pleural 
mesothelioma among males versus the stable trend for females argues against any 
large impact of diagnostic or coding changes (8). 
Many shipyard workers have been exposed to asbestos in the past (mainly 
crocidolite) with a consequently increased frequency of malignant mesothelioma. In 
many coastal regions incidences of mesothelioma are found that belong to the worlds 
highest (9). This is also true for The Netherlands where two studies already reported 
an increased incidence in the Southwestern part of The Netherlands (I 0, "1 "1 ). The here 
reported study is an analysis of "124 pleural mesotheliomas in the areas of Vlissingen 
and Rotterdam, in the recent past both known for their large shipbuilding industries. 
4"1 
METHODS 
This study is an analysis of 124 patients presenting with a malignant pleural 
mesothelioma. The patients were seen in two centers. Seventy-one were seen in the 
University Hospital in Rotterdam, while the other patients (53) were diagnosed in the 
Regional Hospital in Vlissingen. These 124 patients probably form about 80 to 90% of 
all patients that presented with a malignant mesothelioma in the Southwestern part of 
the Netherlands between 1962 and 1985. 
For the histopathological diagnosis of mesothelioma the recommendations of 
the Commission of the European Communities were applied (12). Reevaluation of all 
histologic specimens was done by the Dutch Mesothelioma Panel. For the certainty of 
the diagnosis the following categories were used: 
A. Definite malignant mesothelioma - no doubt as to the histopathological 
diagnosis. 
B. Probable malignant mesothelioma - the reason for the hesitation may be lack 
of material, bad quality, lack of differentiation, absence of certain histological 
details which give rise to slight doubt. 
C. Possible malignant mesothelioma - the diagnosis cannot be denied but there 
is insufficient evidence to come to a positive conclusion. 
D. Improbable malignant mesothelioma - probably not a mesothelioma but the 
diagnosis cannot be absolutely denied. 
E. Definitely not a malignant mesothelioma. 
In categories D and E an other diagnosis should be suggested or made. Only the 
histopathologic categories A and B were included in the study. The analysis includes 
clinical, diagnostic and histologic aspects. 
RESULTS 
The study group consisted of 120 men (97%) and 4 women (3%). Sixty-nine 
(56%) mesotheliomas arose on the right side of the thorax, 51 (41%) on the left side, 
while three (2%) mesotheliomas were double sided. One patient had a simultaneous 
primary pleural- and peritoneal mesothelioma. The median age of the patients at the 
time of diagnosis was 64.7 yrs. (range 26-86 yrs). Almost eighty percent (87 /112 = 
78%) had ages between 50 and 75 years. 
No occupational information was available in twenty patients. Of the other 104 
many had been working in a shipyard for at least several years (62/104 = 60%). In 95 
patients (91%) a positive history of occupational asbestos exposure was found. The 
42 
100 
90 
80 
70 
~ 60 ......... 
~ 50 > 
·:; 
I... 40 :::::l 
(/) 
30 
20 
10 
0 
1 2 3 4 5 6 
time (in years) 
Figure 1. Survival in time of 124 patients with malignant mesothelioma. 
median duration of asbestos exposure was 33.6 yrs. (range 1-52 yrs.). The latent 
period, defined as the interval between the beginning of exposure and the occurrence 
of the first symptoms, also showed a wide range. The median latent period was 41.2 
yrs. (range 17-68 yrs.). The histopathologic diagnosis was known in all subjects. The 
mixed type was the most prevalent and found in 68 of 124 patients (55%). In 40 (32%) 
patients the mesothelioma was of the epithelial type, while in 16 (13%) it was of the 
connective tissue type. In 102 cases the diagnosis was entitled as "definite", whereas 
the other 22 were "probable". 
The most frequently presenting symptoms were dyspnea (81%), chest pain 
(73%) and weight loss (66%). Cough was found in 53% of the patients. Six times (5%) 
a vena cava superior syndrome was one of the presenting symptoms. In 5 patients 
(4%) there were palpable lymph nodes on presentation. Swallowing complaints were 
found in another 4 patients (3%). 
The radiological findings are reported in table 1. Ipsilateral pleural effusion and 
pleural thickening were found most frequently. 
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TABLE I 
Radiographic findings in 124 patients with a malignant pleural mesothelioma on presentation. 
number % 
Pleural effusion ipsilateral 109 88 
contralateral 6 5 
Pleural thickening ipsilateral 95 77 
contralateral 19 15 
Pleural plaques ipsilateral 10 8 
contralateral 8 6 
Extensive contraction of the chest 17 14 
Rib destruction 18 15 
Asbestosis 2 2 
TABLE II 
Diagnostic techniques 
Technique Performed Positive for 
number mesothelioma (%) 
Pleural fluid cytology 105 63 (60%) 
Abrams biopsy 85 58 (68%) 
Thoraco~copy 45 39 (87%) 
Thoracotomy 21 19 (91%) 
Bronchoscopy 3 0 (0%) 
The diagnostic procedures used are shown in table 2. Compared to aspiration 
of pleural fluid and Abrams biopsy, thoracoscopy and thoracotomy were carried out 
less often, but they gave positive findings in high percentages (87% and 91%, 
respectively). 
Therapy mainly consisted of symptomatic treatment Recurrent pleural effusions 
were terminated by drainage. In a number of patients radiotherapy, chemotherapy, 
surgery or immunotherapy (interferon) were tried. No significant effect on survival was 
found. Fourteen patients (11%) did not receive any treatment at all. The average 
survival was 16.5 ± 13 months (median = 11 months). Only five patients were alive 5 
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years after the diagnosis was made. Figure 1 shows the survival-percentages. The 
1-year survival is less than 50% (47%). 
Non-narcotic analgetics were able to relief the pain in 63 patients (of the 98 
patients given non-narcotic analgetics). When however in a later stage pain became 
more severe, opiates had to be given in 49 patients. In one patient chordotomy was 
performed while epidural anaesthesia was given in another patient, both with good 
results. Eight patients had pain relief after local radiotherapy. 
The autopsy findings of 28 patients were available and are l!sted in table 3. 
Metastases were most frequent in the liver (60%) and abdominal lymph nodes (38%). 
TABLE Ill 
Autopsy-findings of 28 subjects with mesothelioma 
metastases in examined in positive 
diaphragm-ingrowth 26 22 (85%) 
pericardium-ingrowth 24 17 (65%) 
liver 25 15 (60%) 
thoracic lymph nodes 24 13 (54%) 
abdominal lymph nodes 26 10 (38%) 
kidneys 25 7 (28%} 
spine 23 4 (17%) 
brain 25 1 (4%) 
other 24 11 (46%) 
DISCUSSION 
In this study we analysed the clinical, diagnostic, and histologic findings in 124 
patients with a malignant pleural mesothelioma. The incidence in men is usually several 
times that in women (13) as is demonstrated in this study. Malignant pleural 
mesothelioma usually affects people between 45 and 75 years (14). The median age 
of our subjects at the time of diagnosis was 64.7 years, while 87 patients (78%) were 
between 50 and 75 years of age. The duration of the asbestos exposure could be 
calculated from the occupational files of most patients. The median exposure was 33.6 
years (range 1-52 yrs.). The latent period was at least 17 years (median 41.2 yrs.), 
which is in the same range as in other studies (15). The survival from the time of the 
first symptoms to death was short (median = 11 months). Although some found 
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different survival times for the various cellular subtypes (16) we did not find significant 
differences. 
In 68 patients (55%) pleural mesotheliomas with a histopathologic diagnosis of 
mixed type were found. Compared to other series this is rather high. The histopatholo-
gic diagnosis of mesothelioma is a difficult one. A strong interobserver variability is a 
well known phenomenon (17,18). There is a considerable risk of misdiagnosing the 
mesothelioma for a pulmonary adenocarcinoma if only a small biopsy is examined. 
Furthermore, in investigating only small portions of tumor, there is considerable risk 
in missing one component. When large portions of tumor tissue are investigated, the 
chances of finding both epithelial and connective tissue components are high. Several 
phenotypic markers have been studied for their efficacy in the differentiation of meso-
theliomas from other (metastatic) malignancies, but they are still of only complementary 
importance (19). We believe that an adequate histopathologic classification can only 
be reached by examination of a large biopsy, performed by an experienced 
pathologist. The material should be searched intensively for malignant elements of both 
epithelial and connective tissue character. Then higher numbers of mixed type will be 
found. Support for this statement was obtained by comparing the percentages of 
epithelial or connective tissue type with mixed type in the diagnostic procedures where 
small portions of tumor (cytology of pleural fluid and Abrams biopsy) or large portions 
of tumor were obtained (thoracoscopy, thoracotomy, obduction). We found that if 
only a "small portion- technique" had been performed the mixed type was present in 
40% of the patients, whereas in "large portion-techniques" this increased to 73%. 
The most frequently found presenting symptoms in our series, dyspnea, pain 
and weight loss are the usual clinical characteristics of pleural mesothelioma (20,21). 
A less common symptom is cough. Six patients presented with a vena cava superior 
syndrome. This means this may not be as infrequent as was suggested by others (22). 
Pleural effusions were detected radiologically in no less than 90% of the patients 
presenting with a malignant mesothelioma. Long term pleural effusions are in 10% due 
to a malignant mesothelioma (23). Like in our series the pleural effusion usually masks 
the tumor. Aspiration of the fluid may disclose the malignancy. In this series of patients 
it was found that asbestos exposure may also give a benign pleural thickening since 
this sign was found in 15% of the patients on the contralateral side of the thorax. 
Furthermore, it is obvious that pleural plaques and asbestosis are no premalignant 
lesions since they were found in a minority of the patients presenting with a malignant 
pleural mesothelioma and the occurrence was not increased as compared to the 
generally asbestos exposed population. 
Cytology of the pleural fluid was positive for malignant mesothelioma in 60%. 
An Abrams biopsy could make the diagnosis of mesothelioma definite in 68%. In only 
46 
seven cases diagnosis was based on cytology alone. Thoracoscopy and thoracotomy 
were positive in much higher percentages. This pattern is not unusual (24). In our view 
the best procedure to be followed is to start with cytology of the pleural fluid, which 
can easily be obtained together with an Abrams biopsy. If this does not give a definite 
diagnosis, a thoracoscopy or thoracotomy will be indicated. 
The results of several treatment programs are invariably bad (25-27). Patients 
with a survival of more than two years are only incidentally found. In our study 
treatment consisted of a mixture of all modalities. Only surgery and immunotherapy 
seemed to prolong survival, but due to the fact that all sorts of selection-bias can have 
taken place, this cannot be regarded as a valid statement. 
In previous years a number of reports emphasised the frequent occurrence of 
metastases in patients with a malignant mesothelioma. Metastatic spread does not 
seem to be linked with histologic type according to some (28), while others found that 
distant metastases were more frequent in connective tissue type tumors (29). In this 
study distant metastases were found in mixed type tumours in 13 cases (68%). The 
numbers of the other histologic types are too small to pronounce upon this matter. 
The most frequent sites of spread outside the thorax were liver (60%) and abdominal 
lymph nodes (38%). Compared to other studies these percentages are rather high. 
The rarity of brain metastases is confirmed (4%)(30). 
In conclusion in this series of malignant pleural mesotheliomas a relatively high 
percentage of mixed types is found. This is probably due to the availability of large 
portions of tumour specimens for histologic examination. If cytology of the pleural 
fluid and an Abrams biopsy do not give a definite diagnosis, we recommend that 
thoracoscopy with biopsies be the diagnostic procedure of choice since this method 
increases the chance of a positive findings. 
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CHAPTER 5 
DIAGNOSIS OF HUMAN MAliGNANT MESOTHEliOMA 
5.1 Expression of epithelial membrane antigen on malignant mesothelioma cells. 
5.2 Cytogenetic analysis of malignant mesothelioma. 
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ABSTRACT 
The presence of epithelial membrane antigen (EMA) on malignant mesothelial 
cells found in pleural and ascitic fluids was demonstrated immunocytochemically using 
a monoclonal anti-EMA antibody. Serous fluids of 25 patients with malignant 
mesotheliomas were investigated. In 23 cases, varying numbers of EMA-positive tumor 
cells were present; in 2 cases, no such cells were found. lmmunoelectron microscopy 
was performed both on Lowicryl-embedded sediments of serous fluids and by applica-
tion of pre-embedding techniques using the immunogold method. Expression of EMA 
by the immunogold method was found selectively on the villi of the malignant 
mesothelioma cells whereas the nonvillous, flat surfaces were largely EMA-negative. 
The results indicate that immunoelectron microscopy may offer a useful adjunct in the 
diagnosis of malignant mesothelioma in serous fluids. 
INTRODUCTION 
The cytologic diagnosis of malignant mesothelioma is hampered by the lack 
of clear morphologic criteria differentiating benign from malignant mesothelial cells and 
malignant mesothelial cells from adenocarcinoma cells. Histochemical staining 
techniques are often applied to reach a higher level of diagnostic accuracy, but even 
this approach is often found to be inconclusive (9,20). Morphometry has also been 
employed to improve diagnostic sensitivity, but this technique is not able to distinguish 
malignant mesothelioma from adenocarcinoma (8). 
Electron microscopy (EM) permits the identification of subcellular features 
specific for mesothelial cells, distinguishing them from adenocarcinoma cells. 
Characteristics specific for malignancy, however, are generally not detectable using this 
latter technique (12, 19). Therefore, EM alone is not sufficient for the conclusive 
diagnosis of malignant mesothelioma (20). 
The recent advance of immunocytochemistry in cytologic diagnostics has been 
reflected in a large number of papers describing the use of (monoclonal) antibodies 
directed against a vast array of antigens (3, 11, 15). For instance, epithelial membrane 
antigen (EMA) has been reported to be diagnostic in pleural and ascitic fluids on the 
basis of its presence on (malignant) epithelial cells and its absence from reactive 
mesothelial cells (3,7). Regarding the expression of EMA on malignant mesothelial 
cells, controversial data have been reported (2, 10, 13). In this paper, we demonstrate 
the presence of EMA on malignant mesothelial cells in the majority of cases of 
malignant mesothelioma. In addition, the ultrastructural localization of EMA on these 
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cells is shown. 
MATERIALS AND METHODS 
Various fluids were assayed for the presence of EMA-positive cells: 56 
cytologically negative serous fluids containing varying numbers of reactive mesothelial 
cells, 39 cytologically positive serous fluids, pleural fluids from 23 cases of malignant 
mesothelioma and ascitic fluids from another 2 cases. In all cases, the clinical 
diagnosis of malignant mesothelioma was confirmed by histology andjor EM. 
Histochemical staining reactions performed on these serous fluids were alsways 
consistent with the diagnosis of malignant mesothelioma. 
Pleural and ascitic fluids were obtained by puncture; the fluid was centrifuged 
and the sediment was smeared on glass slides. The smear was allowed to air dry and 
was then stored in a dry place. After a maximum period of two weeks, the slides were 
stained for EMA using a monoclonal anti-EMA antibody, obtained from Dako 
(Copenhagen, Denmark), in a dilution of I :20 in phosphate-buffered saline (PBS) (0.4 
M; pH 7.4) containing 0.05% gelatin and 0.1% NaN3. This monoclonal antibody was 
previously referred to as E29 (4). Before adding the primary antibody, the smears were 
fixed and endogenous peroxidase activity was simultaneously blocked by incubation 
in methanol containing 3% hydrogen peroxide for 30 minutes. The slides were then 
overlaid with the anti-EMA antibody for 1 hour, rinsed for 10 minutes in two changes 
of PBS and incubated for another 30 minutes with a horseradish peroxidase-
conjugated rabbit anti-mouse (RAM-PO) antibody (Dako) diluted 1:50 in PBS 
containing 5% nonimmune human serum and 5% nonimmune rabbit serum. Antibody 
localization was visualized by incubation of the slides with a TRIS-buffered saline 
solution (0.05 M; pH 7.4) containing 50 mg %of 3,3 diaminobenzidine tetrahydrochlo-
ride (Fiuka, West Germany) and 0.03% hydrogen peroxide. Slides were then washed 
with running tap water, counterstained with hematoxylin and mounted in Malinol. All 
incubations were performed at room temperature. 
For preembedding for immunoelectron microscopy, the sediments of serous 
fluids were fixed in buffered paraformaldehyde (1.5%) and glutaraldehyde (0.1%) in 
PBS (pH 7.4) for 24 hours and then stored in PBS contatining 1% paraformaldehyde 
and 0.1-M sucrose until immunostaining. For immunogold staining, the pellet was 
washed twice in PBS and then incubated with anti-EMA (1 :20) for one hour. The cell 
suspension was washed twice again in PBS, and the pellet was suspended in a dilution 
of 10-nm colloidal gold-labeled goat anti-mouse serum (Janssen, Belgium) diluted 1:10 
in PBS. After incubation for one hour, the cells were centrifuged again and washed in 
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PBS. The final pellet was postfixed in 1% wjv Os04 in 0.1-M phosphate buffer (pH 7.3) 
for 12 hours at 4°C, rinsed in the same buffer, acetone dehydrated and Epon 
embedded for routine transmission electron microscopy (TEM). 
For postembedding imunoelectron microscopy, the sediments of serous fluids 
were fixes in 1.5% v jv paraformaldehyde plus 0.1% glutaraldehyde in 0.1-M phosphate 
buffer (pH 7.2) at 4°C for four hours. Pellets were then transferred into 0.2% wjv agar 
in PBS solution kept fluid at 40°C. The pellet was brought into suspension by gentle 
pipetting. After cooling, the clotted material was stored in a sucro~e buffer of 1-M 
sucrose in 1.1-M phosphate buffer (pH 7.2) with 1% w jv paraformaldehyde at 4°C. 
Subsequently, the pellets were dehydrated in graded ethanol while temperature was 
progessively lowered. Finally, the material was infiltrated with Lowicryl K4M-alcohol 
mixtures and pure catalyzed Lowicryl at -35°C. Polymerization took place under 
ultraviolet light at -40°C for 24 hours. From the Lowicryl-embedded material, 1-JLm-
thick sections were cut with a glass knife and stained with toluidine blue to select 
appropriate areas for ultrathin sectioning. The ultrathin Lowicryl-embedded sections 
were collected on carbon-coated Formvar filmed mesh 1 00 copper grids. 
The immunologic methods for visualization of the mouse monoclonal anti-EMA 
antibodies bound to the antigenic sites were those described by Geuze et al. (5). 
RESULTS 
Three of the 56 smears without cytologic evidence of malignancy contained 
sporadic EMA-positive cells (Table 1). Follow-up revealed the presence of numerous 
malignant epithelial cells in one of these three cases one month later. The other two 
cases were lost to follow-up, but these patients were known to have a metastasized 
TABLE I 
Presence of EMA-positive cells in cytologically positive and negative serous fluids 
Cytology* 
Negative 
Positive 
Negative 
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EMA staining 
Positive 
3 
38 
Total 
56 
39 
* Negative cytology signifies the absence of malignant cells in smears of serous fluids while positive 
cytology indicates the unequivocal presence of malignant epithelial cells. 
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Figure 1. 
Figure2. 
(left) Cluster of malignant mesothelioma cells stained for EMA. The 
periphery of the cells shows intense immunoperoxidase staining (x 250). 
(right) Lowicryl-embedded malignant mesothelioma cell. Postembedding 
immunogold labeling for EMA shows a discontinuous labeling pattern of 
the villous surface (x 45,000). 
adenocarcinoma. In 38 of the 39 smears with overt epithelial malignancy, a high pro-
portion of tumor cells stained for EMA. 
Twenty-three of the 25 smears of patients with malignant mesothelioma 
contained varying numbers of moderately to intensely EMA-stained cells (Table II). 
Staining was observed mainly at the periphery of the cells; at higher magnification, 
heavily stained hairy protrusions of the membrane could be noted (Figure 1). Some 
cells stained fully at the circumference while other cells stained only partially. Clusters 
of cells and so-called "morules" only stained at the periphery. No staining was 
observed at the inner cell boundaries of these aggregates. In two cases, no EMA 
staining of the mesothelioma cells was observed. 
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Figure 3. 
Figure 4. 
(lett) Lowicryl-embedded malignant mesothelioma cell. Postembedding 
immunogold labeling for EMA shows numerous gold granules along the 
surface membrane of the long villi. Notice the absence of immunogold 
staining of the nonvillous surface and the cytoplasm (x 26,000). 
(right) Epon-embedded malignant mesothelioma cell labeled for EMA 
using the preembedding immunogold technique. Glycogen granules 
(arrow) are clearly visible (x 30,000). 
lmmunoelectron microscopy on Lowicryl-embedded sediments of serous fluids 
containing malignant mesothelioma cells showed gold granules predominantly 
situatedat the cytoplasmic outer membrane of the long villi of cells with the ultrastruc-
tural features of mesothelial cells. The staining for EMA revealed a remarkable, 
discontinuous pattern (Figure 2). The nonvillous surfaces of these malignant 
mesothelial cells only sporadically showed gold particles (Figure 3). Similarly, no 
labeling was found at contiguous borders of cells situated in clusters or morules. No 
significant numbers of gold granules were present in the cytoplasm of these cells. 
Preembedding immunoelectron mmicroscopy using either the immunogold or the 
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TABLE II 
Frequency of EMA-positive malignant mesothelioma cells in serous fluids 
% EMA-posi- Qy!ologic gattern (no. of fluids) 
tive cells Clusters* Solitary** Combined*** Total 
0 0 2 
<5 0 2 3 
5-50 3 2 3 8 
>50 6 4 2 12 
* Smears containing malignant mesothelioma cells predominantly arranged in clusters, morules or 
papillary groups, ** Smears containing malignant mesothelioma cells predominantly arranged as single 
cells or small clusters of two to three cells, *** Smears containing both clusters and single cells. 
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Figure 5. Lowicryl-embedded re-
active mesothelial cell. 
Postembedding immu-
nogold labeling for EMA 
did not lead to deposits 
of gold granules on this 
cell (x 60,000). 
immunoperoxidase method yielded 
essentially the same results. In the 
Epon-embedded immunostained 
preparations, the slender, branched 
villi as well as the presence of glyco-
gen granules, fat droplets, the occa-
sionally extensive intermediate fila-
ment pattern and desmosomes could 
be identified easily, indicating the 
mesothelial differentiation of the im-
munostained cells (Figure 4). Pre-
parations incubated with nonrelevant 
monoclonal antibodies (anti-T3 or 
anti-leukocyte-common antigen) did 
not show labeling of mesothelial cells. 
In addition, postembedding immunoelectron microscopy was performed on two 
pleural fluids containing large numbers of reactive mesothelial cells. Cells with the ultra-
structural features of mesothelial cells were not stained, even though large numbers 
of long, slender villi were projecting from their surfaces (Figure 5). 
DISCUSSION 
The presence of EMA on malignant mesothelial cells was found in the majority 
of cases. These findings confirm an earlier study on a few cases of malignant 
mesotheliomas. To et al., (18), using a polyclonal anti-EMA antiserum, found one of 
two cases to be positive. In contrast, Battifora (1) found the only cytologic case he 
tested to be negative. Staining for human milk fat globule (HMFG) glycoproteins or 
EMA on paraffin-embedded tumorous mesothelioma tissue has yielded contradictory 
data. Some authors reported that anti-EMA can distinghuish between adenocar-
cinomas and malignant mesotheliomas since no staining of the latter was observed (2). 
Other authors have been able to demonstrate the presence of EMA on histologic 
specimens of malignant mesothelioma (10, 13, 14). The use of different batches of anti-
EMA antibodies might partially explain these discrepant findings. Battifora and Kopinski 
(2), using the anti-HMFG2 antibody, failed to achieve immunostaining in all 28 
malignant mesothelioma tested while Pinkus and Kurtin (13), using the same 
monoclonal antibody as applied in our study, found 5 of 6 pleural mesotheliomas to 
be immunopositive. 
In the series of cytologically negative smears tested in this study, it appeared 
that reactive mesothelial cells did not express EMA, although a few EMA-positive cells 
were present in three cases (Table 1 ). In one of these three cases, however, the 
pleural fluid contained numerous malignant epithelial cells one month later. A few 
previous papers have indicated the occasional presence of HMFG-2/EMA-positive 
reactive mesothelial cells in serous effusions of a small proportion of patients without 
known malignancy (6, 17). The clinical significance of the occurrence of EMA-positive 
benign mesothelial cells is not known. Apparently, EMA may not serve as a fully 
reliable indicator of malignancy, though its sensitivity must still be considered high. 
Thus far, no anther marker for mesothelial malignancy has been described. Neither 
carcinoembryonic antigen nor the antigen detected by the recently described 
monoclonal antibody 872.3 is present on malignant mesothelioma cells (16,21). 
Electron microscopy has been introduced as an ancillary test in the differential 
diagnosis of malignant mesothelioma, and the ultrastructural characteristics of 
mesothelial cells are now well documented (19). Although epithelial and mesothelial 
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malignant cells can often be distinghuished on the basis of ultrastructural characteris-
tics, the value of EM in distinguishing between benign and malignant mesothelial cells 
is doubtful. Using EMA as a specific and sensitive marker of malignancy, immunoelec-
tron microscopy was applied in this study to differentiate between reactive and 
malignant mesothelial cells on the one hand and between mesothelial and epithelial 
cells on the other hand. Preembedding immunoelectron microscopy gave excellent 
morphologic results combined with intense immunogold or immunoperoxidase labeling. 
Postembedding techniques showed that immunoreactive material was nearly 
exclusively present on the outher surface of the malignant mesothelioma cells. The 
preferential staining of the villi of these mesothelioma cells suggests that, in malignant 
mesothelioma, the appearance of these villi is strongly associated with EMA 
expression. In contrast, the villi of reactive mesothelial cells were not labeled at all. One 
could therefore consider the expression of EMA on malignant mesothelial cells as a 
differentiation-associated phenomenon. Additionally, it was striking that EMA was 
nearly entirely absent from the cytoplasm of the malignant mesothelial cells in the six 
case studied. 
In conclusion, this study indicates that immunoelectron microscopy on 
preparations of serous fluids suspected as being from malignant mesothelioma may 
be helpful in making the diagnosis. 
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ABSTRACT 
Cytogenetic analyses of 40 confirmed malignant mesotheliomas are reported. 
Pleural effusion cells were studied in 90% of the cases by the direct method andjor 
after culture. Biopsy and ascites fluid were also analyzed in some patients. A normal 
karyotype was found in 9 cases and complex karyotypic abnormalities were observed 
in 30 cases. In one case, analysable metaphases were not obtained. The chromoso-
mal changes were all complex and heterogeneous; no consistent, presumably specific 
abnormality was detected. Nevertheless two main patterns of non-random abnormali-
ties were seen i.e. 1) loss of chromosomes no. 4 and 22, 9p and 3p in the large 
majority of abnormal cases and corresponding to a hypodiploid andjor hypotetraploid 
modal chromosome number. 2) gain of chromosomes no. 7, 5 and 20 with also 
deletion or rearrangement of 3p in the hyperdiploid cases, which were a minority in our 
serie. These findings are discussed in view of other reported cytogenetic studies of 
malignant mesothelioma, asbestos exposure and possible mechanism of malignant 
transformation. 
INTRODUCTION 
Malignant mesothelioma (MM) is a mesodermally derived tumor that occurs 
with a still increasing frequency, particularly in regions with mining and shipyard 
industry (1). A history of asbestos exposure is found in at least 80% of the cases (2) 
and a lag phase of 10 a 40 years between exposure and development of tumor is not 
unusual. The most frequent localization is the pleura, although primary sites in pericard 
or peritoneum are not exceptional. In malignant pleural mesothelioma the first 
symptoms are dyspnea and chest pain. Radiological examination often reveals a 
pleural effusion. Cytological discrimination between benign inflammatory or reactive 
effusions, malignant mesothelioma and carcinoma metastases is not always clear (3). 
The physical and radiological signs also lack specificity and so far sure diagnostic 
criteria are missing, but most needed. 
Cytogenetic analysis of hematological malignancies has shown that particular 
chromosomal aberration are specifically associated with subtypes of leukemia or 
lymphoma and that they constitute a diagnostic and prognostic factor independent 
of the other clinical and pathological considerations (4). In solid tumors also specific 
chromosomal rearrangements have been described e.g. t(11 ;22) in Ewing sarcoma 
or t(12;16) in liposarcoma (5-6). Deletion of specific chromosomal regions have also 
been associated with particular cancers e.g. del(13)(q14) in retinoblastoma (7) or 
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del(3)(p21) in small cell carcinoma of the lung (8), findings that suggest the loss of 
regulator genes as the mechanism of tumorigenesis in these particular malignancies. 
So far, cytogenetic analysis of malignant mesothelioma using banding techniques has 
been reported in only a limited number of patients, 2 in vitro cell lines and 5 in vivo cell 
lines maintained on nude mice (9-16). These studies showed extensive aneuploidy, 
preferential involvement of some chromosomes but could not indicate a specific 
chromosomal rearrangement. The complexity of the karyotypes observed suggest 
tumor progression with appearance of secondary changes. Furthermore, many cases 
were studied after that the patient had received cytotoxic therapy or after long period 
of in vitro culture. It is only by studying a large number of primary cases that specific 
cytogenetic primary changes will be found and their eventual diagnostic and prognostic 
value disclosed. We report here on cytogenetic studies of 40 cases of newly 
diagnosed, untreated, malignant mesothelioma. Special care has been taken to include 
only the cases with very good pathological evidence for the diagnosis of malignant 
mesothelioma. The karyotypes were studied on pleural effusion cells in most cases 
andjor from tumor biopsy obtained by thoracoscopy or at autopsy. The abnormal 
karyotypes showed numerous numerical and structural chromosomal changes. In a 
number of cases a recurrent pattern of changes seems to emerge that could become 
of diagnostic value. 
MATERIALS AND METHODS 
Patients 
Patients were referred to us from the departments of Pulmonary Diseases of 
the Academic Hospital and from the other hospitals in Rotterdam and Vlissingen area. 
Rotterdam and Vlissingen are large harbors with important ship-building and ship-
repair facilities, where asbestos was and is still extensively used. As a consequence, 
the occurrence of malignant mesothelioma is currently of about 7 cases/100.000 
inhabitants/year and still increasing. The overwhelming majority of cases have a history 
of occupational asbestos exposure of at least a few months duration, including 
housewives that are getting exposed when dusting off the working cloths of their 
husbands. Pleural fluid was aspirated and used for cytology and pathological 
diagnosis, for cytogenetics and for establishing long term cultures. Treatment is only 
palliative and most patients died at home. But, autopsy was performed on the rare 
cases dying in hospital. As control, cytogenetic analysis of non-malignant reactive 
pleural effusions (post-trauma, infections, heart failure) and of metastatic adenocar-
cinomas were also performed. 
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Pathological diagnosis of malignant mesothelioma. 
Three histological types of MM can be distinguished: Epithelial (E), fibromatous 
(F) and mixed (M). Epithelial and mixed forms exfoliate malignant cells in effusions, 
while the fibromatous MM is intraparietal, and does not exfoliate. The latter type, thus, 
requires biopsy of the tumor for diagnosis and when a pleural exudate is present it is 
often reactive, lacking malignant cells. Cells present in effusions were analyzed by 1) 
light microscopy, 2) immunocytochemistry using antibodies specific for carcinoembryo-
nic antigen (CEA) and epithelial membrane antigen (EMA) and 3) electron microscopy. 
Whenever possible, cytological diagnosis was confirmed by histology of tumor material 
obtained by needle biopsy, thoracoscopy or at autopsy. For this study we retained 
only the patients with a diagnosis of malignant mesothelioma established by at least 
two, preferentially three different techniques i.e. cytology, electron microscopy, 
histology and/or that passed the review committee. In the Netherlands, the histology 
of cases suspected of MM are reviewed by the Dutch mesothelioma panel of 3 
pathologists. 
Cytogenetics 
a) Effusions. Pleural fluids of untreated patients were received in sterile plastic 
tubes containing heparin (5000 units), 5 ml Ham's F10 culture medium with fetal calf 
serum (15% vjv) and antibiotics, and in some colcemid (1-2 J.Lgr). The samples 
reached the laboratory within 30 to 40 minutes where they were processed using a 
direct method (DM). The cells from 1 or 2 tubes containing colcemid were washed with 
RPM! 1640 culture medium, swelled in KCI 0.075 M and fixed according to standard 
procedures. Other samples (not containing colcemid) were put into culture and 
harvested after one to 3 days (short term culture) or after one to 4 weeks (long term 
cultures). In some cases, permanent cell lines were obtained that were subcloned and 
karyotyped (17, 18). For harvesting of the cultures, the mitotic cells were shaked into 
the supernatant fluid, collected in tubes containing colcemid, washed once and 
processed as above. When the shaking method failed to provide enough metaphases, 
colcemid was added to the cultures for a time varying from 1 hour to overnight. 
Subsequently the mitotic cells were loosend by shaking of the culture flasks, and 
harvested as described above. The remaining monolayer was then flooded with KCI-
EGTA (19) for 20 minutes, and scrapped out with a rubber policeman, washed with KCI 
0.075 M and processed as above. The chromosomes were identified using RFA, QFQ 
and GTG banding techniques and analyzed according to the ISCN (1985). 
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b) Biopsy and autopsy tumor material were first cut into pieces and dissociated 
by overnight treatment with collagenase, then put into culture in Ham's FlO culture 
medium containing antibiotics, glutamine and 15% fetal calf serum. When enough 
tumor material was available, additional cultures supplemented with Epidermal Growth 
Factor (EGF) with or without hydrocortisone (HC) were also set up. Successfully 
established cultures were karyotyped as described above. 
RESULTS 
Eighty eight samples from 71 patients were received. Malignant mesothelioma 
was diagnosed in 40 patients, and was the most probable diagnosis in 8 other 
patients. Pleural effusions were of non-malignant origin in 14 patients and from 
metastatic carcinoma in 10 cases. Among the 40 cases of confirmed malignant 
mesothelioma 4 were female (age 72-83) and 36 were male (age: 44-83) (fable 1). 
History of asbestos exposure was positive in 35 cases, unknown in 3 cases and 
probably negative in 2 female patients. 
Survival was short: 73% of the patients died within one year of diagnosis, 34% 
already within 6 months. Only one patient survived beyond the second year. The 
primary site was the pericard in one patient (Me-21) and the pleura in the other, the 
right pleura in 60% and left pleura in 40% of the cases. Pathological diagnosis was 
carefully done on biopsies (Figs. 1a,b) and on cytological samples, including electron 
microscopy (Figs. 1c,d). Epithelial tumors were found in 17 cases, mixed tumors in 13 
cases and fibromatous tumors in 4 cases; in the remaining 6 cases epithelial cells 
were seen in effusion, but because of absence of histology a mixed type could not be 
TABLE 1 
Age distribution, asbestos exposure and pathological diagnosis in 36 males and 4 females with malignant 
mesothelioma 
sex age (years) asbestos exgosure gathological tyge 
44-55 56-70 71-83 + ? E E* M F 
Male: 36 8 22 6 33 3 0 16 6 12 2 
Female: 4 0 0 4 2 0 2 1 2 
Total: 40 8 22 10 35 3 2 17 6 13 4 
E* epithelial by cytology only. 
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Figure 1. A: Epithelial growth pattern in a pleural biopsy of mixed type of 
malignant mesothelioma Me-72 (x250). B: Fibrous growth pattern in 
the same biopsy as A. (x250). C and D: Cytological smears of a 
pleural effusion with several characteristic tumor-cell aggregates and 
single tumor cells showing cytoplasmic vacuolization (C) and 
cytoplasmic membrane protrusions (D) (Me-84) (x250). 
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modal numbers 
Distribution of modal chromosome number of 30 malignant 
mesothelioma stem lines. Each patient is indicated only once by the 
stem line with the lowest chromosome number. ~ cases with 2 stem 
lines e.g. modal chromosome number 42 and 84 or 67 and 135.111 
cases with 3 stem lines e.g. modal chromosome number 43/80/140. 
excluded. Cytogenetic analysis was successful in 39 cases and in one case (Me-45) 
metaphases were not obtained. Clonal abnormalities were found in 30 cases, which 
were classified as hypodiploid (13 cases), hypotetraploid (11 cases) and hyperdiploid 
(6 cases) karyotypes. Repartition of the modal chromosome numbers is given in Fig. 
2. Table 2 gives individual data on patients according to the cytogenetic findings. Each 
group appears heterogeneous regarding age of patients, histological type of tumor, 
and survival. 
Cytogenetic studies. On effusions, the direct method (DM) was most reliable at 
disclosing abnormal metaphases. The quality of the metaphases was irregular, and not 
all cells could always be fully karyotyped. 
Short term culture improved the quality of metaphases, but often only normal 
karyotypes were found and it was soon evident that the direct method was required 
for a valid cytogenetic study. Only a fraction of the samples sustained long term 
cultures, eventually giving rise to established cell lines (20,21). The long term cultures 
(1 to 8 weeks) showed a normal karyotype (NN) or a mixture of normal and abnormal 
cells (AN). The cell lines were subcloned to pure malignant mesothelioma cells with 
the corresponding abnormal karyotype as reported previously (20). Biopsies were all 
cultured before karyotyping. In the appendix, the different tissues and technical con-
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Histograms showing the numerical changes observed in 30 malignant 
mesotheliomas with abnormal karyotype. When clonal evolution was 
seen, the less evolved (simplesV stem line was considered. For 
distinction between hyperdiploid (Ill) and hypotetraploid (II), see text. 
Black boxes indicate loss or gain of 2 copies of a given chromosome 
in a given stem line. The unidentified markers are also given: R = 
ring chromosome, m = minute marker, number in open box indicate 
the average number of markers in a given case. 
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III: hyperdiploid stemtines 
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Histograms showing the involvement of the short and long arm of 
each chromosome in structural abnormalities. Each marker is 
represented only once, even if more copies were seen, as was 
usually the case in the hypotetraploid karyotype. Inversions were 
paracentric or peri centric, in the latter case they have been indicated 
on the arm with the more distal breakpoint, gain of chromosomes are 
either rare duplications, isochromosomes or whole arm translocations 
like 13q or 17q that were often found in marker formation. 
ditions used for cytogenetic studies are given for each sample together with detailed 
description of stem line karyotypes. Non-clonal aberrations (random loss of 
chromosomes and structural changes) were found regularly as well as a tendency to 
tetraploidization in some samples. In 3 cases (Me-61, Me-77 and Me-95) small clones 
with loss of Y as only abnormality were observed and not considered as clonal 
aberrations relevant to malignant mesothelioma. 
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TABLE 2 
Clinical and pathological data of MM patients classified according to cytogenetic findings 
patient sexjage asbestos survival primary histo- gath. criteria (5) 
no. at exposure (Mo) site logical cytology EM hi st. autopsy 
diagnosis (1) (2) (3) type (4) 
A. 10 Patients with Normal Karyotype of Cytogenetic Failure (Me-45) 
Me-21 M,45 ++ 6.5 Peri card E + 
Me-31 M,60 ++ 1.5 P,l M + + 
Me-51 M,60 ++ 7 P,l M + + 
Me-57 M,58 + 16 P,r E + + 
Me-67 M,66 ? 3 P,r M + + 
Me-77 M,83 + 20 P,r M + + + 
Me-78 M,71 ? 10 P,r E* + + 
Me-86 M,51 ++ 9 P,r E + + + 
Me-94 M,61 ++ 11+ P,l E + 
Me-45 M,51 + 18 P,r E + + + 
B. 13 Patients with Hypodiploid Karyotype 
Me-9 M,67 + 20 P,l E nd + 
Me-19 F,75 3 P,r E + + + 
Me-20 M,59 + 2.5 P,l F + 
Me-26 M,50 ++ 11 P,l M + + + 
Me-27 M,67 + 6 P,r M + + + 
Me-72 M,65 + 12 P,r M + + 
Me-73 M,58 ++ 11 P,r M + + + 
Me-83 M,52 ++ 14 P,l M + + + 
Me-84 M,70 + 4 P,r E + + + 
Me-85 M,44 +++ 14+ P,l E* + + 
Me-100 F,76 5 P,l M + + + 
Me-102 M,72 +++ 7 P,l E* + + 
Me-105 M,67 ++ 4 P,r E + + + 
C. 11 Patients with Hypotetraploid Karyotype 
Me-3 M,70 + 19 P,r E + + 
Me-10 M,67 + 10 P,r M + + + 
Me-14 M,48 + 5.5 P,l E + + + 
Me-25 M,78 + 8.5 P,l E + + + + 
Me-41 M,61 ++ 2 P,r E* + + 
Me-48 M,62 ++ 11 P,r M + 
Me-56 M,64 +++ 19 P,r E* + + 
Me-64 M,76 + 11 P,r E nd + + 
Me-88 F,72 +++ 25+ P,r F nd + 
Me-96 M,46 + P,l F nd + 
Me-104 M,68 +++ 14 P,r E* + + 
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D. 6 Patients with Hyperdiploid Karyotype 
Me-13 M,57 + 6 P,r E + + + 
Me-50 M,60 ? 20+ P,r E + + + 
Me-61 M,75 + 4 P,l E + + + 
Me-62 M,64 ++ 11 P,r E + + + 
Me-82 F,83 + 1 P,r F + 
Me-95 M,57 ++ 8 P,l M + + + 
(1) + + + and + + high exposure (workers in insulation, ship building, demolition, cement factory and 
direct handling of asbestos), +:worker in potentially exposed environment,?: no data, (2) Survival from 
time of clinical diagnosis in months, (3) P = pleura, I = left, r = right, (4) E = Epithelial, M = Mixed, F 
= Fibromatous, E = Epithelial by cytology only, no biopsy, (5) Cytology on effusion cells, including 
immunocytology using EMA and CEA specific antibodies, EM = electron microscopy on effusion cells 
and/or biopsy, nd = no data. 
Normal karyotypes were found in 9 patients pleural effusions (Table 2A). In 3 
cases (Me-21, Me-57 and Me-94) the pleural fluid contained none or only very few 
presumably malignant cells and the diagnosis was established histologically. In 2 
cases (Me-67 and Me-86) the direct method was not applied. In 4 cases (Me-31, Me-
51, Me-77 and Me-78) with pathological fluid, adequate number of cells were analyzed 
in OM and culture and failed to show clonal,abnormalities. Data concerning Me-45 of 
whom cytogenetic studies failed are also given in Table 2A. 
All 30 cases with clonal abnormalities showed complex numerical and structural 
chromosomal changes. Karyotypic evolution by duplication of the stem line was 
common and as a consequence most metaphases contained a large number of 
chromosomes. in these cells secondary changes were also seen, either numerical by 
random loss of chromosomes or structural by formation of a new (single copy) marker 
chromosome. 
In 13 patients, a hypodiploid stem line was found in at least a few cells. Cells 
with 75-85 and more than 130 chromosomes were also found as a result of 
duplication of the hypodiploid stem line. In one patient (Me-84) cytogenetic analyses 
of one biopsy provided evidence for aneuploidy due to cell fusion of a normal diploid 
cell with a hypodiploid abnormal cell. 
In 11 cases hypotetraploid karyotypes were found with modal chromosome 
numbers varying from 67 to 90. Analysis of the abnormalities showed similarities with 
the findings in hypodiploid cases suggesting duplication of an earlier (and not 
observed) hypodiploid stem line. Also, 2 copies were found of most rearranged 
chromosomes. 
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Figure 5. Examples of balanced translocations observed in MM karyotypes and 
described in Table 3. These are t(8;17) and t(15;22) in Me-41, t(7;14) in 
Me-104, t(3;4) in Me-100, t(3;18) in Me-95, t(3;12) in Me-56, t(4;10) in Me-
48, t(6;17) in Me-83 and t(4;6;13) in Me-50. In each chromosomal pair, 
the normal homologue is on the left, and missing in 3 instances. 
Figure 6. Marker chromosomes with stretch of unidentified chromosomal material, 
presumably HSR: 7q+ in Me-9, del(5)(q11q22)q+ in Me-48, dup 1q? in 
Me-96, 12q+ in Me-73, 9p+ and 22p+ in Me-102. The normal 
homologue is on the left. R-bands with acridine orange. 
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TABLE 3 
Balanced translocations observed in 11 cases of malignant mesothelioma 
case no. 
Me-9 
Me-20 
Me-26 
Me-41 
Me-48 
Me-50 
Me-56 
Me-83 
Me-95 
Me-100 
Me-104 
trans locations 
t(4;10)(q24;q23) 
t(3;1 O)(q22;q22) 
t(Y;15)(q12;q14 or q15),t(5;11)(q35;p13) 
t(8;17)(p11 ;q11),t(15;22)(q21 ;q11) 
t(4;10)(p11 ;q11) or (q11 ;p11) 
t(4;6;13)(p16;q14;q13) 
t(3;12) (p21 ;q23) 
t(6;17) (p21 ;p12) 
t(3;18)(p14;p11) 
t(3;4) (p21 ;q31) 
t(7;14)(q35;q12) 
In 6 cases with an hyperdiploid karyotype (modal chromosome number from 
49 to 61), the pattern of changes appeared different. 
Numerical chromosome aberrations 
Gains and losses of chromosomes are plotted on 3 histograms (Fig. 3). In 
cases with multiple stem lines by duplication the modal karyotype with the lowest 
chromosome number was used. The hypotetraploid cells were analyzed using the 
tetraploid karyotype as reference and allowing for random loss: thus 1 or 2 copies of 
a chromosome was registered as a loss, 3 or 4 copies as normal and 5 or more 
copies as gain. 
Not unexpectedly, the hypodiploid and hypotetraploid karyotypes showed a 
similar profile with non-random losses of chromosomes 4 (16x) and 22 (15x) followed 
by losses of# 9 (10x), # 10 (8x) and chromosomes of the D-group. 
In the hyperdiploid karyotypes, non-random gain of chromosomes 7 and 20 were 
seen, followed by trisomy 5, 8, 15 and 16 in half of the cases. 
Gain of 5 and 20 was also seen in 3 hypotetraploid karyotypes, concurrently 
(Me-3, Me-88 and Me-96). This suggests that gain of 5 and 20 are either secondary 
changes or that these 3 cases, despite their high modal chromosomal number, were 
misclassified and should have been included in the hyperdiploid category. Remarkably, 
also, two of these cases were of the fibromatous type. 
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TABLE 4 
Marker chromosomes with possible HSR 
patient marker 
no. chromosomes 
Me-9 7q+ 
Me-48 5q+ 
Me-73 12q+ 
Me-96* 1q+ 
Me-102 9p+,22p+ 
* Also 1-3 d.m. in each metaphases. 
Structural abnormalities 
Structural rearrangements were seen in all abnormal karyotypes (Fig. 4). 
Prominent abnormalities were deletion and unbalanced translocations, which also lead 
to partial deletions of the chromosome arm involved. Inversions were seen a few times, 
particularly in rearrangements of chromosomes 1, 2 and 11; duplications and 
isochromosomes were unfrequently found. 
Fourteen balanced translocations, all different, were identified in 11 cases. 
Chromosomes 3 and 4 were involved 4 times and chromosome 10, 3 times. Break-
points were not recurrent but 3p and 10q were involved 3 times each (Table 3, Fig. 5). 
Chromosome amplification, as identified by HSR and dm were seen in only 5 cases 
(Table 4, Fig. 6). 
No clear specific rearrangements or breakpoints were found but some chromo-
somal changes were clearly non-random: i.e. (partial) loss of 3p, 4, 6q, 9p and 22, 
while chromosomes 13, 16, 17 and 19 showed many "whole arm" rearrangements with 
breakpoints around the centromere (p11 or q11). For chromosome 13 e.g. unbalanced 
translocation onto the short arm (13p+ marker) was found in at least one third of the 
cases and numerical loss of 13 was often compensated by translocation of the whole 
long arm onto another chromosome. Structural abnormalities of chromosome 1 were 
very frequent, involving both arms and they were not always fully interpretable. 
Furthermore both chromosomes 1 were often rearranged, some markers were present 
in 2 or more copies and thus no clear picture emerged concerning specific breakpoint, 
and partial gain or loss of chromosome 1 material. 
In contrast, chromosome 2 was seldomly modified, although deletion or 
rearrangement of the short arm did occur a few times and pericentric inversion was 
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found in at least 4 instances. 
The non-random changes of chromosomes 3, 4, 6, 9 and 22 are illustrated in detail 
in Fig. 7. 
Abnormalities of chromosome 3 were seen in 27 (90%) of the 30 abnormal 
karyotypes: particularly frequent were deletions and unbalanced translocations of the 
short arm. The shortest region of overlap of these partial losses appeared to be 
around band 3p21. Three of the balanced translocations had also breakpoints on the 
short arm of chromosome 3 i.e. 3p14, 3p21 and 3p21. Loss of a complete chromo-
some 3 was seen in 2 patients in part of the cells, while additional marker chromo-
somes resulting in gain of the long arm were seen in 3 karyotypes: Me-9, Me-13 and 
Me-14. 
Loss of the short arm of 9 was the most consistent feature of the hypodiploid and 
hypotetraploid karyotypes: only one case (Me-19) of 24 did not show alteration of 
chromosome 9 and in 3 cases (Me-41, Me-83 and Me-96) there was even apparent 
nullisomy for 9p. In contrast, among 6 hyperdiploid cases, one showed trisomy 9 (Me-
62), 4 a normal pair of 9 and only one case a marker 9p+ with loss of the short arm 
distal to p21. 
Loss of chromosome 4 was a non-random event in the hypodiploid and hypo-
tetraploid karyotypes: i.e. in 13 cases monosomy 4 and in 7 cases unbalanced 
translocations resulting in (partial) loss of the long arm (6x) or short arm (1x). Gain of 
# 4 was seen only once (Me-13). Loss of chromosome 22 was also found in more 
than half of the cases, particularly in the hypodiploid and hypotetraploid categories. 
Chromosome 6 is the site of many structural rearrangements that do not always 
lead to loss or gain of material; among these 2 balanced translocations (Me-50 and 
Me-83), a pericentric inversion (Me-84) and various markers in Me-13 and Me-72. Loss 
of the short arm was seen 6 times and of (part of) the long arm 14 times. Chromo-
some 10 was involved in 3 balanced translocations and one inversion. There is a small 
clustering of breakpoints between 1 Oq22 and q24. Examples of stem line karyotype are 
given Figures 8-10. 
Cytogenetics of control pleural effusions 
Cytogenetic analyses of 14 non-malignant pleural effusions was also performed 
using the Direct method. 287 Metaphases were analyzed showing mostly a normal 
karyotype with 2% tetraploid cells, 8% of non-clonal random loss (among which 2% 
with -Y) and 2% non-clonal structural changes, half of these in a single case that had 
previously been irradiated. We also studied 208 metaphases from 10 metastatic 
effusions of various carcinoma. All showed a mixture of normal metaphases (n = 1 00) 
and cells with very abnormal karyotypes. The modal chromosome numbers were: <46 
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Figure B. 
Figure 9. 
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Stem line karyotype of Me-26 with a hypodiploid karyotype, demonstrating 
the non-random loss of# 4, 9, 14 and 22, deletions of chromosomes 1 p, 
3p, 6q, 13q, rearrangement of 9 and two balanced translocations: t(5;11) 
and t(Y;15). The loss of 16 and 18 are incidental in this metaphase. R-
bands with acridine orange. 
Stemline karyotype of Me-14 with a hypotetraploid karyotype: there are 
two copies of most markers. The 2p- and 5p + and some of the 
unidentified markers are changes unique to this cell. R-bands with 
acridine orange. 
Figure 10. Stemline karyotype of Me-95 with a hyperdiploid karyotype, demonstrating 
gain of 1q, 5, 7 and 20, a translocation (3;18) and various structural 
rearrangements. QFA banding technique. 
in 3 cases, 65-70 in 6 cases and 100-120 in one case. Metastic effusion of thyroid car-
cinoma, breast carcinoma and choriocarcinoma (one each) showed highly abnormal 
karyotype with multiple breaks, large abnormal markers, rings, d.m., HSR. In contrast, 
lung adenocarcinoma metastases showed multiple abnormalities that were not 
strikingly different from malignant mesothelioma: structural changes of chromsomes 
1 and 3 were almost constantly present However, the typical association pattern of 
abnormalities found in MM was usually missing and the modal chromosome number 
was often higher in lung adenocarcinoma. Unfortunately, at this stage of the study, a 
cytogenetic marker allowing a safe discrimination between lung adenocarcinoma and 
malignant mesothelioma was not found. 
DISCUSSION 
Cytogenetic analysis of 40 malignant mesotheliomas failed in one case, showed 
a normal karyotype in 9 cases and an abnormal karyotype with multiple and complex 
rearrangements in the 30 remaining cases. The latter were very heterogeneous and 
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an obvious primary abnormality was not detected: indeed a specific change common 
to all abnormal cases was not found and none of the karyotypes showed only a single 
or a few changes. Our analysis of the data showed two major types of chromosomal 
evolution: 1) in 24 out of 30 abnormal cases, chromosome loss and rearrangements 
resulted in a hypodiploid karyotype, that later on became hypotetraploid by duplication, 
endoreduplication or rarely by cell fusion (Me-84). This pattern of evolution showed 
non random loss of chromosomes 4 and 22, and structural changes leading to partial 
deletion of 3p and 9p. In the hypodiploid category rearrangement of the long arm of 
11 and 12 were also frequent. Further clonal progression proceeded by random (?) 
loss of chromosomes towards a near triploid modal chromosome number (as seen in 
most reported cell lines) eventually followed by duplication towards a modal 
chromosome number of 120-125 (Me-25). This type of karyotypic evolution i.e. 
hypodiploidy to hypotetraploidy has also been observed in other tumors e.g. colon 
carcinoma (24). 2) In 6 of the 30 abnormal cases we observed an hyperdiploid 
chromosome number, with non-random gain of chromosomes 7, 5 and 20. Deletion 
of 3p was also often found but not monosomy 4 or deletion of 9p, while chromosome 
22 was structurally rearranged in 3 cases. This second cytogenetic type could be 
relatively more frequent in other studies of MM, which could explain some of the 
discrepancies between our and other reported cases (11, 14-16). In some of these 
cases gain of chromosome 7 appeared to be the first (maybe significant) sign of 
aneuploidy (case 16 in ref. 11 and case 1 in ref. 14). These hyperdiploid cases showed 
also a higher level of genetic instability giving rise to various, sometimes apparently 
unrelated, clones e.g. Me-50, Me-69 and Me-82 in this report and the case 1 reported 
by Stenman et al. (1986). The latter appears as an extreme example of this pheno-
menon. Struct~.~ral abnormalities of chromosomes 1, 5, 6, 10, 13 and 17 were 
ubiquitous, although not present in all the cases. They involved various breakpoints 
resulting in variable unbalance of genetic material and thus they were considered as 
frequently occurring secondary changes. 
Regarding the normal karyotype observed in 1 0 cases, our interpretation is that 
the metaphases analyzed were not of tumoral origin but that they were produced by 
reactive mesothelial proliferation, macrophages and other inflammatory cells always 
present in these exsudates and by contaminating fibroblasts and macrophages in 
cultures. 
We found no correlation between cytogenetic category and clinical variables as 
age of onset, primary site, survival time and histological type of tumor. The fibromatous 
histological type represents about 10% of the tumors: 4/40 in this report, 3/30 in (11 ), 
0/12 in (10) and 1/9 in (16); it is rare in male, but in female patients it is found in 
about half of the cases. The relative prevalence of fibromatous mesothelioma in older 
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women could indicate that exposure to asbestos is not the major etiological factor for 
that type of tumor and that other aggression could play a role, like previous irradiation 
therapy as reported (25). 
Cytogenetically, these fibromatous MM appeared also heterogenous although our 
4 cases (Me-20, Me-82, Me-88 and Me-96) shared some less frequent abnormalities 
like +5, + 7p, +20 (3x each), but also more common changes: -4, -16, -22, structural 
abnormalities of # 1, # 14 and # 18 that were seen in at least 3 of the 4 cases. 
Cytogenetic analysis of 62 MM, using banding techniques were previously reported: 
i.e. 11 cell lines (in vitro and xenografts) and 51 fresh tumor material (effusions and 
biopsies)(9-19). These studies also showed prominent heterogeneity, complex 
structural changes and absence of a common marker. 
Furthermore, comparison of the reported cases between them and with our series 
fails to disclose a similar pattern of karyotypic changes. Tiainen et al. (11) e.g. agree 
with our study on non-random loss of 4, 22, and 9 p, but they emphasized the gain of 
# 7, 11 and 12 which we did not observe to such extend and Gibas et al. (10) found 
rearrangement of 9p in only 2 out of 9 cases while 9q was affected 5 times. Some of 
the variations between studies may be due to difference in the way of analysing the 
data, particularly concerning the numerical changes of tumors with high modal 
chromosome numbers. The other discrepancies are less easy to explain. 
Previous cytotoxic therapy of patients before cytogenetic analysis and many 
passaging in vitro of cell lines will undoubtly induce secondary changes. But many 
cases, and all ours, were studied before treatment and thus the heterogeneity in 
structural changes is most probably genuine and related to genetic differences 
between patients, for instance, chromosomal fragile sites could be inc;lividually and 
geographically different. Differences in type and size of asbestos fibers used could 
also induce particular chromosomal aberrations. 
Presently, chysotile (white asbestos) is the most widely used and less carcinogenic 
than amosite (brown asbestos), croccidolite (blue asbestos) and zeolite mined in 
Turkey. But, this has not always been the case and the long lag phase (25-40 years) 
between exposure and tumor development, and the movement of workers from South 
of Europe to Northern industrialized countries made it almost impossible to collect 
thrustworthy epidemiological data. All asbestos kinds are contaminated by other fibers. 
The remnants found in lungs and tumors are from large particles that are responsible 
for asbestosis, but the small thin (0.5- 2.5 JLm diameter, 10 - 80 JLm long) acid resistant 
fibers that are thought to be responsible for tumoral transformation of mesodermal 
tissue are rarely found in tumors and even less in effusion cells. Asbestos related 
malignant mesothelioma did occur in isolates but unfortunately these tumors were not 
cytogenetically analyzed (26). 
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This extensive cytogenetic study of primary (untreated) malignant mesothelioma 
had two major aims: Firstly to see if a characteristic cytogenetic change could be 
found that would be specific for (subtypes of) MM and of help in diagnosis and 
prognosis as it is the case for other tumors (27) and secondly to investigate whether 
(specific) genetic abnormalities could provide a clue towards the mechanism of 
oncogenesis in these tumors. Regarding the first point, we did not find a consistent 
karyotypic change (see discussion above) nor a cytogenetic marker allowing safe 
discrimination between lung adenocarcinoma and malignant mesothelioma. The 
absence of a specific translocation or chromosomal breakpoint associated with MM 
makes it impossible to investigate concretely a mechanism of oncogene activation by 
specific chromosomal rearrangement like activation of c-ab/ in chronic myeloid 
leukemia with t(9;22)(28) or c-myc activation in lymphomas with chromosomal 
translocations involving 8q24 (29). 
We observed a non-random pattern of chromosome losses i.e. of 9p and 3p as well 
as# 4 and # 22, particularly in the hypodiploid/hypotetraploid types. This suggest that 
in these tumors loss of suppressor genes located on these particular chromosomes 
are playing a role in the development of the cancer, although more studies are needed 
to establish this probability. In hyperdiploid karyotypes, loss or rearrangement of 3p 
was also seen, but it was not always accompanied by loss of an allele, which 
emphasize again the need to study these cases for loss of constitutional heterozygo-
sity, at these particular loci, using polymorphic markers [30]. 
In another study we tested these tumors and cell lines derived from these tumors 
for expression of various oncogenes and an abnormally high expression of c-sis was 
consistently found [31]. 
This finding does not correlate with cytogenetic findings as c-sis maps on 
chromosome 22 and loss of # 22 is a non-random event in these tumors. The high 
expression of c-sis (B-chain of PDGF) is most probably related to the mesodermal 
nature of these tumors and the role played by c-sis enhanced expression in MM 
proliferation is under investigation. 
In MM, two findings are consistant: 1) asbestos exposure and 2) complex and 
heterogeneous cytogenetic changes. It has been demonstrated in vivo, in animal 
experimentation and in vitro that asbestos fibers penetrate living cells, where they 
induce chromosomal breakages and rearrangements [32] and also that they stimulate 
chromosomal integration of DNA fragments in transfection assays [33]. Furthermore, 
for unknown reason, mesodermal tissue is 10 to 1 OOx more sensitive to the action of 
asbestos fibers than bronchogenic epithelium. A scenario can be hypothesized where 
asbestos fibers penetrate mesodermal cells, where they induce multiple chromosomal 
breaks and rearrangements. Some chromosomes carrying fragile sites will be 
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preferentially involved and this may vary individually, geographically and with the type 
of fibers used. As a consequence benign mesodermal proliferation may be induced but 
also malignant mesothelioma, when specific unbalance, e.g. loss of particular 
suppressor genes has occurred. This scenario would account for the long lag phase 
and the high cytogenetic heterogeneity observed. In this hypothesis, multiple, random 
chromosomal changes precede the occurrence of "primary" specific (and presumably 
oncogenic) alterations which makes their identification particularly arduous. Such a 
scheme could be tested in vitro using cultures of normal bronchogenic .epithelium and 
normal mesodermal cells to determine their sensitivity to and the genetic damage 
induced by various amounts of asbestos fibers of various types. This approaches was 
already followed by other investigators, but so far only limited results have been 
obtained [32.33]. 
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APPENDIX 
DETAILED CULTURE AND CYTOGENETIC DATA OF 40 CASES OF MALIGNANT MESOTHELIOMA 
Patient Cytogen. Material & Number of Cells Stemline Karyotypes (4) 
Nr. (1) Class (2) Technique (3) Tot. Norm. Abn. 
Clonal 
ME-3 II P1, DM 30 0 30 85(81-86),XXYY, +del(1)(p31), +del(1)(p31), +del(1) 
(ME-8) P2, DM 48 35 13 (q23), +del(1)(q23), + i(2q), + i(2q), +5, +5, +5( +5), 
cult. 21 21 0 +6,( +6),+ 7( + 7), +der(8)t(3;8)(p14;q22), +der(8) 
t(3;8), + 10, + 11 ( + 11), +12, + 12, + 13, + 14,( + 14),+ 15, 
+ 15,+ 16, +16,+ 18,( + 18), + 19,+19,( +19), +20, +20, 
( +20) +21' +22, +22. 
Me-9 I P, DM 17 8 9 44-46,XY, 1 q-(1 pter-+q11 ::?),3p-(3qter-+p14::?), 
t(4;10)(q24;q23),(-6),7q + (7pter-+q21 ::HSR?::3q) 
-8,9p-,mar.inv(11), 13q+, 14q+,-19,-20, +mar 
(20p;17q), + 2 to 4 markers. 
87-90, same duplicated (25%). 
Me-10 II P, DM 81 72 9 81-83,XXY,del(1 )(p21 p23),del(1)(p21 p23), +der(1) 
line 10 4 6 t(1 ;8)(p21 ;q22), +der(1)t(1 ;8), + inv(2)(q22p11, 
+ inv(2)(q22p11), +der(3)t(3;15)(p22;q21), +del(4) 
(q21), +del(5)(q13q34),del(6)(q11 q21), +del(6) 
(q11 q21), +del(6)(q11 q21), + 7q+ (7pter-+q11 ::7q22-+ 
q11 ::1 p21-+pter], + 7q+,8q+,(8pter-+q24::?13q), +8q+ 
(idem), +del(9)(p21 ), +del(9)(p21 ), +del(1 O) 
(q23q25), +inv(11)(q14q24), +12, + 12,+ 14,+ 14,-15, 
-15, + 16, + 16, + 17, + 18, +der(20),t(15;20)(q21 ;p13), 
+der(20)t(15;20), +21 q+, +21q+, +22,+ring, +marC, 
+2 mar G. 
167: 1 cell, duplication of all markers. 
Me-13 Ill P, DM 15 3 12 61,XXY,+2 mar 1p-(6p?::1q),+1p+(1qter-+p35::6q21 
cult. 18 18 0 -+ter or 13q), +2, +3p+ (3qter-+p14::5q), +4,-6, +mar 
6p-q+ (6p1-+q21 ::8q),+ 7, + 7,-8,+ 11, + 11 q-,13p+ 
(13q::5q) +mar inv13p+, + 15,+ 16, 17p+ (22q?::17q) 
+ 20, + 20p+ ,22p + (22q: :?8p). 
OJ 
'--J 
(X) 
(X) 
Me-14 II P, DM 22 18 4 75(72-78),XX,-Y,-Y,der(1 )t(1 ;?)(p11 ;?),der 1 p-
cult. 18 0 18 (idem), +t(1 p19q), +t(1 p19q), 
line 13 0 13 + 2,del(3) (p22p24),del(3)(p22p24), +der(3) 
t(1 ;3)(q11 ;p21 ), +der(3)t(1 ;3), +der(3)t(3;?) 
(q11 ;?), + i(3p), +5, +5, +, +der(6)t(6;?)(p11 ;?), 
+6p- idem, +del(6)(q11 ), +del(6)(q11 ), +mar 7 
(7pter->cen::?7q32-q11 ::19p or q) +8,( +8), +del 
(9)(p21),+9p+(dup 9 p21p22 or HSR),+9p+ idem, 
+11,(+11),12q+ [?ins (12;3)(q23;q12q28)], 
(+12q+,idem) +14,15p+,+16,+mar 16,+mar 16, 
+ 17, + 17,( + 18),-19,-19, +i(21q),mar 22, 
+ 7 unidentified markers. 
Me-19 I P, DM 31 16 3(+12)* 45,XX, 1 p+ ,inv.(1 p)q-,-2,2p-,-4,5q+ ,6q-,-8,mar 8q-? 
cult. 31 31011 q-,der(12)t(12;?)(p11 ;?), + 13q+ ,-22, + R, +2 mar. 
*Abnormal cells, same markers, not fully analysable. 
Me-20 I P, DM 12 8 3 42-43,XY, (-Y),del (1 )q31 ,t(3;1 0) (q22;q22),-4,del(6) 
cult. 9 6 3 (q22),-7,9p-, 1 Oq-, 14q+ ,del(16)(q21 q23),-18,-22, 
(+mar). 
86, same duplicated markers (one cell). 
Me-21 N P, DM 11 11 0 46,XY /92,XXYY (one cell). 
cult. 10 10 0 
Me-25 II P, DM 31 13 18 67(65-69), inv(X)(p22q12), + inv(X),Y, + Y, 1 p-
(Me-7) cult. 24 24 0 (1 qter->p11 ::Sat)(3-4 copies), +2 copies[del(1) 
B, line 10 0 10 (q12)inv(1) (p36p13) ],der(2)t(2;?)(p12;?), ( + 2), 
+del(3) (p21), +del(3)(p21), +del(5)(q21 q34), 
+del(5), +6,( +6), +8( +8),del(9)(p21),mar(9q::19p), 
+ 10,( + 1 0), + 11 ,( + 11), +mar inv.(11)(p11 q14),-13, 
+ 17,inv(18)(p11 q12),inv(18),(-19),der(20) 
1(20;21 )(p11 ;q11)-21,-21, +22q+, +22q+, +mar 
(17q- or 19q+), +mar 16, +mar 16. 
135 (127-140) same markers, in 15 cells from 
pleural effusion. 
Me-26 I P, DM 32 16 16 42,X,t(Y;15)(q12;q14 or q15), del(1)(p21 p35), 
(Me-37) A, DM 46 14 32 mar 2 [2qter-+q11 ::9p13->q31 ::?], del(3)(p21 ), 
cult. 16 5 11 -4, t(5;11)(q35;p13),del(6)(q16q24),-9, mar 
9p-(9qter-+q21 ::18 like),del(13)(q22q32), 
-14,-22. 
84, same with duplication of markers, 
in 4 pleural effusion cells. 
N.B. in ascites, del(1)(p21 p35) is replaced 
by ring. 
Me-27 I P, DM 47 11 36 44,XY,del (1) (p12p21) ,del (3) (p14p22) ,-4,-6, 
mar(8)[8q::10p),-9,-10,der(11)t(8;11) 
(q22;q23),der(13)t(6;13)(p11 ;q22), 14p+ 
(14q::4p),der(17)t(17;?) (q24;?),-22, 
+3 different E size markers. 
One tetraploid and one octoploid cell. 
Me-31 N P, DM 34 34 0 46,XY /92,XXYY (4 cells). 
Me-41 II P, DM 2 1 1 72(70-75),XXYY, + inv del(1 )(?1 q22->cen::1 p31 
cult. 8 4 4 ->p35::1 q24->qter), + inv del(1),del(3)(q13), 
line 12 0 12 del(3)(q13), +del(3)(p12) + mar(3)(14q- or 
13q-::cen::?::3q),+mar 3, inv(5)(p15q11), 
inv(5), +der(5)t(5;6?)(p15;q15?), + 7, + 7, 
t(8;17)(p11 ;q11),t(8;17),del(9)(p21 ),del(9) 
(p21 ), +9p+, +9p+, + 10, + 11, + 11, +del(12)(p11 p12), 
+del(12),-13-13, +del(14)(q23q31),t(15;22) 
(q21 ;q11),t(15;22), + 15, + 16, + 17, + 17, + 18, 
+20q+,+20q+, +21,+21' +i(21q). 
Me-45 failure P, DM Hemorrhagic fluid, no analysable metaphase. 
cult. 
Me-48 II A+B*cult. 59 11 48 71-75,XXYY, +der(1)t(1 ;?)(p33;?2p or 10q), +2, 
lines 120 0 120 +der(2)t(2;9)(p11 ;p11), +der(2)t(2;9;?) 
(2pter-+p11 ::9 cen::?) +3, +3,t(4;10)(p11 ;q11), 
(*various metastatic sites) t(4;1 0), +del(5)(q11 q22), +5q+ (HSR), +6( +6), 
+ 7q-, + 7q-,+ 7,+8,( +8), +9( +9),+10, +mar(11 p:9p), 
+ 11, + 12,i(13q), 13q+ (1 p), + 17, + 19, +dei(20)(q12), 
+21,+21p+ or i(21q),+22,+mar. 
co (!) 
<0 
0 
Me-50 Ill p cult. 38 11 27 48,XY, + inv(2) (q13q32), + del(3)(p14p22),t(4;6;13) 
(p16;q14;q13), + 7,inv(10)(q11 q24),· 18,20q+ ,-22, 
+mar (11%). 
51,Xq+,Y, 1q-(1 pter->cen::2p21 pter), +2p-[del(2) 
p12p16)inv(2) (q13q32], + del(3)(p14p22),inv.(5) 
(p11 q12), + 7,9p+ (9qter->p21 ::1 q12-+qter) + 12p+ 
[12qter->q13::1q21 ... pter(11%) or 12qter->q13:: 
1 q21 ... p22(89%)), 13q+ (13pter->q33::16p),del(13) 
(q22q32),del(14)(q23q31 ), 15q + (15pter->q24::?) 
del(16)(p11), 16q+ (16pter->q22::?), +mar (89%). 
Me-51 N P, DM 30 30 0 46,XY /46,XY,inv(2)(p16q21) in 2 cells. 
Me-56 II P, DM 12 4 8 83(78-86)X,YY, +del(1)(p33), +del(1)(p33), +2, +2, 
cult. 26 22 4 t(3;12)(p21 ;q23),t(3;12), +3, +3,der(4)t(4;?) 
(q27;?), +der(4),del(5)(q23q34),5p+ 
(18q::5q), +5p+, +6q-(6p::16p),+6q-, +6q-,+ 7, + 7, 
t(8;14)(q21 ;q23),t(8;14), +8q-(del(8)(q21) or 
der 8p20p), + 8q-, +9p+ [9qter->p11: :?22q11 ... qter), 
+11, + 11, + 12, + 12; +del(13)(q21) +del(13)(q21), 
+14, + 14, + 17, + 17, + 18, + 18, + 19, +21, +21, +ring, 
+mar, + fragments. 
Me-57 N P, DM 30 30 0 46,XY 
Me--61 Ill P, cult. 8 4 0 49,XY, 1 p-q + (1 pter->p33::1 p22 ... q42::13q11 ... qter), 
4(-Y) 3p-(3qter->p11 ::?), +5p-q-(del(5)(p12p14) and 
81 cult. 8 8 del(q11 q13)), +del(8)(q12q21 ),·1 0,11 p+ (int. 
B2 cult. 13 4(-Y) 9 dup),·13,mar 14(?inv q24q12),17p+,+mar 19 
(?inv p+q-),20q-,21p+,+mar G (?18q-). 
96-97, duplicated stemline (20-25%). 
45,X,·Y (50% of presumably normal cells). 
Me-62 Ill P, DM 8 7 1 51 -53,XY, +del(3)(p21),·4(50%),del(6)(p22), +8, 
(Me-69) cult. 16 13 3 +9, + 12, + 15, + 16,+21 ,non-clonal t,i.e.t(4;10) 
(p15;q21)(one cell) and t(3;8)(p;p)(one cell). 
Me-64 II P, DM 5 0 5 75-81 ,Xq + ,Y, +del(1 }(q12), +der(1)t(1 ;6}(q11 ;p11), 
cult. 10 0 10 + 1, +2, + inv(2}(p23q12?),der(3)t(3;12}(q24 or 
25;q11), +der(3)t(3;12), +4, +de1(5}(q21 q33), 
+5, +6, + 7, + 7,i(8q), +i(9q), + 10p+ (21q?), +del(11) 
(q21), + 12, + 12q + ,i(13q), +der(13)t(7;13) 
(p11 ;p11), + 14p+ (?21 q), + 14, + 15q+ (tand dic.t 
(15q;13q), + 16, + 16, + 17p+ (18q::17q), + 17, + 18, + 19, 
+20,+20,+21p+(18?),+22p+(7p or 11p),+22p+, 
(+22}(+22). 
70-71 after culture: variable unstable karyotype 
with additional, complex rearranged markers. 
Me-67 N P, cult. 16 16 0 46,XY 
Me-72 I P, DM 12 7 5 42,XY,del(1)(p32),inv(1)(q23q43),del(3)(p13p24), 
B cult. 7 0 7 -4,del (6}(p22), del (6}( q 16), + der(6)t(6; 17) 
line 28 0 28 (q23;q11),der(8)t(8;16?}(p11 ;p11 ?),del(9}(p12), 
-13,der(13)t(4;13}(q11 ;p11),-14,der(16)t(16; 
17)(p11;q11)-17,-17,-22,+mar (22q-? or 17p?). 
Me-73 I P, DM 11 0 11 43-44, mar(X),Y,-1 ,del(1)(q42),-2,der(3)t(3;5) 
cult. 14 11 3 (q22;q13),-4,4p+ ,del(5) (p14) ,5q-,del(6) 
(q12q24),del(7)(q35),(-7),8q +,-9, 10p+ (2q?), 
del(11)(q21),11q+[11pter-+q24::20 like], 12q+[ 
12pter-+q22::?HSR], 13p+ (2p?), 15q+, 15q-,mar 18 
or -18,-19,-21,-22,+ fragments, + ring, + 2 to 
.4 markers G and E size (14%). 
74-86, same markers (57%). 
147-155, same markers (29%). 
Me-77 N P1, DM 26 0 26 46,XY 
(Me-43) P1, DM 16 0 16 
(Me-54) P3, cult. 21 5 16 45,X,-Y (5 cells)/92,XXYY (4 cells). 
Me-78 N P, DM 14 0 14 46,XY 
(Me-76) cult. 13 0 13 
<0 
...... 
CD 
[\) 
Me-82 Ill B, cult. 11 0 11 48-SO,XX, + 5, + mar(7p: :22q),der(14)t(8;14) (q13;p11) 
der(14)t(8;14), +20, + 21 ,with extensive inter-
cellular variations, and variable structural 
changes of chromosomes 1 p, 1 q, 12p, 22 etc. 
94-98, same markers (50%). 
Me-83 I P, DM 11 8 3 42,XY,1 p-, 1q-p+ (inv 1 p11 q31 ,del 1q),2p+ (2qter 
cult. 8 0 8 -+p21: :?12q),del(2)(q31 q34,der(4)t(4;22) 
q11 ;q11 ), +der(4)t(4;15)(q13;q21),del(5) 
(q22q34),t(6;17)(p21 ;p12), +der(6)t(6;17),-B, 
-7,-8,del(9)(p12),del(9)(p13),-10, 11 p+ 
(11 qter-+p15::?),der(12)t(7;12)(q22;q23)-14, 
-15, 18q + [18pter-+q22::11 q21-+pter),20p+ ,-22, 
+marE (in pleural effusion cells). 
75-85,XXY, duplication of most markers, 
in addition no 2p+,-3,2x10q+(10pter-+q23::? 
12q),1x 14q-, 2x 18q-,-Y,+ring,+mar C (inv 12?) 
(in cultured cells). 
Me-84 I P, DM 16 0 16 38,X,-Y, 1 p-(1 q::13q),-3,-4,inv(6)(p23q11 or q12), 
cult. 8 1 7 -9,der(1 O)t(Y;10)(q12;q24 or 25),-11, 13p+ 
(13q::3q),-13,-16,der(17)t(9; 17) (q12;p13) 
-18,der(22)t(11 ;22)(q13.1 ;q13.3). 
76, same duplication of stemline (20%). 
B cult. 15 10 5 81-98,XXY, one copy of markers only = fusion 
of normal diploid with abnormal hypodiploid: 
5 cells from biopsy culture. 
line 20 0 20 38, same stemline with t(6p+ ;11 p-), +der(11)t 
(11 ;22),-der(22)t(11 ;22). 
76, same duplication of stemline (5%). 
Me-85 I P, DM 16 4 12 43-46,XY,del(1)(p11 p31), 1 q+ ,inv(2)(p22q11), 
cult. 20 20 0 del(3)(p13),3q+ ,der(5)t(5;7)(q12;q11), 
del(6)(q16), del(6)(q21 or q22), del 7p15, 
-7,-9, dup(12)(q13q22),del(12)(q12q15), 
13p+ (?21),-14, 14p+, 15p+ (?7p),de;(16)(q22), 
+marC (67%) 
75-87 same with duplication of most markers excepted: 
not present: 1p-,1q+,der(5),15p+ 
new markers in one or 2 copies: 
1 q-(1 pter-+q24: :?) , 2p-,del (5)( q12q34), 1 Op +, 
mar 15(? inv q13q25),17p+, del(18)(q22q23) (33%). 
Me-86 N p cult. 30 30 0 46,XY 
Me-88 II P, DM 11 9 2 73,XXX, + inv. (2) (p24?q32), + del(3) (p22p24) 
+del(3), +5, +5, +5, +del(6)(q16?q24?), + 7, 
+8p+ ,-9, 1 Op-, + 12p+ (13q), 13p+, + 15,-16, 
II +17,+ 17, +17q+, + 17q+, + 18q-, +20, +20, 
+20,+21,+21,+1arge mar,+2 small mar. 
Me-94 N P, DM 10 10 0 46,XY 
Me-95 Ill P, DM 16 8 8 54-58,XY,t(3;18)(p14;p11), +5, + 7,+ 7, +8 or 
(Me-97) 81, cult. 30 30* 0 8p-(19p?::8q), + 11 ,del(12)(q21 q23), 13p+, 
82, 2 cult. 13 4 9 -15,+2 mar(15)(inv del),+16,der(19), 
line 11 0 11 t(11 ;19)(q13;p12?), + 20q +, + 20q+ ,der(22) 
t(1 ;22)(q11 ;q11). + markers (ring or Cor D). 
*45,X,-Y in 24/30 cells from 81. 
Me-96 II 81, cult. 23 0 23 72-78,XXYY, +del(1)(q11), +2,+3,+4, +5, +5, +5, 
+6q-(6p::11 p?), +6q-, + 7q-(7p::16q?), + 7q-, 
+8p+, +8p+ ,del(9)(p21),-9,( + 11), + 12,(-13), 
+ 14, 15q+, 15q+, +17, + inv(18)(p11 q21), +inv 
(18), + 19, +20, +20, +20, +21' +21' +22q-, +22q-, 
+1-2 large marker (1q::HSR),+dm,+variable 
markers eg. 1p-(5p::1q)14p+,22p+,19p-q-, 
etc.).ln general unstable karyotype, chromosome 
number varying between 59 and 80 and in 3 cells 
122 to 140 with duplicated stemline. 
line 17 0 17 Same stemline with add,itional markers: 2p- (1 copy), 
17p+ (2 copies), 4 copies # 4 and 2 copies # 5. 
Me-100 I P, DM 4 0 4 46,XX,dup(1)(p12p22),del(3)(p21 p24) (1 cell) 
cult. 17 2 15 45,XX,dup(1 )(p12p22),del(3) (p21 p24),t(3;4) 
p(21 ;q34),dei(10)(p11 ),del(17)(p12),-22 
CD (41%). 
w 
<0 
.j>. 
Me-102 
Me-104 
(Me-113} 
Me-105 
II 
P, DM 
cult. 
P, DM 
cult. 
P, cult. 
21 
14 
15 
20 
45 
4 
4 
3 
5 
30 
17 
10 
12 
15 
15 
89,XXXX, same stemline, tetraploid (1 cell}. 
41 same markers and in addition -X,-1,-9,-12,-
15,+mar 1p-q+(? inv dup 1q} 
der(10}t(10;12}(p15;q12} (47%}. 
41-42,XY,-1 ,del(3} (p21 ),-4,der(5)t(5;19?}(q33; 
p11},del(7}(q21 or q22}, der(8}t(8;19?) 
(q23;q11}, 9p+ (4q or HSR},ins(11}(q22;p11 
p12},del(12}(q12q23},der(13},t(1 ;13} 
(p11 ;q11},-14,-15,-16, 17p+ (?dup), 18?,-19, 
20?,1(21 q},-21 ,22p+ (HSR), + ring(?15}, +3 
discrete small markers. 
80-82, same with stemline duplication (24%). 
90,XXY, +del(1}(q22}, +del(1}(q22}, +2, +2, +3q-
(3 pter->q13::?}, +3q-, +der(4}t(3;4}(q21; 
q35}, +der(4}t(3;4}, +6,t(7 + 14}(q35;q12}, 
t(7;14},+ 7,+ 7,+ 7,+ 7, +del(7}(q22},+del 
(7}( q22}, + mar(8}, + mar(8} ,del (9}(p21), 
+del(9}(q13q33},+del(9}(q13q33},+ 11, + 11, 
+ 12, + 12, +der(13},t(13;16}(p13;q11}, +der 
(13}t(13;16}, + 14, + 14, + 15, + 16q-(16pter-+ 
cen::?), + 16q-; + 16q-, + 17, + 17, + 18, + 18, + 19, 
+ 19,+20,+20, +21, +21,+mar. 
175-189, same duplicated stemline (11%}. 
45,XY,dup(1) (q32-+q43},del(1) (p12p31) (q31), 
der(2},t(2;15}(p11 ;q15},-3,-5,?ins(6;3} 
(q16;q13q25},der(6},t(5;6} (q12;q21 ),-7, 
der(7}, t(7; 14) ( q31? ;q21 ?) ,der(9}t(7;9} 
(q22;p21},inv(11 }(q13p14, + del(11}(q13}, 
+inv(11}p+(?13q or 6q}, del(12}(q12},12q+, 
-13,-14,-14, 15s+ ,mar(15},del(16}(q23}, 
der(19},t(12;19}(q21 ;q13}, +21, +mar i(5p}, 
+mar i(17p}. 
1. Patient no. consistently used in text and table, in parentheses no. of additional sampling occurring at another date. 2. N = normal karyotype, no clonal abnormalities 
found, 1: hypodiploid, II: hypotetraploid and Ill: hyperdiploid modal chromosome number. For clinical and pathological data see Tables 2 A, B, C and D. 3. P = pleural 
fluid, A: ascites fluid, B: biopsy, P1, P2, refer to different sampling of same patient. DM = Direct method, cult.: culture, line: established cell line from the same patient's 
material. 4. In parentheses clonal changes observed in only part of the cells. Numerical changes are given relatively to the normal diploid karyotype (46,XY or 46,XX), also 
in the hypotetraploid stemline, thus different from the analyses done in Fig. 3 (see text). 
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SUMMARY 
Seventeen human malignant mesothelioma cell lines were isolated from 61 
samples (46 effusions, 9 biopsies and 6 tumors obtained at autopsy) collected from 
patients with a confirmed malignant mesothelioma. The method used is given in detail. 
Cytogenetic analysis of growing cultures is the best indicator to determine whether the 
observed proliferation concerns malignant or normal mesothelial cells. The addition of 
epidermal growth factor (EGF) and hydrocortisone (HC) or EGF alone, to the culture 
medium increases the chances of successful isolation of a malignant mesothelioma cell 
line. 
INTRODUCTION 
Human malignant mesothelioma is a neoplasm originating from mesodermally 
derived tissues of the coelomic cavities. Epidemiological studies have established that 
exposure to asbestos fibers is the primary cause of mesothelioma in the industrial 
world (Wagner et al., 1960). The latent period for mesothelioma ranges from 15 to over 
40 years and the incidence of malignant mesothelioma is increasing. At initial 
presentation most malignant mesothelioma patients have a pleural or peritoneal 
effusion. A reliable diagnosis of malignant mesothelioma on effusions by routine cyto-
logy is limited by the difficulty of distinguishing malignant mesothelioma cells from 
benign mesothelial cells and adenocarcinoma cells (Whitaker and Shilkin, 1984). Even 
with the use of additional techniques such as immunocytochemistry, many malignant 
mesotheliomas are still not diagnosed until autopsy. 
Viable tumor tissues of malignant mesotheliomas for cell biological and 
cytogenetic investigations are difficult to obtain. Several groups have reported the 
successful transplantation of human malignant mesotheliomas into nude mice 
(Chahinian et al., 1980; Reale et al., 1987), but so far the production of in vitro growing 
human malignant mesothelioma cell lines has been extremely difficult. Only a few 
permanent human malignant mesothelioma cell lines have been produced (Ohnuma 
et al., 1979; Behbehani et al., 1982; Tibbets et al., 1984; Shanfang et al., 1985; 
Anderson et al., 1986), and detailed data concerning the isolation procedure have not 
been published. 
Over the last few years we have established a panel of 17 human malignant 
mesothelioma cell lines. The characterization of 3 of these has been described (Versnel 
et al., 1989). We now report in detail the procedures and methods used for the 
isolation of these mesothelioma cell lines from pleural effusions and solid tumor mate-
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rial, as well as the methods of culturing normal mesothelial cells from non-cancerous 
effusions. These cell lines are extremely useful tools for investigation of the properties 
of malignant mesothelioma cells and the development and application of new diag-
nostic methods. 
MATERIAL AND METHODS 
Processing of patient material 
Pleural effusions 
Pleural fluids were collected under sterile conditions in 50-ml tubes with 5,000 
I.U. heparin (Organon, Oss, The Netherlands) and 5 ml Ham's F10 medium (Gibco, 
Paisley, UK), the latter being supplemented with 15% fetal calf serum (FCS) and 
antibiotics. After collection, the material was immediately transported to the laboratory. 
The cells were harvested by centrifugation (1 0 min, 200 g) and the cells from 1-2 tubes 
were plated in a 75-cm2 culture flask (Costar, Cambridge, MA). After overnight 
incubation at 37°C the medium containing the non-adherent cells, mostly lymphocytes 
and erythrocytes, was removed and replaced by fresh medium. 
Biopsy and autopsy material 
Autopsy should be performed within 4 hr of death in order to obtain viable 
samples. At autopsy, different sets of instruments were used for incision of the skin 
and removal of the anterior part of the chest wall. Tumor material was obtained 
preferably from lateral parts of the pleural cavity which had not been previously 
touched by instruments. Material from different parts of the primary tumor and 
metastases was transferred to 50-ml tubes with 5 ml F1 0 medium containing 15% 
FCS and antibiotics. In the culture room the material was placed in a Petri dish (60 x 
15 mm, Costar, Cambridge, MA) and fat, necrotic tissue and lung tissue were 
removed. For each sample new instruments were used. Pieces of approximately 2 
mm3 were obtained by mincing with scissors and incubated (3rC, 5% C02 in air) 
overnight in 1 ml F10 medium with 15% FCS and 8 mgjml collagenase (125 U/mg, 
Cooper, San Diego, CA). The digested material was resuspended with a pipette and 
incubated for another 20 min (3rC). After transfer to a tube and centrifugation (5 min, 
200 g) the cells were plated in a Petri dish with 2 ml F1 0 medium containing 15% FCS. 
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Culture conditions 
Cells were cultured in F10 medium with 15% fetal calf serum (FCS), 0.1 mgjml 
streptomycin-sulfate (Biochrom KG, Berlin, FRG) and 102 Ul/ml penicillin G sodium 
(Gist-Brocades, Delft, The Netherlands). If enough patient material was available, the 
cells were plated on 3 different media: F1 0 medium with 15% FCS, F1 0 medium with 
15% FCS and 10 ngjml epidermal growth factor (EGF; Collaborative Research, 
Lexington, MA) and F10 medium with 15% FCS, 10 ngjml EGF and 0.4 p,g hydrocorti-
sone (HC; Pharma Chemie, Haarlem, The Netherlands). 
Subcloning was performed by limiting dilution in 96-well tissue culture plates 
(Costar). 
Cytogenetics 
For cytogenetic studies of cells in pleural effusions, the fluid was collected in 
50 ml tubes containing 5 ml F1 0 medium with antibiotics, heparin and 1-2 p,g colce-
mid/tube (Gibco). After 30-60 min the cells were centrifuged and metaphases harves-
ted according to standard cytogenetic procedures. This method is referred to as the 
"direct method". 
Metaphase cells from the cultures were obtained by shaking culture flasks with 
exponentially growing cells and collecting the supernatant. After addition of colcemid 
for 15 min the metaphases were harvested. RFA~, QFQ- and GTG-banding techniques 
were used and the karyotype was established according to the ISCN (1985). 
Detection of intermediate filaments 
Gel electrophoresis, immunoblotting and immunofluorescence were performed 
according to Broers et al. (1986). Antibodies used were the chain-specific antibodies 
RCK102, RCK105, RV202, RGE53, RCK106 and LP2K (Ramaekers et al., 1983; 1987; 
Lane et al., 1985). 
RESULTS 
Patient material 
Of the 117 samples collected from patients with suspected malignant meso-
thelioma, 61 were derived from 51 patients whose malignant mesothelioma was 
diagnosed on the basis of cytology, histology andjor electron microscopy (Table 1). 
The diagnosis of malignant mesothelioma was never based on cytology alone. To 
enable a definite diagnosis to be made, the availability of material processed for 
histology andjor electron microscopy was considered essential. The samples not 
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TABLE I 
Incidence of malignant mesothelioma for collected patient material and isolated cell lines 
Collected patient material 
Effusions 
Biopsy 
Autopsy 
85 
21 
11 
* Five cell lines were isolated from 2 autopsies. 
Diagnosis Successful isolation 
of of a malignant 
mesothelioma mesothelioma cell line 
46 10 
9 2 
6 2* 
diagnostic for malignant mesothelioma were effusions from adenocarcinoma metas-
tases (5), from other malignancies (3), or from effusions reactive to lung and pleural 
infections (11); in the case of 29 samples the diagnosis was not determined. From 
the 61 samples derived from 51 malignant mesothelioma patients (46 effusions, 9 
biopsies and 6 autopsies) 17 human malignant mesothelioma cell lines were isolated. 
Method of establishment of malignant mesothelioma cell lines 
From all collected samples cultures were started as described in "Material and 
Methods". At the time of appearance of small groups of growing cells, these were 
subcultured by trypsinization in the same flask or dish and, when confluence was 
reached, transferred to a new flask. Cells were stored in liquid nitrogen and 
cytogenetic analysis was performed. When a small percentage of chromosomally 
abnormal cells was found, immediate subcloning was performed to prevent overgrowth 
of malignant cells by normal mesothelial cells, so that a fully abnormal cell line could 
be isolated. Growing subclones were screened again for cytogenetic aberrations. 
Cultures showing no growth or only cytogenetically normal cells were kept for at least 
2 months as we had observed in a few instances that the malignant mesothelioma cells 
started growing after 2 months. 
Malignant mesothelioma cell lines from autopsy and biopsy material 
Four malignant mesothelioma cell lines were isolated from tumor obtained at 
autopsy of 2 malignant mesothelioma patients, and 2 others from pleural biopsies 
(fable II). These cell lines were isolated on F10 medium with 15% FCS and no other 
supplementation. 
Isolation of cell lines from autopsy material was often hampered by infections 
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from contiguous lung tissue. In fact, metastases outside the thoracic cavity were a 
better source of material, as demonstrated by the 4 cell lines Mero-48a, b, c and d 
obtained from a single patient (fable II). These 4 cell lines have similar growth patterns, 
morphology and cytogenetics (fable Ill). 
Biopsies were found to be a poor source of material for cultures: they are 
usually very small and sometimes had been obtained blindly with an Abrams needle. 
Usually a number of very small biopsies are taken, and pathological diagnosis cannot 
be performed on the same sample that is used for culture. 
Malignant mesothelioma cell lines from effusions 
Ten malignant mesothelioma cell lines were isolated from 7 effusions under 
varying culture conditions (fable IV). We found no direct relationship between the 
percentage of tumor cells (varying from morphologically not detectable to 60%) and 
the success-rate of establishment, probably because very cellular fluids often contain 
many non-viable cells. Hemorrhagic fluid seemed unfavorable for the isolation of cell 
lines. 
Connell and Rheinwald (1983) reported that the addition of EGF and HC 
promotes the growth of normal mesothelial cells. Initially we did not add EGF and HC 
to the culture medium used for the establishment of mesothelioma cell lines. We found, 
however, that the growth of the malignant mesothelioma cell lines Mero-14 (from 
effusion) and Mero-25 (from autopsy material) was inhibited by EGF and HC, while 
TABLE II 
Origin of isolated human malignant mesothelioma cell lines from solid tumor material 
Cell line Patient material Histology of tumor 
Mero-25 Autopsy pleura Biphasic 
Mero-48a Autopsy pleura Biphasic 
Mero-48b Omentum Epithelial 
Mero-48c Liver Epithelial 
Mero-48d Peri card Biphasic 
Mero-72 Biopsy pleura Biphasic 
Mero-96 Biopsy pleura Fibrous 
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Table Ill 
Cytogenetic data of the malignant mesothelioma cell lines 
Cell lines 
Mero-14(2) 
Mero-25(2) 
Mero-41 (2) 
Mero-48a,b,c,d 
Mero-72 
Mero-82 
Mero-83 
Mero-84a,b,c 
Mero-91 
Mero-95a,b 
Mero-96 
Number of 
chromosomes 
(range) 
72-75 
127-140 
68-75 
71-75 
41-43 
48-50/94-98 
42/75-85 
38/76 
42-43/84-86 
54-58 
55-78 
Consistent numerical 
change (1) 
-4,-10,· 13,-18,· 19,-20,-21 
-4, "7, -9, "12, "13, "14, "15, "18, "19 
-2,·4,--6,-13 
-10,-14,-16 
-4,-13,· 14,-17,·22 
+5, +20, +21 ,-X 
-7,--8,-1 0,· 14,-15,·22 
-4,-9,· 11 ,· 13,· 16,·18 
-2,-4,-22 
+5,+ 7,+ 7, +11, + 16 
+2, +5,-7, +8,-9, + 14, +20, +21 
Number of structural abnormalities 
in chromosomes number: 
3 5 6 9 11 12 13 17 22 other 
2 3 
2 
1 2 
1 1 
2 1 
2 
3 
2 2 
2 
3 
2 2 
2 
2 
2 
4 
7 
2 
2 
2 
3 
5 
3 
1) Reference karyotype diploid/tetraploid respectively· unidentified markers and rearranged chromosomes are not included, 2) Full description of karyotype in 
Versnel (1989). 
TABLE IV 
Characterization of mesothelioma cell lines isolated from pleural effusions 
Malignant meso- % of morphologically % of cytogenetical- Growth of cytogenetically abnormal cells 
thelioma cell detected tumor cells ly abnormal cells in culture medium2 SUQQiemented with: 
lines isolated cells in the effusion in the effusion 1No additions EGF EGF + HC 
Mero-14 <5 18 + ND3 ND 
Mero-41 50 40 + 
Mero-64 <5 100 + 
Mero-82 <5 ND ND + 
Mero-83 60 10 + 
Mero-84a,b,c 30 100 + + + 
Mero-95a,b 50 40 + ND + 
1detected with the direct method, 2F10 + 15% FCS, 3ND: not done. 
addition of EGF only slightly enhanced their proliferation (Versnel et al., 1989). After 
this observation we started to culture malignant mesothelioma cells not only in F1 0 
medium with 15% FCS but also in the same medium supplemented with EGF or with 
both EGF and HC. Seven cultures of pleural effusions resulted in the successful 
isolation of malignant mesothelioma cell lines. Five cell lines were isolated from medium 
supplemented with EGF and HC, 2 from medium supplemented with EGF only and 3 
from unsupplemented medium (Table Ill). The addition of EGF and HC or EGF alone 
to the medium used for the isolation of malignant mesothelioma cell lines did increase 
the overall efficiency of establishment. After their establishment, none of these cell lines 
required EGF and/or HC for growth. Cell lines isolated independently under different 
culture conditions but originating from the same effusion show similar cytogenetic 
features. 
Normal mesothelial cell cultures 
Non-cancerous effusions, mostly from patients who had heart failure were used 
for the establishment of normal mesothelial cell cultures. These effusions were cultured 
on medium supplemented with EGF and HC according to Connell and Rheinwald 
(1983). The normal mesothelial cultures had a limited lifespan of approximately 15 
passages and proliferating cells had a normal karyogram. Cytological analysis was 
consistent with the mesothelial morphology of the cells and expression of cytokeratins 
and vimentin ·was found. Normal mesothelial cells were also often seen in pleural 
effusions of malignant mesothelioma patients. These cells quickly became adapted to 
in vitro conditions and tended to overgrow the malignant mesothelioma cells, which 
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emphasizes again the need for early subcloning in the procedure of isolation of 
malignant mesothelioma cell lines. 
Characteristics of the malignant mesothelioma cell lines 
After establishment, there was no intrinsic difference between lines derived from 
effusion cells or from solid tumor material. Each cell line has its own in vitro properties 
but they share features characteristic of their (malignant) mesothelial origin. 
i. Cell morphology. The malignant mesothelioma cell lines showed a spindle shaped 
or epithelial appearance with numerous nucleoli. Multinucleate cells and mitotic 
figures did frequently occur in all malignant mesothelioma cell lines. These 
characteristics were absent in cultured normal mesothelial cells. 
All malignant mesothelioma cell lines expressed the epithelial membrane 
antigen (EMA) which was not present on cultured normal mesothelial cells (Van 
der Kwast et al., 1988). Figure i shows the morphology of the malignant 
mesothelioma cell lines Mero-25 and Mero-48b. Ultrastructural studies of Mero-14, 
Mero-25 and Mero-41 showed that these cell lines have characteristics consistent 
with malignant mesothelioma (Versnel et al., 1989). 
2. Growth properties. The doubling time of the malignant mesothelioma cell lines 
was variable. For some cell lines the doubling time was approximately 24 hr (e.g. 
Mero-82) and for others (e.g. Mero-25) it was 48 hr. The malignant mesothelioma 
cell lines did not undergo senescence, which occurred with cultured normal 
mesothelial cells at approximately passage 1 5. The characteristics of the cell lines 
were not changed by freezing and thawing using an established procedure for 
conservation of viable cells (10% DMSO, liquid N2). 
3. Intermediate filament expression. All malignant mesothelioma cell lines expressed 
several cytokeratins and vimentin as detected with specific mAbs against these 
filaments. Three cell lines (Mero- 14, Mero-25 and Mero-41) were studied for 
intermediate filament expression by immunoblotting. These results confirmed the 
presence, detected by immunofluorescence of vimentin and the cytokeratins 18, 
8, 7 and 19. These findings are consistent, although not exclusive for the 
mesothelial origin of the cell lines. 
4. Cytogenetics. All cell lines exhibited an abnormal karyotypes (Fig. 2, Table Ill). 
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At the beginning, only cell lines with a high modal chromosome number could 
be isolated. Later on, hypodiploid and hyperdiploid lines were also successfully 
established. Each cell line has its own specific karyotype with specific markers 
which are similar to those found in fresh tumor cells of this particular patient, and 
which persist after subcloning. Tetraploidization is responsible for the high or 
biphasic modal chromosome number as most of the markers are found in 
duplicate. Intercellular variation exists and is mainly due to irregular loss of chro-
mosomes, particularly of normal chromosomes with a high copy number. An ex-
ample of hypodiploid karyotype is given in Figure 2. Analyses of the data did not 
reveal a particular translocation or abnormality specific for this type of tumor. 
Figure 1. 
Figure2. 
Phase contrast morphology of the malignant mesothelioma cell lines 
Mero-25 (a) and Mero-48b (b) in tissue culture. 
Hypodiploid karyotype from Mero-84: arrows indicate structural rearrange-
ments. 37, X, t(Y;10)(q12; q24 or 25), 1p-(13q::1q), -3, -4, inv(6), -9, -11,-
12, 13p+(13q::3q), -13, -16, der(17) t(9;17)(q12;p13}, -18, -19, der(22) 
t(11;22) (q13.1;q13.3}. Loss of 12 and 19 is incidental in this particular 
cell. The large majority of Mero-84 metaphases showed a/so loss of the 
der(Y). The der(13} has been aligned to chromosome 11 because of 
partial homology. 
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Preferential loss of some chromosomes (e.g. 4) and frequent involvement of some 
chromosomes (e.g. 1, 3, etc.) in marker formation is indicated in Table Ill. 
5. Tumorigenicity. The malignant mesothelioma cell lines Mero-14, Mero-41 and 
Mero-48a, b, c were repeatedly injected into 8- to 12-weeks-old BALB/c nujnu 
female mice (Bomholtgard, Rij, Denmark) subcutaneously or intraperitoneally, 
but never produced tumors. S.c. injection of 108 cells of Mero-25 produced a 
tumor on one occasion (size over 1 cm3). Histologically, this tumor exhibited the 
same features as the original tumor cells of the patient Me-25 and it was possible 
to grow these cells in vitro. Further passage through nude mice was not 
attempted. Growth in semi-solid medium (methylcellulose 3%) of Mero-14 and 
Mero-25 was attempted a few times and was never successful. 
6. Oncogene expression. The cell lines were tested in Northern blot analysis for 
expression of oncogenes including c-myc, c-H-ras, Ki-ras, c-fms, but no significant 
differences from normal mesothelial cells were found. Interestingly, elevated 
expression of the c-sis (PDGF-B) and PDGF A-chain genes compared to normal 
mesothelial cells has been found in 10 malignant mesothelioma cell lines studied 
to date (Versnel et al., 1988). 
DISCUSSION 
So far, 17 human malignant mesothelioma cell lines resulted from the 
processing of 61 samples from patients suffering from malignant mesothelioma. The 
addition of EGF and HC or EGF alone to the culture medium appears responsible for 
the elevated success rate since these growth factors were employed. However, their 
effect on individual samples is unpredictable. When Mero-83 was established, no 
proliferation of malignant mesothelioma cells was detected in medium with EGF and 
HC, while in the culture medium with EGF only a malignant mesothelioma cell line was 
isolated. On the other hand, for Mero-41 and Mero-64 our observations were different: 
cultures in medium with EGF and HC resulted in malignant mesothelioma cell lines 
while in the cultures with EGF alone no malignant growth could be detected. This is 
why no supplementation was used when biopsies were cultured. The size of the 
samples was too small so that one type of culture had to be chosen. We know that 
medium with EGF and HC also stimulates growth of normal mesothelial cells. 
Cytogenetic analysis of growing cultures is the best indicator of whether the 
observed proliferation can be attributed to the malignant mesothelioma cells or to 
normal mesothelial cells. After subcloning, each malignant mesothelioma cell line was 
100% cytogenetically abnormal and had a quite stable karyotype. The cytogenetic 
aberrations in the malignant mesothelioma cell lines are consistent with the karyotype 
of the tumor cells present in the original patient material. The various malignant 
mesothelioma cell lines obtained from pleural effusions and solid tumor tissue 
proliferate in vitro without showing signs of senescence. 
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ABSTRACT 
Three human malignant mesothelioma cell lines, designated Mero-14, Mero-25 
and Mero-41, have been isolated from effusions and from autopsy material of con-
firmed cases of malignant mesothelioma. Light and electron microscopy, cytogenetics, 
growth requirements, and intermediate filament expression of these cell lines were 
studied and, where possible, compared with the original tumor material of the patient. 
Cytologic and ultrastructural morphology was consistent with the mesothelial nature 
of the cells. All cell lines displayed a hyperdiploid karyotype similar to that of the tumor 
cells obtained directly from the patient. All three malignant mesothelioma cell lines had 
marker chromosomes 1, 3, 9 and 22, as well as other markers that were occasionally 
present in these cell lines and in other malignant mesotheliomas studied. Growth 
kinetic studies in medium supplemented with epidermal growth factor (EGF) showed 
increased proliferation and a decreased proliferation in medium supplemented with 
hydrocortisone (HC) or EGF plus HC. The three malignant mesothelioma cell lines 
were positive for the cytokeratins 7, 8, 18, and 19 based on immunofluorescence and 
immunoblotting tests with chain specific monoclonal antibodies. The characteristics of 
these cell lines support the assumption that Mero-14, Mero-25 and Mero-41 are 
derived from malignant mesotheliomas and have retained their original character. 
INTRODUCTION 
Human malignant mesotheliomas are rare tumors that occur most frequently 
in the pleura and less frequently in the pericardium and peritoneum. A strong rela-
tionship has been found between asbestos exposure and the development of a meso-
thelioma (1). Despite better controlled use of asbestos, the incidence of mesothelioma 
is still increasing, because of the long lag time between asbestos exposure and the 
appearance of the tumor. 
The first symptom of malignant mesothelioma is usually a pleural effusion. 
Cytologic diagnosis is difficult as there are no consistent morphologic criteria for 
differentiation between benign and malignant mesothelial cells on the one hand and 
adenocarcinoma cells on the other (2). Additional techniques, such as immunocyto-
chemistry, electron microscopy, morphometry, and chromosomal analysis have proved 
to be useful but are still not sufficient to establish the diagnosis of malignant 
mesothelioma with certainty in all cases (3-6). 
Biochemical analyses of the cytoskeletal composition of mesothelioma cells 
have suggested the usefulness of intermediate filament typing. Cytokeratin 5 seems 
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to be a valuable marker for discriminating between malignant mesotheliomas and 
adenocarcinomas (7). Coexpression of vimentin and cytokeratins often occurs in 
malignant mesotheliomas and has also been proposed to be discriminative between 
mesotheliomas and adenocarcinomas (8-10). However, some of the latter cancers 
may occasionally show simultaneous expression of both cytokeratins and vimentin 
(11-14). Specific tumor cell lines are invaluable tools to gather more insight into the 
cellular and molecular biologic characteristics of malignant mesotheliomas. We report 
here on three continuously growing malignant mesothelioma cell lines that were 
established from patient material. Light and electron microscopy, cytogenetics, growth 
requirements and intermediate filament expression patterns of these cell lines have 
been studied and, where possible, compared to the original patient material. 
MATERIAlS AND METHODS 
Patient material 
Malignant mesothelioma cell lines were derived from pleural effusion of the 
patients Me-14 and Me-41 and from autopsy tumor material of patient Me-25. All three 
patients were men over the age of 60, with a history of asbestos exposure. All patients 
presented with dyspnea, weight loss, and a large pleural effusion on chest x-ray. There 
were no signs of other malignancies. All patients died within 1 year after the first 
symptoms. 
Isolation of cell lines and growth conditions 
Mero-14 and Mero-41 were isolated from the pleural effusion of patients Me-14 
and Me-4 i, respectively. Mero-25 was isolated from autopsy material of patient Me-25. 
The effusion cells were collected in 50 ml tubes with 5000 IU heparin (Organon, Oss, 
Holland) and 5 ml Ham's F10 medium (Gibco, Paisley, United Kingdom) supplemented 
with 15% fetal calf serum (FCS), glutamine, and antibiotics. The cells were plated at 
high density and after 24 hours the medium containing non-adherent cells was 
replaced with fresh medium. The pleural fluid of patient Me-41 was also cultured in F1 0 
medium supplemented with 10 ngjml epidermal growth factor (EGF; Collaborative 
Research Inc., Lexington, MA) or 10 ng EGF and 0.4 ttg/ml Hydrocortisone (HC). 
When a continuously growing culture was established, cells were routinely 
subcultured two or three times a week by trypsinization. These three cell lines were 
the first three we isolated from a panel of seventeen human malignant mesothelioma 
cell lines (15). The investigations reported here were done after stable establishment 
of the cell lines between 3 and 6 months after sampling of material. The lines have 
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been frozen and thawed a number of times and have been subcloned later on. Cyto-
genetic analysis and intermediate filament expression were studied again 1 year later 
and the findings were consistent with earlier studies. 
Cytology and transmission electron microscopy 
For diagnosis, routine cytology was applied as described previously (2). For 
transmission electron microscopy, the sediments of pleural effusions were fixed in 
phosphate-buffered 4% paraformaldehyde (pH 7.2) and 1% glutaraldehyde, postfixed 
in 1% (wjv) Os04 in 0.1 M phosphate buffer (pH 7.2) for 12 hours at 4°C, rinsed in 
the same buffer, acetone dehydrated, and Epon embedded. Cell lines cultured on 
Melinex plastic (I.C.I., Rotterdam, the Netherlands) were similarly prepared for routine 
transmission electron microscopy. 
Cytogenetics 
For cytogenetic studies of cells in pleural fluid, the effusion was collected in 
50-ml tubes containing heparin and 1-2 f.Lg colcemid per tube (Gibco, Paisley, United 
Kingdom). After 30-60 minutes metaphases were harvested following standard 
cytogenetic procedures. 
For cytogenetic studies of cell lines, metaphase cells were obtained by shaking 
the culture flasks containing exponentially growing cell cultures. The supernatant was 
collected in centrifugation tubes and Colcemid was added for 15 minutes. The 
metaphases were then harvested as in the direct method. RFA-, QFQ- and GTG-
banding techniques were used, and the karyotype was established according to the 
ISCN (1985). 
Growth kinetics 
Before the growth kinetic assays were performed, the cells were cultured for 
at least 10 days in FiO medium with 15% FCS and EGF, EGF plus HC, or HC only. 
Cells were cultured sixfold (4000 cells/culture) in the appropriate media in a 96 well 
tissue culture plate. At 18 hours before harvesting 3H-thymidine (0.5 f.LCi/culture) was 
added and the samples were harvested on days 2, 3, 4, 5, and 6, respectively. 
lmmuno(cyto)chemistry of intermediate filament proteins 
The intermediate filament protein expression patterns of the three cell lines 
were assayed by indirect immunofluorescence and Western blotting. Monoclonal 
antibodies and antisera that recognize various subsets of cytokeratins, vimentin, 
desmin, and controls were used. The specificity of the antibodies is given in Table 1, 
together with references to their preparation and characterization (16-20). The 
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numerical designation of the cytokeratins refers to the catalog of Moll et al. (21). The 
indirect immunofluorescence technique was performed as described previously (16). 
Gel electrophoresis and immunoblotting assays 
Cells were harvested from 75 cm2 culture flasks, spun down using a MSE Minor 
centrifuge at 1200 g for 5 minutes, washed once with PBS and stored at - 20°C until 
use. Gel electrophoresis and immunoblotting were done essentially as described by 
Broers et al. {20). 
TABLE 1 
Intermediate filament protein (IFP) expression by cell lines Mero-14, Mero-25 and Mero-41 as detected 
by indirect immunofluorescence, using specific antibodies 
Antibody IFP recognized Mero-14 Mero-25 Mero-41 References 
pKer Several cytokeratins + + + (16} 
RCK102 Cytokeratins 5 and 8 + + + (18} 
RGE53 Cytokeratin 18 + + + (17) 
RCK106 Cytokeratin 18 + + + (17} 
RCK105 Cytokeratin 7 + + + (18} 
LP2K Cytokeratin 19 +(5% of + + (19} 
the cells) 
RKSE60 Cytokeratin 1 0 (12} 
pVim Vimentin + + + (12} 
RV202 Vimentin + + + (18} 
RD301 Desmin (20} 
FITC conjugated 
rabbit anti-
mouse-lgG 
FITC conjugated 
goat anti-
rabbit-lgG 
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RESULTS 
Isolation of the cell lines 
Two continuously growing cell lines called Mero-14 and Mero-25 were isolated 
in F1 0 medium with 15% FCS, from the effusion and autopsy material of patients Me-14 
and Me-25, respectively. The pleural effusion of patient Me- 41 was cultured in F10 
medium with 15% FCS, but also in F10 medium with supplementation of EGF plus HC 
or EGF only. In this case, a continuously growing cell line (Mero-41) was only obtained 
with FlO medium supplemented with EGF plus HC. 
Histologic. cytologic. and ultrastructural characteristics of patient material and cell 
lines 
Diagnosis of malignant mesothelioma was established by cytology, histology 
andjor electron microscopy. Clinical findings supported this diagnosis in the three 
investigated patients. 
Histology revealed that patient Me-14 had an epithelial-type malignant 
mesothelioma. At the autopsy of patient Me-25, the pleura and the pericard were 
found to be diffusely infiltrated by cells with a spindle-shaped morphology as well as 
by strands of cells with an epithelial appearance (biphasic pattern). Transmission elec-
tron microscopy also revealed ultrastructural features characteristic of malignant meso-
thelioma, that is the tumor cells showed long slender villi, glycogen granules, and 
extensive intermediate-sized filament arrays. 
The highly cellular pleural effusion derived from patient Me-41 contained several 
morulae of tumor cells with a collagenous core. Tumor cells expressed the epithelial 
membrane antigen (EMA), which is considered a marker for malignancy in serous 
effusions (15). Transmission electron microscopy showed the same ultrastructural 
features characteristic of the mesothelial nature of the tumor cells as described above. 
Cell line Mero-14 consisted of spindle shaped cells with polymorphic and 
hyperchromatic nuclei, with prominent and atypical nucleoli. Ultrastructurally the cells 
displayed pseudopodiae, but slender villi were not observed. The cytoplasm contained 
some disperse glycogen granules, numerous polysomes, some Golgi membranes and 
several fat droplets. An extensive perinuclear intermediate filament network was 
present in addition to a terminal web of intermediate filaments. 
Cell line Mero-25 displayed large polymorphic nuclei with a coarse chromatin 
pattern. Ultrastructurally, the cells with an epithelial appearance formed several slender 
villi projecting from the surface. Some tight junctions were seen at contiguous areas. 
The cytoplasm contained small numbers of disperse glycogen granules and numerous 
polysomes in addition to several Golgi membranes and a few fat droplets. Both dense 
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TABLE 2 
Cytogenetic data of the mesothelioma cell lines Mero-14, Mero-25 and Mero-41 
-
Patient Number Modal chro- Number of copies of normal chromosomes 
cell of cells mosome nr. 
line studied (range) 1' 2, 3, 4, 5, 6, 7, 8, 9, .···10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, X,Y 
Mero-14 13 75( 72- 78) 0 3 0-1 2 4 2 2 3 2 2 3-4 1 2 3 2 3 4 2 0 1 2 1 20-1 
Mero-25 15 135(127-140) 0 2-3 2-3 3-4 3-4 6-8 3-4 6-8 0 6-8 6-8 3-4 2-3 3-4 3-4 3-4 4-6 0 3 1-2 0 3-4 02-3 
Mero-41 12 72( 68- 75) 2-3 2 0 2 0 2 4 0 0 2-3 3-4 2 0 
Types of markers and number of copies in ( ) 
Mero-14 
Mero-25 
Mero-41 
1p-(2) 1q-(2) 3p+(2) i(3p)(2) 3p-(2) 6p-(2) Mar(7)(1) 9p+(2) 12q+(2) Mar16(2) Mar22(1) 
inv(1)q-(3-4), 1 p-(6-8), 2p+ (2), 3p-(4), 5q-(3-4), 9p-(3), Mar(9q::19p)(3), inv(18)(3-4), 20p+ (1-2) 
22q+ (3-4), inv(X)(2-3) 
inv del (1 )(2), 3p-(1 ), 3q-(2), Mar3(2), inv5(2), 5p+ (1 ), 8p-(2-3), 9p-(2), 9p+ (2), 12p-(2), 14q-(1) 
15q-(1), 17p+(2), 20q+(2), i(21q)(1), 22q+(2) 
2-3 1-2 2-3 2 2-3 3-4 2 3-6 0-2 22 
unidentified markers 
7 
4 
and fine bundles of perinuclear intermediate filaments were present. 
Cell line Mero-41 consisted of epithelial-like cells with large polymorphic nuclei. 
Occasionally, prominent nucleoli were found within the nucleus. Ultrastructurally, the 
cells showed a few villous structures and the cytoplasm contained several fat droplets 
and numerous polysomes, but only a few Golgi membranes. Both dense and fine 
bundles of intermediate filaments were found. Multinucleate cells occurred in all cell 
lines. 
Cytogenetic characteristics 
Metaphases obtained directly from effusions showed a mosaicism consisting of 
cells with a normal karyotype as well as highly abnormal cells with high numbers of 
chromosomes and a number of structural abnormalities. The marker chromosomes 
were characteristic of a given line and were sometimes found in multiple copies in all 
abnormal cells. 
In the case of the cell lines, all metaphase cells were abnormal and showed the 
same markers as the effusion cells of the patients of origin (Table 2). Possible identifi-
cation of the marker chromosomes is given in Table 3. Occasionally, minor progressive 
changes of a marker were observed, such as for example the marker 3q- in Me-14 
effusion cells was replaced by i(3p) in the cell line Mero-14. 
In the Me-25 biopsy material cultured for a few days, and in a small percentage 
of the mitoses from the Me-25 effusion, the karyotype was found to contain 67 
chromosomes (range 65-69). However, the cell line Mero-25 contained 135 chromo-
somes, which was also found in the majority of the effusion cells at diagnosis. 
Growth kinetics 
The growth of normal mesothelial cells is promoted by the addition of EGF plus 
HC as described by Connell et al. (22). We could confirm these results in 3H-thymidine 
incorporation experiments with normal mesothelial cells isolated from the pleural 
effusion of a non-cancerous patient (unpublished results). The growth characteristics 
of the malignant mesothelioma cell lines Mero-14 and Mero-25 in media with different 
supplements were analyzed. The addition of either EGF plus HC or HC only inhibited 
the growth of the malignant mesothelioma cell lines Mero-14 and Mero-25 (fig. 1). 
Addition of EGF only increased the proliferation slightly as compared to the growth in 
medium without EGF supplementation (fig. 1). The cell line Mero-41 was not tested in 
this assay. After its establishment, this cell line did no longer require EGF and HC for 
its growth. 
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TABLE 3 
Possible cytogenetic interpretation of the markers 
Mero-14 Mero-25 Mero-41 
1 p- 1 qter-+p11: :? 1p- 1 qter-+p11: :sat inv del (1) ?1 q22-+cen::1 p31-+p35::1 q24-+qter 
1q- 1 p::19q lnv(1q-) inv(1) (p13p36)del(1 )(q12) 
2p+ 2qter-+p12::? 
3p- del(3)(p23) 3p- del(3)(p12) 
3q- del(3)(q13) 
3q- 3pter-+q11: :? 3p- del(3)(p21) Mar(3) 3qter-+p11 ::?::cen::?14q-
or sometimes i(3p) 
3p+ 3qter-+p21 ::1 q11-+qter 
5q- del(5)(q21 q34) inv(5) lnv(5)(p15q11) 
6p- 6qter-+cen: :? 
inv(X) inv(X)(p22q12) 
mar(7) 7pter-+cen::? 7q32-+q11::19p or q 
8p- 8qter-+p11 ::?17p 
or sometimes i(Bq) 
9p+ dup(9)(p21-+p22) or HSR 9p- del(9)(p21) 9p- del(9)(p21) 
9p+ 9q::19p 9p+ dup inv(9)(p13p22) 
MarC ?inv(11 )(p11 q14) 
12q+ 12pter-+q23: :3q12-+qter 12p- del(12)(p11p12) 
14q- del(14)(q23q31) 
15q- der(15)t(15;22)(q21 ;q11) 
Mar(16) ? Mar(16) ? 
17p+ 8p::17q 
inv(18) inv(18) (p11 q12) 
MarE ?17q- or ?19q+ 
20p+ 20qter-+p11 ::21 q11-+qter 20q+ dup20q or der(20)t(15;20)(q?;q?) 
i(21q) isochromosome 21q 
22q+ 22pter-+q13::? 22q+ ? duplication 22q+ der(22)t(15;22)(q21 ;q11) 
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3H-thymidine incorporation in Mero-14 (left) and Mero-25 (right). Cell lines 
were cultured in F1 0 medium with 15% FCS and different supplements. 
Ill F1 0 medium with 15% FCS; 0 F1 0 medium, 15% FCS, and 10 
ngjml EGF; 1::!.. F10 medium, 15% FCS, 10 ngjml EGF, and 0.4 p.gjml 
HC;. F10 medium, 15% FCS and 0.4 p.gjml HC. 
Detection of cytokeratins in Mero-14(a), Mero-25(b), and Mero-41(c) by 
indirect immunofluorescence using the polyclonal cytokeratin antibody 
pKer. a-c) x 500. 
i2i 
Intermediate filament protein expression 
In order to support the mesothelial nature of the isolated cell lines and to inves-
tigate whether Mero-14, Mere-25 and Mero-41 contained intermediate filament pro-
teins (IFP) typical of mesothelioma (7), several antibodies to IFP were applied in the 
indirect immunofluorescence assay and in immunoblotting tests. Table i and Figures 
2-4 summarize the results of these studies. 
When the polyclonal rabbit antiserum to skin keratins was applied to methanol 
fixed cells, Mero-14, Mero-25 and Mero-41 all showed filamentous staining reactions, 
albeit in different patterns and intensities (compare Figs. 2 a, b, and c). The same 
holds true for the broadly cross-reacting monoclonal antibody RCK1 02. 
When the monoclonal antibodies, each specific for only one cytokeratin 
polypeptide, were applied to the cell lines, it became obvious that all three cell lines 
contained cytokeratin 18 and cytokeratin 7 in virtually all cells. 
When monoclonal antibody LP2K, specifically reacting with cytokeratin 19, was 
applied to Mero-14, only about 5% of the cells were found to show a filamentous 
staining reaction. Mero-25 and Mero-41 showed a filamentous reaction in virtually all 
cells present in the culture. Furthermore, all cells showed filamentous staining reactions 
when incubated with the polyclonal or monoclonal antibody to bovine lens vimentin 
(pVIM and RV202, respectively), but again typical differences in the distribution patterns 
and staining intensity were found. No reactions were seen when antibodies to 
cytokeratin 10 (RKSE 60), desmin (RD301), or only second step antibodies were 
applied (see Table 1). 
Cytoskeletal preparations of the different cell lines were analyzed by one- and 
two-dimensional gel electrophoresis as well as by immunoblotting assays. The 
one-dimensional gels of these cytoskeletal preparations revealed protein bands at the 
molecular weight levels of vimentin, actin, and cytokeratins 7, 8, 18 and 19 (Fig. 3, 
lanes 1), however, in varying amounts. For example, in Mero-14, the vimentin protein 
band was most pronounced, while in Mero-25 and Mero-41, this IFP occurred in 
concentrations comparable to those of the cytokeratins. Two-dimensional gel 
electrophoresis (Figs. 4 a, g, and j) confirmed these findings. 
The individual protein bands were identified using the Western blotting technique 
in combination with the specific monoclonal antibodies. In all three cell lines 
cytokeratins 18, 8, 7 and 19 as well as vimentin were detected with the antibodies 
RCK106, RCK102, RCK105, LP2K and RV202, respectively (see Fig. 3). RCK102 also 
reacted with a protein band migrating just below vimentin in the one-dimensional 
immunoblots of all three cell lines (Fig. 3, lanes 3). This antibody has been shown 
previously in immunoblotting studies on keratin preparations of human epidermis and 
from human squamous cell carcinomas to recognize cytokeratin 5 next to cytokeratin 
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Figure3. One-dimensional SDS-containing polyacrylamide gel electrophoresis and 
subsequent protein immunoblotting tests of cytoskeletal preparations from 
Mero-14 (panel A), Mero-25.{panel B), and Mero-41 (panel C). lanes 1: 
Coomassie brilliant blue stained gels; lanes 2: protein blots incubated 
with RCK106 (anti-cytokeratin 18); lanes 3: lanes 2, subsequently incu-
bated with RCK102 (anti-cytokeratin 5 + 8); the asterisk indicates 
immunoreactivity with the extra protein band between vimentin and 
cytokeratin 8; lanes 4: lanes 3, subsequently incubated with RCK 105 
(anti-cytokeratin 7). lanes 5: protein blots incubated with LP2K 
(anti-cytokeratin 19); lanes 6: protein blots incubated with RCK105 
(anti-cytokeratin 7). The immunoreaction at the level of actin is probably 
caused by the presence of breakdown products of cytokeratin 7; lanes 
7: protein blots incubated with RV202 (anti-vimentin). Note that the 
antibody also reacts with the vimentin breakdown products. Abbrevia-
tions: v: vimentin; a: actin; 7, 8, 18, and 19 indicate the corresponding 
cytokeratin polypeptides. 
8. Although the immunostained protein band migrates in the position of cytokeratin 5, 
two-dimensional immunoblotting could not confirm the occurrence of this cytokeratin 
polypeptide in the mesothelioma cell lines. Two-dimensional immunoblots, which were 
subsequently incubated with antibodies RCK106, RCK102, RCK105, RV202, and LP2K, 
confirmed the one-dimensional immunoblotting studies with respect to cytokeratins 18, 
8, 7, and 19 (Fig. 4). 
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Two-dimensional gel electrophoresis (a,g,j) and immunoblotting assays 
of these gels (b-f,h,i,k,l) of cytoskeletal preparations from cell lines Mero-
41 (a-f), Mero-14 (g-i), and Mero-25 (j-1). The protein blots were subse-
quently incubated with RCK106 (b,h,k), RCK105 (c,h,k), RCK102 (d,i,l), 
RV202 (e,i,l) and LP2K (f,i,l). Abbreviations: v: vimentin; a: actin; 7,8,18 
and 19 indicate the corresponding cytokeratin polypeptides; NEpHGE, 
first-dimension non-equilibrium pH gel electrophoresis; SDS, second 
dimension SDS polyacrylamide gel electrophoresis. 
DISCUSSION 
Three continuously growing cell lines have been derived in vitro from untreated 
malignant mesothelioma cells from three different patients. The malignant mesothelio-
ma character of the three cases has been demonstrated cytologically, histologically 
and/or ultrastructurally. 
The isolated cell lines show individual cellular morphology and growth cha-
racteristics. Cytomorphologic and ultrastructural studies showed that these cell lines 
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have characteristics consistent with mesothelioma and definitely different from that of 
adenocarcinomas. 
Cytogenetic studies demonstrated that the cell lines shared the same chro-
mosomal aberrations as the primary tumor cells obtained from the patient material 
and that they thus represented in vitro proliferation of the same tumor. Although no 
chromosomal aberrations specific for malignant mesothelioma could been identified on 
the basis of this study, the nature of the abnormalities observed in the cell lines follow 
the same pattern of monosomy and marker formation as observed in a large series of 
mesothelioma patients that we have studied: two types of clonal changes were (a) 
most frequently a hypodiploidjhypotetraploid karyotype characterized by relative loss 
of chromosomes 4, 6, 13, and 22 or (b) an hyperdiploid karyotype with among other 
changes extra copies of chromosome 7 (A. Hagemeijer et al., manuscript in prepa-
ration). Gibas et al. (6) investigated the karyotype of 14 patients with a malignant 
mesothelioma and suggested the nonrandom involvement of chromosomes 1, 2, 3, 6, 
9, 11, 17, and 22 in this tumor. In the three malignant mesothelioma cell lines 
described in this study we found structural abnormalities of chromosomes 1, 3, 9, and 
22 (Table 3). Other markers were only occasionally present in these cell lines and in 
other mesotheliomas studied. This may be due to the fact that patients Me-14, Me-41, 
and Me-25 had not received therapy at the time that the pleural effusions were 
collected. Two recent publications on cytogenetics of malignant mesothelioma also 
emphasize the absence of specific changes (23,24). Structural abnormalities of 
chromosome 3 reported by Popescu et al. (23) are consistent with our findings. 
Lechner et al. (25) reported that asbestos treatment of normal mesothelial cell 
cultures induced hypodiploidy and selective loss of chromosomes 11 and 21. In cell 
lines Mero-14, Mero-25, and Mero-41, however, the chromosomes 11 and 21 were 
present in numbers that might be expected in these cells. 
Connell and Rheinwald (22) described the stimulating effect of EGF plus HC 
supplements on the proliferative capacity of normal mesothelial cells, whereas addition 
of EGF or HC only did not promote the growth of the normal mesothelial cells. In 
contrast to the observation in normal mesothelial cells the growth of the cell lines 
Mero-14 and Mero-25 was found to be inhibited by the addition of EGF plus HC in 
similar concentrations. This negative effect appeared to be caused by HC, as the 
addition of HC only decreased the proliferation of Mero-14 and Mero-25, whereas the 
addition of EGF slightly increased their growth rate. 
Extensive studies on intermediate filament protein expression support the as-
sumption that Mero-14, Mero-25 and Mero-41 are derived from mesotheliomas and 
have retained this character. First of all, the detection of cytokeratins in all three cell 
lines proves their epithelial nature. The fact that the cell lines additionally express 
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vimentin also seems to be in support of the mesothelial derivation, because normal 
and malignant mesothelial cells have been shown to be able to coexpress cytokeratins 
and vimentin in vivo (8). However, one should realize that many cell types initiate the 
synthesis of vimentin when brought into tissue culture (26). 
Further proof of the mesothelioma! nature of the three cell lines has come from 
the study of their individual cytokeratin polypeptides. Blobel et al. (7), showed that 
mesotheliomas can contain cytokeratins 7, 8, 18, and 19 and occasionally some other 
cytokeratins. Especially the presence of cytokeratin 5 in some of these tumors is 
noteworthy in this respects because normal mesothelial cells apparently do not 
express this cytokeratin polypeptide and contain only cytokeratins 7, 8, 18, and 19 
(27-30). Aside from our findings that the cell lines contain cytokeratins 7, 8, 18 and 
19, based on immunofluorescence and immunoblotting tests with chain specific 
monoclonal cytokeratin antibodies, we were not able to confirm the presence of a 
cytokeratin 5-like protein using two dimensional gel electrophoresis and immune-
blotting. 
Connell and Rheinwald (22) found that during rapid growth, normal mesothelial 
cells reduce cytokeratin levels, elevate vimentin expression, and adopt a fibroblastoid 
shape. Reduction of the growth rate, on the other hand, would result in increase of the 
keratin content, decrease of vimentin, and an epitheloid phenotype of the cells. In the 
malignant mesothelioma cell lines Mero-14, Mero-25, and Mero-41, keratin and 
vimentin expression appeared to be present during rapid growth as well as in confluent 
cultures. The cell line with the highest vimentin:keratin ratio (Mero-14) had the highest 
proliferation rate, fibroblastoid shaped cells, and in transmission electron microscopy, 
no villi could be distinguished, in contrast to Mero-25 and Mero-41. The observed 
correlation between the vimentin:cytokeratin ratio, proliferation rate, and phenotype in 
normal mesothelial cells seems to hold true for malignant mesothelioma cell lines as 
well. However, in contrast to normal mesothelial cells, the vimentin:cytokeratin level and 
the phenotype of the investigated malignant mesothelioma cell lines appeared to be 
typical for each cell line and could not be altered by affecting the growth rate. 
In summary, characterization of the cell lines support the assumption that 
Mero-14, Mero-25 and Mero-41 are derived from malignant mesotheliomas and have 
retained this character. They exhibit features of mesothelial cells such as ultrastructural 
organization and intermediate filament protein expression. Their response to growth 
factors is different from that of benign mesothelial cells, as is the highly abnormal 
karyotype, and the latter has been associated with malignant mesothelioma (6). 
Establishment of tumor cell lines has notably extended the possibilities for cell 
biologic and genetic investigations of tumors. Malignant mesothelioma is a rare tumor 
for which viable tissue specimens are difficult to obtain, and the availability of 
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characteristic cell lines is therefore particularly important. To our knowledge only a few 
malignant mesothelioma cell lines have been described (31-33). The use of such cell 
lines should promote research aiming at the study of the mechanism of oncogenesis 
of this particular cancer, and development of specific diagnostic tools, which are 
needed for better diagnosis and safer therapeutic decisions in the clinical management 
of patients presenting with pleural effusions. 
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CHAPTER 7 
EXPRESSION OF PDGF AND PDGF RECEPTORS IN HUMAN 
MALIGNANT MESOTHELIOMA 
7.1 Epression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human 
malignant mesothelioma cell lines derived from primary and metastatic tumors 
7.2 Expression of the c-sis oncogene in pleural effusion cells and tumor material of 
human malignant mesotheliomas 
7.3 Expression of PDGF receptors in human malignant mesothelioma cell lines and 
cultured normal mesothelial cells 
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CHAPTER 7.1 
EXPRESSION OF C-SIS (PDGF B-CHAIN) AND PDGF A-CHAIN GENES IN TEN 
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ABSTRACT 
Ten human malignant mesothelioma cell lines from primary and metastatic sites 
were studied for the expression of c-sis (PDGF B-chain) and PDGF A- chain genes. 
Malignant mesothelioma cell lines expressed strongly the c-sis oncogene which is 
barely detectable in normal mesothelial cells. The PDGF A-chain gene expression was 
slightly elevated in malignant mesothelioma cell lines compared to the expression in 
normal mesothelial cells. Cytogenetic and Southern blot analysis did not provide 
evidence for genomic amplification or rearrangement of the c-sis oncogene. These 
results suggest that malignant mesothelioma cell lines show constitutively enhanced 
expression of the c-sis and PDGF A-chain genes that could play a role in the etiology 
of this type of malignancy. 
INTRODUCTION 
Exogenous growth factors control the proliferation of normal diploid cells in 
culture. Malignant cells in culture are often independent of exogenous growth factors 
(Holley, 1975). This independence can be explained by the autocrine production of 
growth factors or truncated growth factor receptors (Todaro and De Larco, 1978; 
Sporn and Todaro, 1980; Heldin and Westermark, 1984). A direct relationship between 
growth factors and oncogenes has been observed for the platelet-derived growth 
factor (PDGF) and the oncogene v-sis of Simian Sarcoma Virus (SSV). The amino acid 
sequence of the B-chain of human PDGF has been found to be nearly identical to the 
oncogene product p28sis (Waterfield et al., 1983; Doolittle et al., 1983). Moreover in 
SSV transformed cells a PDGF-Iike growth factor has been detected (Deuel et al., 
1983). PDGF is mitogenic to cells with functional PDGF receptors like connective tissue 
cells. The human c-sis (PDGF B) oncogene has been mapped to chromosome 22 
(Swan et al., 1982; Dalla Favera, 1982). The PDGF A-chain was recently cloned and 
mapped to chromosome 7p22-p21 (Betsholtz et al.; 1986, Morton et al., 1987). 
The single mRNA transcript from the c-sis gene has been found in several 
normal cell types like endothelial cells, cytotrophoblasts and activated macrophages 
(Barrett et al., 1984; Goustin et al., 1985; Martinet et al., 1986). Expression of the c-sis 
mRNA has also been found in several human tumor cell lines like osteosarcomas, 
glioblastomas, fibrosarcomas and occasionally in melanomas (Eva et al., 1982; 
Pantazis et al., 1985; Graves et al., 1984; Westermark et al., 1986). In some of these 
cell lines secretion of PDGF-Iike proteins has been detected (Betsholtz et al., 1983; 
Betsholtz et al., 1984; Nister et al., 1984). A general problem in these studies is that 
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little is known about the expression of c-sis in the normal counterparts of these tumor 
cells. 
The diagnosis of malignant mesothelioma is difficult since there are no 
morphologic criteria for differentiation between benign and malignant mesothelial cells 
and adenocarcinoma cells (Whitaker et al., 1984). The incidence of malignant 
mesotheliomas has a strong relationship to asbestos exposure (Wagner et al., 1960). 
Gerwin et al. (1987a, b) have recently detected the expression of c-sis in several malig-
nant mesothelioma cell lines. We investigated the expression of the c-sis and PDGF 
A-chain genes in a panel of ten malignant mesothelioma cell lines derived from primary 
and metastatic tumor sites. Control mesothelial cells were also studied. All cell lines 
were karyotyped and Southern blot analysis of c-sis was performed in six cell lines. 
MATERIALS AND METHODS 
Cell lines and growth conditions 
Ten human malignant mesothelioma cell lines, Mero-14, -25, -41, -48a, - 48b, 
-48c, -48d, -72, -82 and -84, were isolated from pleural effusions, biopsy or autopsy 
material as described previously (Versnel etal., submitted). All malignant mesothelioma 
cell lines were isolated from patients with cytologically, histologically and/or 
ultrastructurally confirmed malignant mesotheliomas. Cytological and ultrastructural 
morphology of the malignant mesothelioma cell lines was consistent with their 
mesothelial origin and expression of vimentin and cytokeratins was found. Several of 
the cell lines have been maintained in vitro for more than 50 passages without showing 
signs of senescence. The cell line Mero-48a was derived from a primary tumor 
(pleura), while -48b, -48c and -48d cell lines were isolated from metastatic sites 
(omentum, liver and pericard) at autopsy of a mesothelioma patient. The malignant 
mesothelioma cell lines were cultured in Ham's F10 medium (Gibco, Paisley, United 
Kingdom) supplemented with 15% fetal calf serum (FCS). 
Five normal mesothelial cell cultures were established from pleural effusions or 
biopsy material from patients without a malignant mesothelioma. Cytologically these 
cells were recognized as mesothelial cells and expression of vimentin and cytokeratins 
was found. The karyotype of the normal mesothelial cell cultures was normal diploid 
and they had a limited lifespan of approximately fifteen passages. The cells were 
cultured in the same medium as described above supplemented in addition with 10 
ngjml Epidermal Growth Factor (EGF, Collaborative Research Inc., Lexington, M.A.) 
and 0.5 JLg/ml Hydrocortisone (HC). 
Both cell types were routinely subcultured two or three times a week. 
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Northern blot analysis of 25 p.g total RNA of placenta, normal mesothelial 
cells and the malignant mesothelioma eel/lines hybridized to 32P-Iabeled 
c-sis and GAPDH probes. 
RNA isolation and Northern blot analysis 
Cells were harvested with a rubber policeman and homogenized in an 
Omni-mixer (DuPont, Newtown, C.T.). Total RNA was isolated using LiCI/Urea method 
(Auffray and Rougeon, 1980). Electrophoresis of 20 or 25 p.g total RNA was performed 
on a 1% agarose gel with formaldehyde (Maniatis et al., 1982). As marker an RNA 
ladder was used (BRL; Gaithersburg, MD). After blotting to nitrocellulose (Thomas et 
al., 1980) hybridization was performed according to Jeffreys and Flavell (1977). Filters 
were washed at 65°C to 0.1 x sse and exposed to a Fuji-RX film. 
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DNA isolation and Southern blot analysis 
DNA isolation was performed according to the method described by Jeffreys 
and Flavell (1977). Restriction enzyme-digested DNAs were electrophoresed on 0.7% 
agarose gels and were transferred to Gene Screen Plus filters (New England Nuclear, 
Boston, M.A.). Hybridization to 32P-Iabeled probes was performed according to 
Bernards and Flavell (1980). 
Probes 
A 1.7 BamH1 c-sis fragment (Groffen et al., 1983) was used. The PDGF A- chain 
probe was the 1.3 kb £coR1 fragment kindly supplied by Betsholtz et al. (1986). The 
bcr probe was a 3' 1.2 kb Hindiii-Bgl DNA fragment kindly supplied by Dr. G. 
Grosveld. The GAPDH probe was a 0.7 kb £coRI-Pst1 fragment (Benham et al., 1984). 
Cytogenetic analysis 
Metaphase cells were obtained by shaking culture flasks with exponentially 
growing cells. The supernatant with metaphase cells was collected and after 15 min 
colcemid incubation the metaphases were harvested according standard cytogenetic 
procedures. RFA-, QFQ- and GTG-banding techniques were used and the karyotype 
was established according to the I.S.C.N. (1985). 
RESULTS 
Expression of c-sis and PDGF A-chain mfl.NA in mesothelioma cell lines 
RNA was isolated from ten human malignant mesothelioma cell lines and five 
cultured normal mesothelial cell lines. Placental RNA was used as a positive control for 
c-sis transcripts and showed a band of 4.0 kb. All human malignant mesothelioma cell 
lines showed a 4.0 kb mRNA that strongly hybridized to the c-sis probe (figure 1, A 
and B). In Mero-25 and Mero-41 a weak cross hybridization of the c-sis probe with the 
2.3 kb PDGF A-chain transcript was detected. In normal mesothelial cells no signal was 
detected (figure 1A). It is only after long exposure (5- 10 days) of 10 J.Lg poly(A) + RNA 
that faint c-sis specific transcripts were detected in normal mesothelial cells (data not 
shown). The level of c-sis transcription varied between the malignant mesothelioma cell 
lines but was always elevated. In the malignant mesothelioma cell lines isolated from 
primary and metastatic sites from the same patient (Mero-48a, -48b, -48c and -48d) 
c-sis transcripts were present in approximately equal amounts (figure 1 B). Northern 
blot analysis with a PDGF A-chain probe showed expression of the 2.8, 2.3 and 1.9 kb 
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Northern blot analysis of 20 p.g total RNA of normal mesothelial cells and 
the malignant mesothelioma cell lines hybridized to 32P-Iabeled PDGF A-
chain and GAPDH probes. 
PDGF A-specific transcripts in malignant mesothelioma cell lines, normal mesothelial 
cells and placenta. The level of expression of the PDGF A-chain gene was elevated in 
malignant mesothelioma cell lines compared to normal mesothelial cells. PDGF A-chain 
transcripts from the cell lines Mero-25, Mero-41, Mero-48a, Mero-48b, Mero-48c, 
Mero-48d, Mero-72, Mero-82 and normal mesothelial cells are shown in figure 2. The 
quality and the amounts of RNA applied were controlled by rehybridization of the filters 
to a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe. All lanes from 
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Southern blot of Xba1 digested DNA's of normal mesothelial cells and 
the malignant mesothelioma cell lines Mero-14, Mero-25 Mero-41, 
Mero-48a, Mero-48b, Mero-48c and Mero-48d hybridized to a 32P-Iabeled 
c-sis probe. 
cultured cell lines showed approximately equal amounts of RNA (figures iA, i B and 
2). In placental RNA it is only after a long exposure (2 days) that a GAPDH transcript 
was detected. This observation is consistent with the reported difference in GAPDH 
expression found between cultured cells and tissues (Benham et al., i984). 
Cytogenetic aberrations in malignant mesothelioma cell lines 
The c-sis and PDGF A-chain gene have been mapped to chromosomes 22qi 3. i 
and 7p2i-22, respectively. All ten human malignant mesothelioma cell lines showed 
highly abnormal karyotypes with modal chromosome numbers ranging from 38 to 75 
and were characterized by the presence of numerous markers. Findings concerning 
ploidy and chromosomes #7 and #22 are given in table i. No constant structural 
rearrangements of chromosomes 7 and 22 were observed. 
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TABLE 1 
Cytogenetic data concerning chromosomes #7 and #22 of 10 malignant mesothelioma cell lines 
Cell line modal number of number of cogies of chromosome 
chromosomes normal #7 rearranged #7 normal #22 rearranged #22 
Mero-14 75 2 [7p-->cen::inv7 1 [22pter-->q13::?] 
q32q11 ::19p] 
Mero-25 67 2 none 1-2 1 [22q+] 
Mero-41 74 4 none 3 2[der(22)t(15;22) 
(q21 ;q11}] 
Mero-48a 71-75 3 1 [7q-] 2 none 
Mero-48b 71-75 2 2[7q-] 3 none 
Mero-48c 71-75 2 1 [7q-] 3 none 
Mero-48d 71-75 2 1 [7q-] 2 none 
Mero-72 42 2 none 1 1 [22q-] 
Mero-82 49 2 1 [7p::22q]* 2 1 [7p::22q]* 
Mero-84 38 2 none none 
* Same marker chromosome. 
The number of copies of 22 (normal and involved in marker chromosomes) 
were usually equal to or lower than the average number of other autosomes, while the 
number of copies of 7p was equal or slightly higher than the average number of other 
autosomes: e.g. 4 copies of 7 in hypotetraploid karyotypes of Mero-41 and Mero-48a 
and -48b. The karyotype of the cultured mesothelial cells was normal diploid. 
Southern blot analysis of the c-sis gene in malignant mesothelioma cell lines 
DNA from normal mesothelial cells and six malignant mesothelioma cell lines 
(Mero-14, Mero-25, Mero-41, Mero-48a, Mero-48b and Mero-82) was investigated for 
rearrangements in the c-sis gene. In Xba I digested DNA's the c-sis probe hybridized 
to a band of 8.2 kb (figure 3). Digestion of malignant and normal cell DNA with two 
other restriction enzymes (EcoR1 and Hindlll) revealed also the specific germline 
bands and no rearranged fragments (data not shown). The filters with Xbal, EcoR1 and 
Hindlll digested DNA were rehybridized with bcr and c-sis probes (data not shown). 
The results indicate absence of genomic amplification or loss of copies of c-sis. The 
difference in band intensities in figure 3 and the chromosomal counts in table 2 are 
caused by difference in loading and was not consistently present in the other digests 
and correlated with the bcr bands. 
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DISCUSSION 
Expression of the c-sis (PDGF B-chain) and PDGF A-chain was demonstrated 
in ten human malignant mesothelioma cell lines from primary and metastatic tumor. 
Malignant mesothelioma cell lines expressed strongly the c-sis oncogene which is 
barely detectable in normal mesothelial cells. Gerwin et al. (1987 a,b) first reported 
expression of PDGF A- and B-chains in human malignant mesothelioma cell lines. They 
found high levels of either PDGF A- or PDGF B-chain message or both in malignant 
mesothelioma cell lines. Within our panel of malignant mesothelioma celllineswe found 
variable though elevated amounts of c-sis transcripts, while little variation in the PDGF 
A-chain expression was observed. 
All the human malignant mesothelioma cell lines so far investigated expressed 
the c-sis oncogene. This is in contrast with the findings in human osteosarcoma and 
melanoma cell lines where c-sis expression is not a consistent feature of all tumor cell 
lines investigated (Eva et al., 1982; Betsholtz et al., 1986; Westermark et al., 1986). 
Westermark et al. (1986) reported that the c-sis expression in a human melanoma cell 
line from a primary tumor was highly elevated compared to cell lines from metastases. 
In our study, malignant mesothelioma cell lines from primary and metastatic tumors 
showed no significant differences in the level of c-sis expression. Moreover, preliminary 
results suggest that c-sis expression was not restricted to malignant mesothelioma cell 
lines in culture, but can also be detected in total RNA isolated from pleural effusions 
and autopsy material of malignant mesothelioma patients. 
To investigate the mechanism of c-sis activation the malignant mesothelioma cell 
lines were studied for chromosomal aberrations of chromosome 22 and DNA 
rearrangements in the c-sis gene. Although aberrations in chromosome 22 were 
detected in several of the malignant mesothelioma cell lines there was no specific 
marker present in all the investigated cell lines. The c-sis expression can not be due 
to an elevated copy number of the c-sis containing chromosome as several cell lines 
have only two copies of chromosome 22. Restriction enzyme analysis with different 
enzymes did not reveale a rearrangement in the c-sis gene and hybridization with a bcr 
probe indicated an absence of genomic amplification of the c-sis gene. There were no 
indications that rearrangements on DNA or chromosomal level are responsible for the 
c-sis activation. Therefore altered regulation on the transcriptional level has to be 
considered. 
Expression of the PDGF A-chain gene was found to be higher in malignant 
mesothelioma cell lines than in normal mesothelial cells. The three transcripts detected 
were the same as in placental RNA and as described by Betsholtz et al. (1986). In 
these cell lines, the number of copies of chromosome 7p corresponded to the ploidy 
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of the line which suggests that increased expression of PDGF A is probably a 
characteristic feature of malignant mesothelioma cell lines. The produced PDGF (A 
andjor B) could possibly function as an autocrine growth factor if the PDGF is 
secreted and if PDGF receptors are present on the malignant cell lines. Another 
possibility is the paracrine effect of the produced PDGF on connective tissue cells that 
results in the connective tissue growth which is frequently encountered in malignant 
mesotheliomas. Whether the expressed PDGF B- and PDGF A-chains in the malignant 
mesothelial cells are assembled as AB heterodimers or AA and BB homodimers and 
whether PDGF receptors occur on malignant mesothelioma cells remains to be 
established. Furthermore, it would be of great interest to study whether the expression 
of c-sis is also consistently enhanced in freshly obtained tumor material, because c-sis 
expression might become a useful marker for diagnosis of malignant mesotheliomas. 
In summary, we have demonstrated enhanced expression of the c-sis oncogene 
in ten human malignant mesothelioma cell lines from primary and metastatic origin. 
This contrasts with the barely detectable level of c-sis expression in control mesothelial 
cells. Cytogenetic and restriction enzyme analysis revealed no indications for a 
mechanism responsible for the c-sis activation. These cell lines are extremely valuable 
for further investigations of the role of c-sis and PDGF A-chain expression in malignant 
transformation. 
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CHAPTER 7.2 
EXPRESSION OF THE C-SIS ONCOGENE IN PlEURAl EFFUSION CEllS AND 
TUMOR MATERIAL OF HUMAN MALIGNANT MESOTHELIOMAS 
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ABSTRACT 
Recently the expression of the c-sis oncogene was detected in human malignant 
mesothelioma cell lines. In the present study expression of the c-sis oncogene was 
demonstrated in total RNA isolated from freshly obtained material of eight malignant 
mesothelioma patients. The level of c-sis transcription varied between the different 
patients and did not correlate with the morphologically detected percentage tumor cells 
and/or macrophages, which can express the c-sis oncogene as well. 
INTRODUCTION 
Cellular proto-oncogenes are normal cellular genes with potential oncogenic 
activity (1 ,2). Several proto-oncogenes are known to be involved in normal proliferation 
and differentiation (3-5). This implies that aberrations in the expression of these 
proto-oncogenes or structural changes in their products may directly influence the 
growth of cells (6). Although the mechanism of activation is often unknown, expression 
of a number of oncogenes has been found in human tumors and data are accumula-
ting about the relevance of this expression for diagnosis and prognosis. Monnat et al. 
(7) studied the expression of c-myc, c-H-ras, c-fos and c-K-ras in 17 patients with 
colon carcinoma and found a correlation between high levels of mRNA of these genes 
and biologically aggressive tumors. In human breast cancer expression of a ras protein 
has been found to be associated with the progression of the cancer (8). 
The diagnosis of malignant mesothelioma is difficult as malignant mesothelioma 
cells cannot be easily distinguished from benign reactive mesothelial cells and 
adenocarcinoma cells (9). Recently, expression of the c-sis oncogene has been 
demonstrated in human malignant mesothelioma cell lines while cultured normal 
mesothelial cells did not show expression of this oncogene (1 0,11 ). The oncogene 
product p28sis is nearly identical to the B-chain of the platelet-derived growth factor 
(PDGF), which is a mitogen for connective tissue cells {12, 13). We investigated whether 
c-sis expression is also detectable in freshly obtained tumor material of eight malignant 
mesothelioma patients. Total RNA was isolated from patient material and analysed by 
Northern blot. 
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MATERIALS AND METHODS 
Patient material 
Pleural effusions were collected in 50 ml tubes with 5000 IU heparin (Organon, 
Oss, The Netherlands) and 5 ml Ham's F10 medium (Gibco, Paisley, United Kingdom) 
supplemented with 15% fetal calf serum. After collection the material was immediately 
transported to the laboratory and the cells were harvested by centrifugation (10 min, 
200 g). Subsequently, the pellets were quickly frozen in liquid nitrogen and stored at 
-70°C. 
Autopsy was performed within 4 hours after death. Tumor material was frozen 
in liquid nitrogen immediately after autopsy and stored at -70°C. 
Diagnosis 
Diagnosis was established by routine cytology and always confirmed 
ultrastructurally andjor histologically (14). 
RNA isolation and Northern blot analysis 
RNA isolation and Northern blot analysis were performed as described (11). The 
probes used were a 1.7 BamHI c-sis fragment (15) and a 0.7 kb EcoRI-Pstl GAPDH 
fragment (16). 
TABLE I 
Incidence of tumor cells and macrophages and expression of the c-sis oncogene in the collected patient 
material 
patient material malignant meso- macro- c-sis tran-
thelioma cellsa) phagesa) scription b) 
(%) (%) 
Me-25 pleural effusion 10 70 + 
Me-62 pleural effusion 20 70 ++ 
Me-67 pleural effusion 65 5 + 
Me-83 pleural effusion 60 5 + 
Me-84 pleural effusion 30 5 + 
Me-85 pleural effusion 10 10 ++ 
Me-102 pleural effusion 90 5 ++ 
Me-77 tumor (autopsy) + 
a) Cytologically detected, b) Estimated from Fig. 1. 
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Figure 1. 
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Northern blot analysis of 20 J.Lg total RNA of placenta, cultured normal 
mesothelial cells, two malignant mesothelioma cell lines (Mero-25 and 
Mero-84) and the patient material Me-25, -62, -67, -77, -83, -84 and -85. 
The blot was hybridized to 32?-labeled c-sis (top) and GAPDH probes 
(bottom). 
Total RNA was isolated from tumor tissue from one and pleural effusion cells 
from eight malignant mesothelioma patients. Placental RNA and RNA from two 
malignant mesothelioma cell lines (Mero-25 and Mero-84) were used as positive 
controls and showed after hybridization with a c-sis probe a band of 4.0 kb (i 1). This 
band was lacking in the negative control of RNA isolated from cultured normal 
mesothelial cells. Figure 1 shows a Northern blot hybridized to the c-sis probe with the 
control RNA, and RNA from seven of the eight investigated patients Me-25, 62, 67, 77, 
83, 84 and 85. The level of the detected c-sis transcription varied between the different 
patients. The quality and the amount of RNA applied were controlled by rehybridization 
with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe (Figure 1). 
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Findings concerning the percentage of tumor cells and macrophages in the pleural 
effusions and a summary of the results from the Northern blot analysis are shown in 
table 1. 
DISCUSSION 
Expression of the c-sis oncogene was demonstrated in RNA isolated from tumor 
containing material of eight malignant mesothelioma patients. The band detected in the 
RNA from the patient material was of the same size as the bands in placental RNA and 
RNA from the malignant mesothelioma cell lines Mero-25 and Mero-84. The latter cell 
lines were isolated from the same patient material as the RNA samples Me-25 and 
Me-84, in which c-sis specific transcipts were detected as well (11). 
Elevated expression of the c-sis oncogene has been reported for malignant 
mesothelioma cell lines (1 0,11) and several tumor cell lines isolated from different 
tumor types (18-20). Except for a few cases of acute myeloblastic leukemia (AM L) and 
chronic myelocytic leukemia (CML) (21-23) expression ofthe c-sis oncogene in freshly 
obtained tumor material has not been reported so far. Slamon et al. (24) investigated 
twenty different tumors from 54 patients for expression of amongst others the c-sis 
oncogene but did not find c-sis specific transcripts. 
The detection of c-sis expression in total RNA from patient material and 
especially pleural effusions is hampered by the low incidence of tumor cells and the 
presence of other cells e.g. macrophages which can express the c-sis proto-oncogene 
(25). The RNA in situ hybridization technique offers the possibility to distinguish c-sis 
positive cells with different morphology at the single cell level. This technique has been 
developed in our laboratory (26,27) but so far can only be applied to lymphocytes. 
Application on malignant mesothelioma cells in pleural effusions is hampered by high 
background and a weak signal. The latter could be due to low accessibility of the RNA. 
Diagnosis of malignant mesothelioma on pleural effusions is often difficult due 
to lack of criteria to distinguish malignant mesothelioma cells from adenocarcinoma 
cells and reactive mesothelial cells (9). The detected c-sis expression by RNA in situ 
hybridization techniques may be useful for the diagnosis of malignant mesothelioma. 
The specificity of c-sis expression for malignant mesotheliomas is currently under 
investigation. Furthermore, it should be possible to enhance the differentiation between 
different c-sis positive cell types by application of a double staining technique, which 
combine membrane antigen labeling with the detection of RNA transcripts. Such 
procedures have to be developed and might be very useful in diagnostic procedures. 
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In summary, we have demonstrated that the expression of the c-sis oncogene, 
which has been detected in malignant mesothelioma cell lines, is also present in freshly 
obtained tumor material. Further investigations will reveal whether this observation is 
useful as a diagnostic tool and applicable in routine pathology. 
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CHAPTER 7.3 
EXPRESSION OF PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA 
CELL LINES AND CULTURED NORMAL MESOTHELIAL CELLS 
M.A. Versnel1, L. Claesson-Welsh4, A. Hammacher4, M.J. Bouts\ Th.H. van der 
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ABSTRACT 
In human malignant mesothelioma cell lines elevated expression of the PDGF 
B-chain (c-sis) gene was previously reported, while normal mesothelial cells barely 
express this gene. Expression of the PDGF A-chain gene was only slightly elevated 
in these cell lines compared to normal mesothelial cells. For an autocrine function of 
the produced PDGF in these cells expression of PDGF receptors is a prerequisite. In 
this paper we report on the inversed pattern of expression of PDGF A- and B-type 
receptors in normal and malignant mesothelial cells. Cultured normal mesothelial cells 
expressed the PDGF A-type receptor mRNA and had weak to undetectable levels of 
the PDGF B-type receptor mRNA and protein. In contrast, malignant mesothelioma 
cell lines were found to express PDGF B-type receptor mRNA and protein, while the 
PDGF A-type receptor mRNA was hardly detectable. The presence of plasma 
membrane associated B-type receptors was demonstrated by binding experiments 
with 1251-PDGF-BB. Nevertheless, immunoelectron microscopy revealed that the 
majority of the PDGF receptors was found in lysosomes and presumptive vesicles in 
the cytoplasm. In summary, these results indicate that all components for a PDGF-
dependent growth stimulation of malignant mesothelioma cells are present. 
INTRODUCTION 
The platelet-derived growth factor (PDGF) was initially isolated from human 
platelets and identified as a dim eric molecule consisting of A- and B-polypeptide chains 
(Johnsson et al., 1982; Ross et al., 1986). The PDGF B-chain is nearly identical to the 
protein encoded by the v-sis oncogene (Doolittle et al., 1983; Van den Ouweland et 
al., 1985; Waterfield et al., 1983). The PDGF A-chain gene is 60% similar to the B-
chain (Betsholtz et al., 1986). Expression of a single PDGF gene or both genes has 
been found in a variety of normal and tumor cell lines (Barret et al., 1984; Eva et al., 
1982; Martinet et al., 1986; Westermark et al., 1986). All possible dimeric combinations 
of A and B chains (AA, AB and BB) have been identified in normal and transformed 
cells (Heldin et al., 1986; Hammacher et al., 1988; Stroobant and Waterfield, 1984). 
The oncogenic effect of c-sis has been attributed to an autocrine growth stimulating 
activity, which requires that the cells producing c-sis also have functional receptors for 
the produced factor (Todaro and De Larco, 1978; Sporn and Todaro, 1980; Heldin and 
Westermark, 1984). 
Binding experiments with the different isoforms of PDGF to cultured cells 
revealed the existence of two distinct receptor types, denoted type-A and type-B 
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_Heldin et al., 1988; Hart et al., 1988). The PDGF B-type receptor binds PDGF-BB with 
high affinity, and with lower affinity PDGF-AB, while it does not bind PDGF-AA. The A-
type receptor binds all three dimeric forms with high affinities. The human PDGF A- and 
B-type receptor were recently cloned and were found to be structurally related (Yard en 
et al., 1986; Claesson-Welsh et al., 1988; Gronwald et al., 1988, Matsui et al., 1989; 
Claesson-Welsh et al., 1989b). 
Malignant mesotheliomas are mesodermally derived tumors. Human malignant 
mesothelioma cell lines have been found to express both PDGF A- and B-chain genes 
(Gerwin et al., 1987; Versnel et al., 1988). In contrast, normal mesothelial cell cultures 
were found to express the A-chain gene while B-chain transcripts were barely 
detectable (Versnel et al., 1988). Here, we report that whereas cultured normal 
mesothelial cells express the PDGF A-type receptor and weak levels of the B-type 
receptor, the reverse is true for mesothelioma cell lines that generally express the B-
type receptor, but have a weak to undetectable level of the A-type receptor. 
MATERIALS AND METHODS 
Cell lines and growth conditions 
The malignant mesothelioma cell lines and normal mesothelial cell cultures were 
isolated and cultured as described (Versnel et al., 1989). 
RNA isolation and Northern blot analysis 
RNA isolation and Northern blot analysis were performed as described (Versnel 
et al., 1988). The filters were washed at 42°C to 0.3xSSC and exposed to a Fuji-RX 
film. 
Probes 
The PDGF B-type receptor probe was a 1 kb Pst fragment derived from eDNA 
clone HPDGFR-2A3 (Ciaesson-Welsh et al., 1988) and the PDGF A-type receptor probe 
was a 1.5 kb EcoRI fragment (Ciaesson-Welsh et al., 1989). The fragments correspond 
to the extracellular domain of the B-and A-type receptors, respectively. The GAPDH 
probe was a 0.7 kb EcoRI-Pstl fragment (Benham et al., 1984). 
PDGF and radiolabeled ligands 
PDGF-AA and PDGF-BB were recombinant material produced in yeast cells 
(Ostman et al., 1989) and 1251-labeled by the method of Bolton and Hunter (1972) to 
specific activities of 55,000 and 80,000 cpmj J.Lg, respectively. 
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Radioreceptor assay 
Cells were plated in 12-well plates (Costar, Cambridge, MA). When confluence 
was reached, the cells were washed with phosphate buffered saline (PBS) and 
incubated for 24 hours in serum free F1 0 medium at 37°C. Prior to binding, the cells 
were washed with 1 ml PBS supplemented with bovine serum albumin (BSA), 1 mgjml 
(Boehringer, Mannheim, F.R.G.). Binding was performed for two hours at ooc in a 
volume of 350 JLI PBS-BSA containing radiolabeled ligands with or without unlabeled 
PDGF (250 ng per well). After five washes with ice cold PBS-BSA the cells were lysed 
in 2% Triton X-100 in H20. 
1251-radioactivity was determined in a gamma counter. 
Metabolic labeling and immunoprecipitation 
Cells were cultured as described above. After washing twice with PBS, the cells 
were incubated in methionine-free DMEM (Flow Laboratories, Irvine, United Kingdom). 
After one hour, the medium was changed to 10 ml methionine-free medium containing 
2% dialyzed fetal calf serum, and 50 JLCi 35S-methionine (Amersham International, 
Amersham, U.K.). After 6 hours labeling the cells were lysed as described (Ciaesson-
Welsh et al., 1987). The lysate was centrifuged for 0.5 min at 10,000 g. The super-
natant was precleared by overnight incubation at 4°C with normal rabbit serum and 
protein A-Sepharose (Pharmacia, Uppsala, Sweden) and then incubated overnight at 
4°C with the rabbit antiserum PDGFR-3, which specifically recognizes the PDGF B-
type receptor (Ciaesson-Welsh et al., 1989b). Further procedures were performed as 
described (Ciaesson-Welsh et al., 1987). lmmunoprecipitates were analysed by sodium 
dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis according to Laemmli 
{1970) using 6% polyacrylamide gels. 
lmmunocvtochemistry 
For immunoelectron microscopy we used cultured cells as described above and 
tumor cells from the pleural fluid of a patient with a well-established diagnosis of 
malignant mesothelioma. Fixation and embedding procedures for ultracryotomy were 
performed as described before (Willemsen et al., 1988). The antiserum used was the 
anti-PDGF B-type receptor antibody PDGFR-HL2 that recognizes the intracellular part 
of the B-type receptor (Weima et al., submitted). PDGF B-type receptors were 
visualized by the indirect immunogold method using gold probes as marker (Willemsen 
et al., 1988). As a control for specificity sections were incubated with normal rabbit 
serum instead of the primary antibody. The observed background labeling was 
negligible. 
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Figure 1. 
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Northern blot analysis of 5 Jl.g poly(At RNA from placenta, normal 
mesothelial cells and malignant mesothelioma eel/lines hybridized to a l 2P]-Iabeled PDGF A-type receptor probe and a GAPDH probe. 
Expression of the PDGF A- and B-type receptor mRNA molecules in normal and 
malignant mesothelial cell lines 
RNA was isolated from human malignant mesothelioma cell lines and normal 
mesothelial cell cultures. The 7 kb PDGF A-type receptor mRNA was clearly detectable 
in poly(A) + RNA from normal mesothelial cells, while malignant mesothelioma cell lines 
showed even after long exposure a weak to undetectable expression (Figure 1). For 
the PDGF B-type receptor, placental RNA was used as a positive control and showed 
a 6 kb mRNA molecule. All twelve investigated malignant mesothelioma cell lines 
except Mero-95 expressed the 6 kb PDGF B-type receptor specific mRNA (Figures 2A 
and 28). The level of PDGF B-type receptor expression varied between the different 
cell lines: strong expression in Mero-14, -72, -96, -48a, -48b, -48c and -48d, 
intermediate expression in Mero-41 and -82, and weak expression in Mero-25 and -
84. The normal mesothelial cell cultures showed a weak expression of the PDGF 
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Northern blot analysis of 20 p.g total RNA from placenta, normal 
mesothelial cells (NM1-4) and 12 malignant mesothelioma cell lines 
hybridized to a [32?]-labeled PDGF B-type receptor probe and a GAPDH 
probe. 
B-type receptor in three out of four cultures tested (Figure 2A). The amount of RNA 
applied and the quality were controlled by rehybridization of the filters with a GAPDH 
probe. In placental RNA GAPDH transcripts were only detectable after long exposure. 
Variable expression of the PDGF B-chain in this panel of malignant mesothelioma cell 
lines was reported previously (Versnel et al., 1988). In five cell lines an inverse relation-
ship was observed between levels of expression of PDGF B-type receptor and PDGF 
B-chain mRNA: the malignant mesothelioma cell lines Mero-41 and Mero-82 had a 
high c-sis expression and a weak PDGF B-type receptor expression whereas Mero-
14, Mero-72 and Mero-96, which had a weak c-sis expression, were found to have a 
strong PDGF B-type receptor expression. In the malignant mesothelioma cell lines 
derived from a primary tumor (Mero-48a) and its metastases (Mero-48b, c, d) the 
expression of the c-sis and the B-type receptor was intermediate. A summary of these 
data is shown in Table 1. 
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TABLE I 
...... 
01 (X) 
SUMMARY OF DATA ON PDGF AND PDGF RECEPTOR EXPRESSION, AND CYTOGENETIC DATA CONCERNING CHROMOSOME #4 
and #5 IN MALIGNANT MESOTHELIOMA CELL LINES 
PDGF A* PDGF 8* PDGF A-t~Qe PDGF 8-t~Qe receQtor modal chro- number of coQies 
mRNA (c-sis) receQtor mRNA lmmunopre- RRA mosome normal 4 normal 5 rearranged 5 
mRNA mRNA RRA** cipitation number 
Mero-14 + + + +++ ND + 75(72-78) 2 4 0 
Mero-25 ++ + ± + + 135(127-140) 3-4 3-4 3-4xdel(5)(q21 q34) 
Mero-41 +++ +++ + ND + 72(68-75) 2 0 2xinv(5)(p15q11) 
1x5p+ [5qter+p15::6q15ter] 
Mero-48a ++ ++ NO ++ ND ND 71-75 2* 2 2x5q-[del(5)(q11q22)] 
Mero-48b ++ ++ ± ++ + + 71-75 2* 2 1xdel(5)(q11 q22) 
1xdel(5)(q11q22)q+ 
Mero-48c ++ ++ ± + ++ ND + 71-75 2* 2 1x5q+(HSR) 
1xdel(5)(q11q22) 
Mero-48d ++ ++ ND ++ ND ND 71-75 2* 2 2xdel(5)(q11 q22) 
Mero-72 + ++ NO +++ ND ND 41-43 1 2 0 
Mero-82 +++ ++ ± + + + 48-50 2 3 0 
Mero-84 ++ + ND ± ND + 38 1 2 0 
Mero-95 + ++ ND + ± 54-58 2 3 0 
Mero-96 + ++ ND ND +++ + ND 72-78 3 2-3 0 
normal 
mesothelial + + ND -/±/+ + ND 
cells 
*Versnel et al., 1988, **Radioreceptor assay, ND=not done. 
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Figure. 3 Binding of 125/-PDGF-AA and 1251-PDGF-BB by 4 human malignant 
mesothelioma cell lines. 
The PDGF A-type receptor has been mapped to chromosome 4 (Matsui et al., 
1989; Stenman et al., 1989). Loss of one copy of chromosome 4 is frequently 
observed in malignant mesothelioma cell lines. However, this cannot explain the 
absence of PDGF A-type mRNA expression as loss of chromosome 4 is not a 
consistent feature of all the investigated cell lines (Table 1). 
The PDGF B-type receptor has been mapped to chromosome 5 (Yarden et al., 
1986). The level of expression in the malignant mesothelioma cell lines does not 
correlate with the number of copies of chromosome 5 or with a specific marker for 
chromosome 5 (Table 1). 
Radioreceptor assay with 1251-PDGF-AA and 1251-PDGF-BB. 
To investigate whether PDGF A-type and PDGF B-type receptors were present 
on the malignant mesothelioma cell lines, binding experiments with 1251-PDGF-AA and 
1251-PDGF-BB were performed. For competition an excess of unlabeled PDGF-AA and 
PDGF-BB was used. Eight malignant mesothelioma cell lines were investigated and 
were found to bind 1251-PDGF-BB (Figure 3 and table 1). The binding of iodinated 
ligand was competed for by incubation with an excess of unlabeled PDGF-AA or 
PDGF-BB. Mero-95, which did not express detectable levels of PDGF B-type receptor 
mRNA, had only a low binding of 1251-PDGF-BB. The malignant mesothelioma cell lines 
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lmmunoprecipitation using an antiserum reactive with the PDGF 8-type 
receptor from metabolically labeled malignant mesothelioma cell lines 
(lane a: Mero-25, Jane b: Mero-82, lane d: normal mesothelial cells NM-
4, lane e: normal mesothelial cells NM-1. Lane c shows the immunopreci-
pitation using an irrelevant antiserum and metabolically labeled Mero-
82 cells. 
Mero-14, Mero-48c and Mero-82 displayed a low specific binding of 1251-PDGF-AA 
(Figure 3). In the other investigated malignant mesothelioma cell lines the binding was 
not significantly over the background (Table 1). Normal mesothelial cells could not be 
tested with this assay as these cells could not resist the intensive washing procedures. 
lmmunoprecipitation 
The presence of PDGF B-type receptors in normal and malignant mesothelial 
cells was also demonstrated by immunoprecipitation. For the detection of low numbers 
PDGF receptors the cell lines Mero-25, Mero-48b, Mero-82 and Mero-95 and two 
normal mesothelial cell lines were metabolically labeled with 35S-methionine and 
subjected to immunoprecipitation with an antiserum reactive with the PDGF B-type 
receptor. SDS gel electrophoresis revealed bands of approximately 180 kd in the 
malignant mesothelioma cell lines as well as in the normal mesothelial cell cultures, i.e. 
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Figure 5 
c 
a. Subcellular distribution of PDGF B-type receptor in malignant 
mesothelioma cells of a patient using specific antiserum. The antigen is 
found on the plasma membrane and often in small vesicular structures 
(arrows). b. Detail of the rough endoplasmic reticulum of Mero-14 cells 
showing labeling for PDGF B-type receptor. c. Higher magnification 
showing a lysosomal structure in Mero-14 cells with weak labeling for 
PDGF B-type receptor. 
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the expected size of the PDGF B-type receptor. Figure 4 shows the immune-
precipitated 180 kd molecule from Mero-25, Mero-82 and two normal mesothelial cell 
lines (lanes a, b, d and e, respectively). After immunoprecipitation with an irrelevant 
antiserum the 180 kd band was not observed (lane c). From Mero-95, which did not 
express detectable levels of PDGF B-type receptor mRNA, only a weak band of 180 
kd was precipitated (data not shown). 
lmmunoelectron microscopy 
The subcellular localization of the PDGF B-type receptor was investigated by 
immunoelectron microscopy of ultrathin frozen sections of malignant mesothelioma 
cells in a pleural effusion (Figure 5A) and of the malignant mesothelioma cell line Mero-
14 (Figure 5B and C). The distribution of the gold particles observed in the patient 
material and the cultured malignant mesothelioma cell lines was similar. Figure 5A 
shows labeling for the PDGF B-type receptor in the patients tumor cells on the plasma 
· membrane with preference for the microvilli. Also a labeling pattern just below the 
plasma membrane often associated with small presumptive vesicular structures could 
be detected. Furthermore labeling was found of the rough endoplasmic reticulum 
(Figure 5B) and lysosomal structures (Figure 5C). 
DISCUSSION 
We report here that normal mesothelial cells express PDGF A-type receptor 
mRNA, whereas these cells were found to have only weak or undetectable levels of 
PDGF B-type receptor mRNA and protein. In contrast, malignant mesothelioma cell 
lines were found to express PDGF B-type mRNA and protein, but only weak or 
undetectable levels of A-type mRNA. Since normal mesothelial cells are cultured in 
medium supplemented with epidermal growth factor (EGF) and hydrocortisone (HC), 
whereas malignant mesothelioma cells are cultured without these supplements, it was 
possible that the expression of PDGF receptors in normal mesothelial cells was 
influenced by these supplements. However, addition of EGF and HC to malignant 
mesothelioma cell lines did not change the expression of PDGF A-type receptors, as 
determined by binding experiments and Northern blotting, making this possibility 
unlikely (data not shown). 
Recently we described clear but variable expression of the c-sis (PDGF B) 
oncogene in ten malignant mesothelioma cell lines while c-sis was barely detectable 
in normal mesothelial cells (Versnel et al., 1988). Expression of the PDGF A-chain was 
found to be slightly enhanced in the malignant mesothelioma cell lines compared to 
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normal mesothelial cells. These results taken together with the demonstration of PDGF 
B-type receptors on normal and malignant mesothelial cells suggest that PDGF-BB 
produced by the malignant mesothelioma cells could function as an autocrine growth 
factor and play a role in the stimulation of growth of the tumor cells. Since normal 
mesothelial cells express both PDGF A-chain and A-type receptor mRNA, it is possible 
that PDGF-AA is involved in autocrine stimulation of normal mesothelial cells. 
Recently, Huang and Huang (1988) reported that in v-sis or c-sis transformed 
cells the majority of the newly synthesized PDGF receptors did not reach the cell 
membrane and that these receptors were rapidly degraded. According to this 
observation a cytoplasmic interaction between the c-sis gene product and its receptor 
was suggested. The presence of membrane associated PDGF receptors on the 
malignant mesothelioma cell lines was investigated by binding experiments with 1251-
PDGF-AA and 1251-PDGF-BB. The specific binding of 1251-PDGF-AA to the different 
malignant mesothelioma cell lines was low or around detection level. This observation 
is cohsistent with the lack of clearly detectable PDGF A-type mRNA expression. All 
malignant mesothelioma cell lines investigated were found to bind 1251-PDGF-BB, which 
indicates towards the presence of plasma membrane associated PDGF B-type 
receptors. lmmunoelectron microscopical studies of PDGF B-type receptors in 
malignant mesothelioma cell lines revealed that although plasma membrane associated 
PDGF B-type receptors occur, most receptors are found in lysosomes and presump-
tive vesicles in the cytoplasm. This observation might indicate towards an intracellular 
degradation of PDGF B-type receptors and a possible intracellular interaction between 
PDGF and its receptor. 
It was reported that SSV-transformed mouse fibroblasts and normal rat kidney 
cells secreted PDGF while no PDGF was detected in the conditioned medium of SSV-
transformed monkey fibroblasts (Huang et al., 1984). The detected amounts of 
secreted PDGF were found to correlate with the rate of tumor growth after injection into 
nude mice. The failure of SSV-transformed monkey fibroblasts to secrete detectable 
levels of PDGF suggests an intracellular interaction of PDGF with its receptor. The 
malignant mesothelioma cell lines investigated so far were also found to secrete minor 
amounts of PDGF protein and attempts to grow malignant mesothelioma cell lines in 
nude mice resulted only once in a tumor (M.A. Versnel, unpublished results). These 
observations are consistent with an intracellular interaction. 
In summary, we have demonstrated expression of the PDGF B-type receptor 
in a panel of human malignant mesothelioma cell lines, which were previously reported 
to express PDGF B- and PDGF A-chain genes. Cultured normal mesothelial cells were 
found to express PDGF A-type receptors while malignant mesothelioma cell lines had 
a weak to undetectable expression of this gene. These results indicate that all 
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components for a PDGF-dependent autocrine growth stimulation of malignant 
mesothelioma cells are present. Furthermore, malignant and normal mesothelial cells 
could be a useful model for the study of mechanism involved in the regulation of 
expression of PDGF A- and B-type receptors. 
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Diagnosis of human malignant mesothelioma is difficult as malignant mesothe-
lioma cells lack specific characteristics. The major problem in diagnosis of malignant 
mesothelioma by cytology is to distinguish malignant from benign mesothelial cells and 
malignant mesothelial cells from adenocarcinoma. The purpose of this study was to 
improve the diagnosis of human malignant mesothelioma and to increase our insight 
into the growth regulation and transformation of normal mesothelial cells. 
8.1 Diagnostic methods for malignant mesothelioma 
Most patients with malignant mesothelioma have a pleural effusion at initial 
presentation. Diagnosis of malignant mesothelioma is limited by the difficulty of 
distinguishing malignant mesothelioma cells from benign mesothelial cells and 
adenocarcinoma by routine cytology. A reliable diagnosis on pleural effusions is 
important as it prevents more invasive diagnostic procedures like thoracoscopies or 
percutaneous biopsies. In this thesis improvement of diagnosis was attempted by the 
study of cytogenetic aberrations and by immunocytochemical and immunoelectron 
microscopical investigations. 
Several groups have studied the expression of epithelial membrane antigen 
(EMA) in malignant mesothelioma but their results are controversial. Malignant 
mesotheliomas were found negative for EMA by Battifora et al. (1984) while others 
found malignant mesotheliomas positive for EMA (Marshall et al., 1984; Pinkus et al., 
1985; Sloane et al., 1983). In section 5.1, immunocytochemistry and immunoelectron 
microscopy were used for the study of the expression of EMA on pleural effusion cells 
of 25 patients with a malignant mesothelioma. EMA-positive cells were detected in 23 
samples. In three cases of the 56 investigated cytologically negative control smears, 
EMA-positive cells were detected. One month later the pleural effusion of one of these 
patients was found to contain numerous malignant epithelial cells. The significance of 
the EMA-positive cells in the other two cases is unknown but other investigators also 
found occasionally EMA-positive cells in benign effusions (To et al., 1981; Gosh et al., 
1983). In the other remaining 53 smears the reactive mesothelial cells were found to 
be EMA-negative. The conclusion that can be drawn from this study is that malignant 
mesothelial cells in pleural effusions express EMA and that this marker is useful, 
although not fully reliable as an indicator for malignancy. These data confirm the results 
reported by Croonen et al. (1988) who found EMA-positivity for pleural effusion cells 
of six malignant mesothelioma patients. Moreover, the detected EMA expression in 
malignant mesothelioma cells in pleural effusions is in line with the EMA expression in 
histologic specimen of malignant mesothelioma. The absence of EMA-expression 
reported by Battifora et al. (1985) could be due to usage of different antibodies against 
EMA. Experiments with different EMA- or Human Milk Fat Globule-specific antibodies 
169 
revealed that at least nine different epitopes can be distinguished (Hilkens et al., 1984). 
Immunocytochemistry did not allow distinction between EMA-positive carcinoma 
or mesothelioma cells. However, malignant epithelial and malignant mesothelial cells 
can be discriminated on the basis of their ultrastructural features. In order to 
distinguish reactive from malignant mesothelial cells on the one hand and mesothelial 
from epithelial cells on the other hand immunoelectron microscopy with monoclonal 
antibodies against EMA was applied. The EMA antigen was found to be predominantly 
expressed on the outer surface of the villi of the malignant mesothelioma cells, while 
the villi of normal mesothelial cells were negative. The immunoelectron microscopical 
staining for EMA on pleural effusions of patients suspected of a malignant mesothelio-
ma would be a useful addition to the standard diagnostic procedures. However, the 
technique is rather elaborate and therefore not applicable for routine pathology. 
Cytogenetic aberrations in leukemia were found to have diagnostic and 
prognostic value (Yunis, 1983). In solid tumors also characteristic abnormalities with 
the possibility of diagnostic application have been detected (Teyssier, 1989). Moreover, 
these specific chromosomal aberrations have been found useful indicators for 
oncogenes involved in the various types of tumors. Cytogenetics of malignant 
mesothelioma were studied by several groups but mostly on solid tumor material and 
many patients had received therapy before analysis. 
We investigated the cytogenetics of a groups of 40 malignant mesothelioma 
patients which were untreated at the time of analysis. Since diagnosis of malignant 
mesothelioma is difficult, diagnosis has been established by at least two of the 
following techniques: cytology, electron microscopy and histology. About 90% of the 
investigated specimen were pleural effusions. Our experience is that the direct method 
for cytogenetics of malignant mesothelioma is preferred above short term culture as 
overgrowth by normal cell types frequently was observed in these cultures. In 30 cases 
(27 pleural effusions) clonal abnormalities were found, once no metaphases were 
detected and in the other 9 cases only normal karyotypes were found. The detected 
aberrations were heterogeneous and of structural and numerical nature. However, no 
aberration was detected which was present in all cases investigated. In 4 cases normal 
karyotypes were found while cytological diagnosis of malignant mesothelioma was 
evident. The other 5 cases with normal metaphases were consistent with cytological 
findings or due to lack of material for the direct method. 
Two patterns of clonal abnormalities were observed. In 24 of the 30 cases a 
hypodiploid or hypotetraploid karyotype was found with most frequently non-random 
loss of the chromosomes 4, 22 and partial deletion of 3p and 9p. Loss of suppressor 
genes, which are located on these chromosomes, could play a role in the development 
of a malignant mesothelioma. Further investigations should be performed in this 
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direction. The hypodiploid karyotype evolved after duplication or in one case cell fusion 
to hypotetraploidy. A similar pattern of evolution has been found in colon carcinoma 
(Muleris et al., 1987). The second pattern of abnormalities was a hyperdiploid 
karyotype with deletion of 3p and non-random gain of chromosomes 7, 5 and 20. 
This pattern was found in 6 of the 30 abnormal cases. 
Cytogenetic analysis of malignant mesothelioma reported by others also showed 
a heterogeneous pattern of abnormalities and absence of a consistent marker. 
However, the pattern of abnormalities observed by several groups differ considerably. 
This can be due to other methods used for the analysis of the data, treatment of 
patients before analysis, passage in culture before analysis, exposure to different kinds 
of asbestos and genetic differences. The enormous amount of cytogenetic abnorma-
lities found in malignant mesothelioma could possibly be the direct consequence of the 
asbestos exposure. Several investigators found in vitro chromosomal aberrations after 
asbestos exposure (Sincock et al., 1975). Particularly mesothelial cells were found to 
be sensitive to asbestos induced chromosomal aberrations (Lechner et al., 1985). 
Diagnostic usefulness of the observed abnormalities was evaluated by 
cytogenetic analysis of effusions of non-malignant-, metastatic carcinoma-, and lung 
adenocarcinoma origin. Distinction between effusions of non-malignancy, metastatic 
carcinoma and malignant mesothelioma on the basis of patterns of cytogenetic 
aberrations was possible. However, no clear marker was found for the differentiation 
between lung adenocarcinoma and malignant mesothelioma. Furthermore, so far no 
correlation was observed between the cytogenetic pattern observed in malignant 
mesotheliomas and clinical data, like survival and histological type of tumor. But study 
of a larger group of patients might reveal such correlations. 
Since human malignant mesothelioma cell lines were found to have an elevated 
c-sis expression (section 7.1), we investigated whether this observation is significant 
for the diagnosis of malignant mesothelioma. The detection of c-sis expression has to 
be performed on the mRNA level as no specific antibodies against the protein are 
available yet. Total RNA isolated from pleural effusion cells and tumor material of eight 
malignant mesothelioma patients was analysed by Northern blot for c-sis expression 
(section 7.2). Bands of similar size, specific for c-sis, were found in the tumor material 
of eight malignant mesotheliomas and two malignant mesothelioma cell lines isolated 
from two of these patients. No correlation between the level of c-sis expression and 
the morphologically detected percentage of tumor cells and/or macrophages was 
observed. This approach was hampered by the variable and frequently low incidence 
of tumor cells and the presence of other cells (e.g. macrophages) which can also 
express the c-sis oncogene (Martinet et al., 1986). The mRNA in situ hybridization 
technique offers the possibility to detect mRNA molecules at the single cell level. For 
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the discrimination between different c-sis positive cell types a double staining 
technique, which combines membrane antigen labeling with the detection of RNA 
transcripts is essential. This technique was recently developed (Bakkus et al., 1989a; 
b). Investigations in progress will reveal whether this technique is applicable for 
diagnostic purposes and whether the c-sis expression is a useful marker for the 
diagnosis of malignant mesothelioma. For this evaluation an mRNA in situ hybridization 
for c-sis in combination with a membrane antigen labeling specific for macrophages 
should be performed on pleural effusion cells of malignant mesothelioma patients, 
adenocarcinoma patients and patients without a malignancy. Nevertheless efforts 
should be directed towards the generation of antibodies that specifically recognize the 
different isoforms of PDGF. These antibodies will be preferred above the rather 
complicated RNA in situ hybridization technique and could be useful for the diagnosis 
of malignant mesothelioma. Furthermore they will allow the study of the role of different 
isoforms of PDGF in vivo. 
8.2 Establishment and characterization of human malignant mesothelioma cell lines 
The production of in vitro growing human malignant mesothelioma cell lines is 
essential for the study of malignant mesothelioma as viable tumor tissues are difficult 
to obtain and the incidence of tumor cells in pleural effusions is often very low (e.g. 
5%). Furthermore, is the continuous availability and the constant quality of malignant 
mesothelioma cell lines an advantage for cell biological investigation. 
In chapter 6 the production of a panel of human malignant mesothelioma cell 
lines from pleural effusions, biopsies and tumors obtained at autopsies is described. 
These in vitro growing malignant mesothelioma cell lines did not show signs of 
senescence, which is in contrast to cultured normal mesothelial cells that were found 
to have a limited lifespan. The processing of patient material and the culture conditions 
were described in section 6.1. The malignant mesothelioma cell lines were found to 
have a variable doubling time that was not influenced by freezing and thawing. Some 
cell lines have a doubling time of approximately 24 hours while others 48 hours. 
Because the growth of normal mesothelial cells was promoted by the addition of EGF 
and HC (Connell et al., 1983) the effect of the addition of these growth factors on the 
isolation of malignant mesothelioma cell lines was investigated. Since these growth 
factors were employed a number of malignant mesothelioma cell lines was isolated on 
medium with EGF and HC or EGF only while in most cases no growth was observed 
when the same cell samples were seeded in medium without these supplementations. 
Although application of EGF and HC resulted in an elevated success-rate, their 
effect on individual samples was unpredictable. The growth of several malignant 
mesothelioma cell lines was stimulated by the addition of EGF to the culture medium 
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whereas EGF in combination with HC inhibited the growth of these cell lines. Another 
group of malignant mesothelioma cell lines was isolated on culture medium with EGF 
and HC while no growth was observed on medium with EGF only. In a single case 
growth occurred in all three culture media. 
Only a few malignant mesothelioma cell lines have been described by others 
and no detailed data about the isolation procedure were given (Ohnuma et al., 1979; 
Behbehani et al., 1982; Tibbets et al., 1984; Shangfang et al., 1985; Anderson et al., 
1986; Hsu et al., 1988). RPMI1640 with different concentrations of serum was mostly 
used as culture medium, while in our study F1 0 medium was used for the isolation of 
malignant mesothelioma cell lines. Furthermore, other authors did not add EGF and 
HC or EGF only to their culture media. This could be the reason for the small number 
of malignant mesothelioma cell lines described in the literature. 
A serious problem with the isolation of malignant mesothelioma cell lines is the 
determination whether the observed proliferation concerns malignant or benign 
mesothelial cells. Cytogenetic abnormality is the best indication for malignant cell 
growth. When cytogenetically abnormal cells are detected in the primary culture, 
immediate subcloning is necessary to obtain a 100% cytogenetically abnormal 
malignant mesothelioma cell line. The malignant mesothelioma character of isolated 
cell lines could also be determined by cytomorphological and ultrastructural studies. 
Moreover, the karyotype of the cell line has to be consistent with the aberrations 
detected in the original patient material. 
Coexpression of cytokeratins and vimentin is a characteristic feature of 
mesothelial cells. Cytokeratins and vimentin were expressed in the malignant 
mesothelioma cell lines at a constant level independent of the growth rate of the cells. 
This is in contrast to normal mesothelial cells which were found to have reduced 
keratin and elevated vimentin levels during rapid growth. Reduction of the growth rate 
did increase the keratin content and decrease the vimentin levels (Connell et al., 1983). 
In section 6.2 the study of the individual cytokeratin polypeptides of three malignant 
mesothelioma cell lines is described. The three investigated malignant mesothelioma 
cell lines were found to be positive for the cytokeratins 7, 8, 18 and 19 by immunofluo-
rescence and immunoblotting with chain specific monoclonal antibodies. This is in 
agreement with the results of Blobel (1985) who investigated histological specimen of 
malignant mesothelioma patients for their cytokeratin content. He found next to the 
cytokeratins 7, 8, 18 and 19 cytokeratin 5 in several epithelial and biphasic malignant 
mesotheliomas while this keratin was not expressed by normal mesothelial cells or lung 
adenocarcinomas. In the three investigated malignant mesothelioma cell lines, 
however, cytokeratin 5 was not detected in two dimensional gelelectrophoresis and 
immunoblotting. 
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The establishment and comparison of the properties of human malignant 
mesothelioma cell lines from different populations exposed to different types of 
asbestos fibers will be interesting. Especially the correlation between the cytogenetic 
characteristics of the tumor cells and the type of asbestos fibers to which the patient 
was exposed could possibly give more insight into the role of asbestos in the 
generation of malignant mesothelioma. 
8.3 Expression of PDGF chains and PDGF receptors in human malignant mesothe-
lioma cell lines 
The panel of human malignant and normal mesothelial cell lines that was 
established has been used for the study of the expression of several genes involved 
in growth regulation. Section 7.1 describes the study of the messenger RNA 
expression of the PDGF A- and B-chain genes in ten malignant mesothelioma cell lines. 
These cell lines were found to have a strong expression of the PDGF B-chain or c-sis 
gene, which is barely detectable in normal mesothelial cells. The expression of the 
PDGF A-chain gene in the malignant mesothelioma cell lines was slightly elevated 
compared to normal mesothelial cells. These results are summarized in section 7 .3, 
table 1. Our data confirm previous observations of Gerwin et al. (1987) concerning 7 
mesothelioma cell lines and 4 normal mesothelial cell lines. All our investigated 
malignant mesothelioma cell lines, the ten described in section 7.1 and five which were 
recently isolated, were found to have an elevated but variable c-sis expression. In at 
least two of the seven investigated malignant mesothelioma cell lines of Gerwin et al. 
no c-sis expression was detected. It should be questioned whether these are indeed 
malignant mesothelioma cell lines as the origin and characteristics of these cell lines 
is unclear. 
It seems that c-sis expression can be regarded as a consistent feature of 
malignant mesothelioma cell lines. This is in contrast with human osteosarcoma and 
melanoma cell lines, where c-sis expression was not detected in all cell lines 
investigated (Eva et al., 1982; Betsholtz et al., 1986; Westermark et al., 1986). For 
human malignant melanoma it was described that a cell line from the primary tumor 
had a much higher c-sis expression than cell lines from the metastases (Westermark 
et al., 1986). In our panel of malignant mesothelioma cell lines from primary and 
metastatic origin of the same patient no significant difference was detected in the level 
of c-sis expression (section 7.1). 
In section 7.3 expression of PDGF A-type and PDGF B-type receptors on normal 
and malignant mesothelioma cell lines was studied. Expression of the PDGF A-type 
receptor was investigated by Northern blot analysis with a probe specific for the PDGF 
A-type receptor and binding experiments with 1251-PDGF-AA. Normal mesothelial cells 
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were found to express the 7kb PDGF A-type receptor mRNA, while malignant 
mesothelioma cell lines hardly expressed this messenger. The binding of 1251-PDGF-
AA to the malignant mesothelioma cell lines varied from low to undetectable. Normal 
mesothelial cells could not be tested with this technique as these cells did not resist 
the extensive washing procedures. Since PDGF-AA can only bind to the PDGF A-type 
receptor these experiments indicate that PDGF A-type receptors are present at very 
low density on the eight investigated malignant mesothelioma cell lines. The presence 
of PDGF 8-type receptors on normal and malignant mesothelial cell was demonstrated 
by Northern blot analysis, immunoprecipitation and binding experiments with 
radiolabeled PDGF-88. We found in the malignant mesothelioma cell lines a variable 
level of expression of PDGF 8-type receptor mRNA and in the normal mesothelial cell 
lines a weak to undetectable expression of this receptor (section 7.3). 
The presence of PDGF 8-type receptor protein in normal and malignant 
mesothelial cell lines was also demonstrated by immunoprecipitation with an antiserum 
specific for the PDGF 8-type- receptor. Experiments with 1251-PDGF-88 revealed a 
specific binding of PDGF-88 to malignant mesothelioma cells. The binding of PDGF-
88 to malignant mesothelioma cell lines indicates that functional receptors for this 
growth factor occur on the membrane of malignant mesothelioma cells. The results of 
the expression of the PDGF A-type and 8-type receptor in normal and malignant 
mesothelial cells are summarized in section 7 .3, table 1. 
8.4 Regulation of the expression of genes coding for PDGF chains and PDGF 
receptors 
In order to study the mechanism responsible for the elevated c-sis and PDGF 
A-chain gene expression the malignant mesothelioma cell lines were investigated for 
cytogenetic aberrations in the chromosomes 7 and 22, where the PDGF A- and B-
chain genes are located, respectively. The number of copies of chromosome 7 was 
normal or increased and the number of copies of chromosome 22 was decreased. 
However, no specific chromosomal or genomic rearrangements were detected in the 
chromosomes 7 and 22. Gerwin et al. (1987) also did not find consistent changes. 
However, it cannot be excluded that DNA rearrangements outside the by Southern blot 
analysis investigated region are present. In order to detect these rearrangements 
inverse field gelelectrophoresis has to be performed. However, from other c-sis 
expressing cell lines no data are available that indicate towards such a mechanism of 
activation of the c-sis oncogene. Therefore activation of the c-sis oncogene on the 
transcriptional level has to be considered. 
Recently some support for this hypothesis came from investigations of the K562 
cell line. During induced megakaryocytic differentiation the c-sis mRNA level increased 
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200-fold (Aiitalo et al., 1987; Pech et al., 1989). This induction of c-sis mRNA 
expression was found to be dependent of protein synthesis. Furthermore, a positive 
regulatory sequence in the c-sis promotor was found to bind nuclear factors and to 
function as a trans-activator in induced K562 cells and in a bladder carcinoma cell line 
that expressed the c-sis oncogene. However, the identified regulatory region was found 
not to be involved in the expression of the c-sis oncogene in two other tumor cell lines. 
Moreover, experiments with uninduced K562 cells indicate that the c-sis promotor is 
constitutively active in these cells. These results suggest that regulation beyond the 
level of transcription should be considered as well. 
As the PDGF A- and B-type receptors are expressed at different levels in the 
normal and malignant mesothelial cell lines the regulation of the expression of these 
receptors is an important subject for further studies. Recently it was suggested that 
changes in isoform composition of the produced PDGF and in the type of PDGF 
receptor expressed could be a mechanism of regulation in the PDGF response 
(Bowen-Pope et al., 1989). This hypothesis was supported by observations in 3T3 
cells. When these cells were exposed to TGF,B a decrease of PDGF A-type receptor 
expression and an increase of PDGF B-type expression was found (Bowen-Pope et al., 
1989). These results indicate that PDGF A- and B-type receptor expression in vitro 
could be modulated by growth factors. It is unlikely that TGF,B plays a similar role in 
PDGF receptor expression in malignant mesothelioma cell lines as both normal and 
malignant mesothelial cells were found to secrete approximately similar amounts of 
active TGF,B (Gerwin et al., 1987). However, it has to be studied whether e.g. EGF and 
HC that is added to the normal mesothelial cultures plays a role in PDGF receptor 
expression in normal and malignant mesothelial cell lines. 
In several malignant mesothelioma cell lines an inverse relationship between c-
sis and PDGF B-type receptor mRNA was observed (section 7.2). This is in contrast 
with results obtained from SSV transformed fibroblasts in which high levels PDGF B-
type receptor were found to correlate with high levels of sis gene product, while non-
transformed cells did not have a rapid turnover of the PDGF B-type receptor (Huang 
and Huang, 1988). However, comparison of PDGF B-type receptor and c-sis levels in 
normal and malignant cells is in agreement with this observation. Analysis of the effect 
of transfection of the PDGF B-type receptor gene and/or c-sis gene on the level of c-
sis and PDGF B-type mRNA in normal and malignant mesothelial cells might reveal 
how the expression of these genes is related to each other. 
8.5 Autocrine stimulation 
Many data supporting the autocrine stimulation model were obtained in SSV 
transformed cells. It has been demonstrated that only cell types that have functional 
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PDGF receptors are susceptible for SSV transformation (Leal et al., 1985). In these 
cells next to expression of the PDGF B-chain the presence of the appropriate growth 
factor receptor is considered a prerequisite for an autocrine function of the produced 
PDGF. In the malignant mesothelioma cell lines next to PDGF B-chain and PDGF B-
type receptor expression also the PDGF A-chain gene is expressed, while the PDGF 
A-type receptor is absent or present in very low amounts. Expression of the PDGF A-
chain in combination with B-chain and B-type receptor expression was also found in 
freshly obtained human gliomas (Hermansson et al., 1988). Howeyer no data about 
PDGF A-type receptor expression were available and the PDGF A-chain gene was 
expressed at a much higher level than the B-chain and B-type receptor genes. Until 
now the role of PDGF A-chains in malignant mesotheliomas is unclear. It is possible 
that A- and B-chains are assembled as heterodimers that can function as autocrine or 
paracrine growth factors. However, the possibility that AB heterodimers can function 
as an autocrine growth factor in malignant mesothelioma cells, which have no or very 
low levels of A-type receptors, is unlikely according to the "PDGF receptor subunit 
model" (Chapter 2.5) and recent observations in human fibroblasts. Analysis of the 
differential effect of the three isoforms of PDGF on several functional parameters in 
these cells indicate that PDGF-AB binds to and dimerizes an A- and B-type receptor 
(A. Hammacher et al., submitted). Thus AB heterodimers produced by malignant 
mesothelioma cells probably have a paracrine effect (Fig. U). Another possibility is 
that BB-homodimers are produced in combination with AA andjor AB-dimers (Figs. 
1.2, 1.3 and 1.4). The produced BB can function as an autocrine growth factor or just 
as the AA andjor AB dimers, have a paracrine effect. The paracrine effect of the 
different isoforms of PDGF that could be produced by the malignant mesothelioma 
cells may be on surrounding connective tissues cells and normal mesothelial cells. To 
investigate the latter possibility effects of exogenous addition of different isoforms of 
PDGF on cultured normal mesothelial cells should be studied. An observation that 
indicates towards a role of B-chain production in the transformation of mesothelial cells 
is made in SV40 large T-antigen transfected normal mesothelial cells. In these cells 
expression of the PDGF B-chain gene was observed, while there was no change in the 
level of PDGF A-chain gene expression compared to normal mesothelial cells (Gerwin 
et al., 1987). Though these cells were not immortalized they were found to have a 
prolonged lifespan compared to normal mesothelial cells. Moreover, a function of 
PDGF-BB as an autocrine growth factor in malignant mesothelioma is supported by the 
striking difference in PDGF B-chain expression between normal mesothelial cells and 
malignant mesothelioma cells and the expression of the appropriate receptor for this 
growth factor. 
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Figure 1. Possible effects for the different PDGF molecules that could be produced 
by malignant mesothelioma celi lines. 
It is presently unclear whether interaction between the c-sis gene product and 
the PDGF B-type receptor takes place via an extracellular loop or is an intracellular 
interaction. In the malignant mesothelioma cell lines immunoelectron microscopical 
investigations with antibodies against the PDGF B-type receptor revealed that although 
plasma membrane associated PDGF B-type receptors occur, also receptors are 
present in presumptive vesicles and lysosomes in the cytoplasm. These results are 
consistent with observations in sis-transformed NRK cells and fibroblasts (Keating et 
al., 1988; Huang and Huang, 1988). The majority of the newly produced PDGF recep-
tors in these cells do not reach the cell surface and are rapidly degraded. It was 
suggested that this was due to interaction of the sis gene product with the receptor in 
the endoplasmic reticulum and/or Golgi apparatus in contrast with the hypothesis that 
the c-sis product is secreted and binds to receptors at the cell surface. The first 
hypothesis is supported by the observation by Robbins et al. (1985) that the major 
part of the v-sis gene product remained cell associated and that only a small amount 
was secreted. Another observation that supports an intracellular interaction is that anti-
PDGF-antibodies could only partially inhibit the proliferation of some SSV-transformed 
cells and were unable to reverse the transformed phenotype of these cells completely 
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Autocrine stimulation by an extracellular and intracellular pathway. A 
Extracellular autocrine pathway for the c-sis gene product. B. Intracellular 
interaction between the gene product of c-sis and its receptor. 
(Huang et al., 1984; Johnsson et al., 1985). Two findings in malignant mesothelioma 
cell lines support an intracellular interaction between c-sis and its receptor. First, the 
three malignant mesothelioma cell lines investigated so far were also found to secrete 
minor amounts of PDGF (M.A. Versnel et al., unpublished results). Secondly, 
immunoelectron microscopic investigations revealed that PDGF B-type receptors are 
present in presumptive vesicles in the cytoplasm of malignant mesothelioma cells 
(section 7.3). The expression of PDGF A- and PDGF B-chain genes and the presence 
of PDGF B-type receptors in human malignant mesothelioma cell lines indicates that 
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PDGF BB indeed can function as an autocrine growth factor. Furthermore, intracellular 
interaction between the produced PDGF and its receptor should be considered (Fig. 
2). 
The role of PDGF chains and PDGF receptors in the malignant transformation 
of mesothelial cells can be further elucidated by several approaches. The effect of 
exogenous addition of different isoforms of PDGF on functional parameters that are 
known to be involved in PDGF response in other cell types has to be studied. Another 
approach is to transfect mesothelial cells with constructs of PDGF chain- and PDGF-
receptor genes and to analyse their effect on cell growth and other parameters. 
Investigations of a possible autocrine loop of PDGF-BB in malignant mesothe-
lioma cell lines should be directed towards specific interference somewhere in the 
autocrine pathway. Suramin is an agent that interferes with the binding of PDGF to its 
receptor. The proliferation of five malignant mesothelioma cell lines was found to be 
inhibited by suramin addition to the culture medium (M.A. Versnel, unpublished 
results). Since the effect of suramin is not specific for the interaction of PDGF with its 
receptor but for other growth factor-receptor interactions, as well more specific 
methods for interference should be developed. A possibility is interference at the 
mRNA level which can be approached by transfection with an antisense sis or PDGF 
B-type receptor construct under the control of a strong promotor. Another possibility 
is to block the interaction between the receptor and growth factor at the protein level 
by antibodies against the binding domain of the PDGF B-type receptor or antibodies 
that bind to PDGF-BB in such a way that interaction with the receptor is no longer 
possible. 
If the data concerning the PDGF chain and receptor expression in malignant 
mesothelioma cell lines correspond to the in vivo situation and PDGF is an autocrine 
growth factor that interacts with membrane bound PDGF receptors on these cells 
intrapleural application of a PDGF antagonist could have therapeutic consequences 
for malignant mesotheliomas. 
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SUMMARY 
Human malignant mesothelioma is a tumor of the coelomic cavities, that 
originates from mesodermally derived tissues. Malignant mesotheliomas most frequent-
ly are found in the pleura. The occurrence of malignant mesothelioma is strongly asso-
ciated with asbestos exposure. Although in recent years asbestos usage has been 
greatly deminished the incidence of malignant mesothelioma is still increasing. This is 
due to the long latent period (15-45 years) between asbestos exposure and the 
development of the tumor. 
In this thesis clinical, diagnostic and cell biological aspects of human malignant 
mesothelioma were studied. The purpose of these studies was to improve the 
diagnosis of human malignant mesothelioma on the one hand and to investigate the 
growth regulation and transformation of normal and malignant mesothelial cells on the 
other hand. 
For this investigation material was collected of malignant mesothelioma patients 
form the areas of Rotterdam and Vlissingen in the Netherlands. A retrospective study 
of the medical records of 124 malignant mesothelioma patients is described in chapter 
4. A history of asbestos exposure, with a median duration of 33.6 years was found in 
91% of the patients. The median latent period was 41.2 years and the median survival 
after diagnosis 11 months. Radiologic investigations showed most frequently the 
presence of a pleural effusion. 
Diagnosis of malignant mesothelioma on pleural effusion cells is difficult because 
malignant mesothelioma cells lack specific characteristics that can be used for the 
differentiation from adenocarcinoma cells and reactive mesothelial cells. Therefore we 
investigated the usefulness of immunoelectron microscopy and cytogenetics for 
diagnostic application on pleural effusion cells (chapter 5). 
Expression of epithelial membrane antigen (EMA) on malignant mesothelioma 
cells of 25 patients was studied by immunocytochemistry. In 23 cases EMA positive 
cells were detected and in two such cells were not found. lmmunoelectron microscopy 
revealed that EMA was localized predominantly on the villi of the malignant mesothelio-
ma cells. The combination of ultrastructural investigations with immunogold staining for 
EMA enabled us to discriminate between malignant mesothelioma cells and malignant 
epithelial and reactive mesothelial cells. 
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Cytogenetic analysis of 40 malignant mesotheliomas revealed complex 
karyotypic abnormalities in 30 cases, in 9 cases the karyotype found was normal and 
in a single case the metaphases could not be analysed. The chromosomal abnor-
malities were heterogeneous and of structural and numerical nature. Although two 
patterns of non-random changes were observed no consistent specific abnormality 
was found. In 24 of the 30 cases a hypodiploid or hypotetraploid karyotype with loss 
of the chromosomes 4, 22, 9p and 3p was found. In 6 cases a hyperdiploid karyotype 
with deletion of 3p and gain of the chromosomes 7, 5, and 20 was found. The 
diagnostic significance of the abnormalities observed in malignant mesothelioma was 
investigated by comparison with the cytogenetics from lung adenocarcinoma, 
metastatic carcinoma and non-malignant pleural effusions. The latter two types of 
pleural effusion could be distinguished by cytogenetics from malignant mesothelioma. 
However, differentiation between lung adenocarcinoma and malignant mesothelioma 
by cytogenetics was not possible. 
The production of in vitro growing malignant mesothelioma cell lines is a 
prerequisite for cell biological study of malignant mesothelioma as viable tumor tissues 
are difficult to obtain and the incidence of tumor cells in pleural effusions is often very 
low. The method used for the establishment of 17 malignant mesothelioma cell lines 
from 61 samples of patient material is described in chapter 6.1. To determine during 
the establishment whether the observed proliferation is of malignant mesothelioma cells 
or contaminating normal mesothelial cells cytogenetic abnormality was found to be the 
best indicator for malignant cell growth. The addition of epidermal growth factor (EGF) 
and hydrocortisone (HC) to the culture medium increased the chance of a successful 
isolation. However, the effect of addition of these growth factors on individual samples 
was impredictable. 
The characteristics of three malignant mesothelioma cell lines (Mero-14, Mero-
25 and Mero-41) are described in chapter 6.2. light and electron microscopical 
investigations revealed that the morphology of the cell lines is consistent with the 
mesothelial nature of the cells. All three cell lines had a hyperdiploid karyotype similar 
to that found in the original patient material. Addition of EGF to the culture medium 
caused an increase of the proliferation of the cell lines Mero-14 and Mero-25. A 
decreased proliferation was found after addition of HC or EGF plus HC. In all three cell 
lines expression of the cytokeratins 7, 8, 18 and 19 was detected by immuno-
fluorescence and immunoblotting with chain specific monoclonal antibodies. These 
characteristics show that the cell lines are derived from malignant mesotheliomas and 
have retained their original character. 
The expression of PDGF chain and PDGF receptor genes in malignant 
mesothelioma cell lines is described in chapter 7. Ten human malignant mesothelia-
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ma cell lines appeared to have an elevated expression of the PDGF B-chain or c-sis 
gene compared to the barely detectable level of mRNA expression in normal 
mesothelial cells. Expression of the PDGF A-chain gene in malignant mesothelioma 
cells was found to be slightly elevated compared to normal mesothelial cells. 
Subsequently, we investigated whether PDGF B-chain gene expression is also present 
in freshly obtained tumor material. Total RNA was isolated from tumor cells of eight 
malignant mesothelioma patients and analysed by Northern blotting for PDGF B-chain 
gene expression (chapter 7.2). In these samples a variable level of expression of the 
PDGF B-chain Was observed. This expression did not correlate with the morphologi-
cally detected percentage tumor cells. 
For a possible function of the by malignant mesothelioma cells produced PDGF 
as an autocrine growth factor, expression of PDGF receptors is thought a prerequisite. 
Therefore we investigated the expression of PDGF A- and B-type receptors in 
malignant and normal mesothelial cells (chapter 7.3). Malignant mesothelioma cell lines 
expressed PDGF B-type receptor mRNA and protein, while the PDGF A-type receptor 
mRNA was hardly detectable. In contrast, cultured normal mesothelial cells express 
PDGF A-type receptor mRNA and had a low to undetectable levels of PDGF B-type 
receptor mRNA and protein expression. The expression of PDGF A- and B-chain genes 
and the presence of PDGF receptors on malignant mesothelioma cell lines suggest 
that the produced PDGF could function as an autocrine growth factor and play a role 
in the malignant transformation of mesothelial cells. 
The studies described in this thesis have enlarged our knowledge about the 
characteristics of malignant mesothelioma cells. The isolated panel of malignant 
mesothelioma cell lines will be a useful tool for the further development of diagnostic 
techniques. Furthermore, cultured normal and malignant mesothelial cells are a useful 
model for the study of the regulation of the expression of PDGF chain- and PDGF 
receptor genes. 
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SAMENVATTING 
Het humane maligne mesothelioom is een tumor van de coeloomholte, die 
ontstaat uit weefsels van mesodermale oorsprong. Maligne mesotheliomen worden het 
meest frequent in de pleura gevonden. Het ontstaan van een maligne mesothelioom 
wordt sterk geassocieerd met blootstelling aan asbest. Hoewel het gebruik van asbest 
de laatste jaren sterk verminderd is, neemt de incidentie van het maligne mesothelioom 
nag steeds toe. Dit wordt veroorzaakt door de lange latentie periode (15-45 jaar) die 
ligt tussen de blootstelling aan asbest en het ontstaan van de tumor. 
In dit proefschrift worden de klinische, diagnostische en celbiologische aspekten 
van het maligne mesothelioom bestudeerd. Het doel van deze studie was verbetering 
van de diagnostiek van het maligne mesothelioom enerzijds en onderzoek van de 
groeiregulatie en transformatie van normale en maligne mesotheelcellen anderzijds. 
Voor deze studie werd materiaal van maligne mesothelioom patienten uit de 
regia's Rotterdam en Vlissingen verzameld. Een retrospectief onderzoek van de 
medische gegevens van 124 maligne mesothelioom patienten wordt in hoofdstuk 4 
beschreven. Asbestblootstelling met een gemiddelde duur van 33,6 jaar werd in het 
verleden van 91% van de patienten gevonden. De gemiddelde latentieperiode was 41 ,2 
jaar en de gemiddelde overleving na diagnose 11 maanden. Radiologisch onderzoek 
toonde meestal de aanwezigheid van pleuravocht aan. 
De diagnostiek van het maligne mesothelioom op pleuravochtcellen is moeilijk 
omdat maligne mesothelioomcellen geen specifieke eigenschappen hebben die 
onderscheid tussen adenocarcinoomcellen en reaktieve mesothelioomcellen mogelijk 
maken. De bruikbaarheid van immunoelectronen microscopische en cytogenetische 
analyse voor diagnostische toepassing op pleuravochtcellen wordt besproken in 
hoofdstuk 5. Expressie van het epitheliaal membraan antigeen (EMA) op maligne 
mesothelioomcellen van 25 patienten werd bestudeerd met immunocytochemie en 
immunoelectronen microscopie. In 23 gevallen werden EMA positieve cellen 
gedetecteerd en in twee werden dergelijke cellen niet gevonden. lmmunoelectronen 
microscopie toonde aan dat EMA voornamelijk gelokaliseerd was op de villi van de 
maligne mesothelioomcellen. De combinatie van ultrastruktureel onderzoek met 
immunogoud kleuring van EMA stelde ons in staat maligne mesothelioomcellen te 
onderscheiden van maligne epitheelcellen en reaktieve mesotheelcellen. 
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Cytogenetisch onderzoek van 40 maligne mesotheliomen toonde complexe 
karyotypische afwijkingen aan in 30 gevallen; in 9 gevallen was het gevonden 
karyogram normaal en eenmaal konden de metafasen niet geanalyseerd worden. De 
chromosomale afwijkingen waren heterogeen en van strukturele en numerieke aard. 
Hoewel twee patronen van non-random veranderingen werden waargenomen, is geen 
consistente specifieke afwijking gevonden. In 24 van de 30 gevallen werd een 
hypodiplo"id of hypotetraplo"id karyotype gevonden, waarbij verlies van de chromoso-
men 4, 22, 9p en 3p optrad. In 6 gevallen werd een hyperdiplo"id karyogram gevonden 
met deletie van 3p en een toename van het aantal chromosomen 7, 5 en 20. Het 
diagnostische belang van de in maligne mesotheliomen waargenomen afwijkingen 
werd onderzocht door cytogenetisch onderzoek van pleuravocht van longadenocar-
cinomen, metastatische carcinomen en niet-maligne aandoeningen. De laatste twee 
typen pleuravocht konden met behulp van cytogenetica van maligne mesotheliomen 
onderscheiden worden. Echter, onderscheid tussen long adenocarcinomen en maligne 
mesotheliomen met behulp van cytogenetica bleek niet mogelijk. 
De produktie van in vitro groeiende maligne mesothelioom cellijnen is een 
voorwaarde voor celbiologisch onderzoek van het maligne mesothelioom aangezien 
vitaal tumormateriaal moeilijk te verkrijgen is en de incidentie van tumorcellen in 
pleuravocht vaak erg laag is. De methode die is gebruikt voor het produceren van 17 
maligne mesothelioom cellijnen uit 61 monsters van patientenmateriaal wordt 
beschreven in hoofdstuk 5.1. Om gedurende de ontwikkeling van een maligne 
mesothelioomcellijn te bepalen of de waargenomen proliferatie van de maligne 
mesothelioomcellen is of van contaminerende normale mesotheelcellen was een 
afwijkend karyogram de beste indicator voor maligne celgroei. De toevoeging van 
epidermal growth factor (EGF) en hydrocortison (HC) aan het kweekmedium 
verhoogde de kans op een succesvolle isolatie. Echter, het effekt van de toevoeging 
van deze groeifaktoren op individuele monsters is onvoorspelbaar. De karakteristieken 
van drie maligne mesothelioomcellijnen (Mero-14, Mero-25 en Mero-41) worden 
beschreven in hoofdstuk 6.2. Licht- en electronenmicroscopisch onderzoek toonden 
aan dat de morfologie van deze cellijnen overeenkomt met de mesotheliale oorsprong 
van de cellen. Aile drie cellijnen hadden een hyperdiplo"id karyogram dat hetzelfde was 
als in het oorspronkelijke patientenmateriaal. Toevoeging van EGF aan het kweek-
medium veroorzaakte een toename van de proliferatie van de cellijnen Mero-14 en 
Mero-25. Een afname van de proliferatie werd gevonden na toevoeging van HC of EGF 
en HC. In aile drie de cellijnen werd expressie van de cytokeratines 7, 8, 18 en 19 met 
behulp van immunofluorescentie en immunoblotting met keten-specifieke antilichamen 
gevonden. Deze eigenschappen tonen aan dat de cellijnen afkomstig zijn van maligne 
mesotheliomen en hun oorspronkelijk karakter hebben behouden. 
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De expressie van genen die coderen voor de platelet-derived growth factor 
(PDGF) en PDGF receptoren in maligne mesothelioomcellijnen wordt beschreven in 
hoofdstuk 7. Tien humane maligne mesothelioomcellijnen bleken een verhoogde 
expressie van het PDGF B-keten gen of c-sis gen te hebben ten opzichte van het 
nauwelijks te detecteren niveau van mRNA expressie in normale mesotheelcellen. 
Expressie van het PDGF A-keten gen in maligne mesothelioomcellijnen was Iicht 
verhoogd ten opzichte van normale mesotheelcellen. Vervolgens onderzochten wij of 
de PDGF B-keten genexpressie oak in vers tumormateriaal aanwezig was. Totaal RNA 
werd geTsoleerd uit materiaal van acht maligne mesothelioompatienten en met behulp 
van de Northern blot analyse voor PDGF B-keten gen expressie onderzocht (hoofdstuk 
7.2). In deze monsters werd een variabel niveau van PDGF B-keten gen expressie 
gevonden dat niet correleerde met het morfologisch gedetecteerde aantal tumorcellen. 
De door maligne mesothelioomcellen geproduceerde PDGF zou als een 
autocriene groeifaktor kunnen funktioneren als maligne mesothelioomcellen PDGF 
receptoren tot expressie brengen. Daarom hebben we de expressie van PDGF A-type 
en B-type receptoren in maligne en normale mesotheelcellen onderzocht (hoofdstuk 
7.3). Maligne mesothelioomcellijnen brachten PDGF B-type receptor mRNA en eiwittot 
expressie, terwijl PDGF A-type receptor mRNA nauwelijks te detecteren was. In 
tegenstelling hiermee brachten gekweekte normale mesotheelcellen PDGF A-type 
receptor mRNA tot expressie en hadden een lage tot niet detecteerbare PDGF B-type 
mRNA en eiwit expressie. De expressie van PDGF A- en B-keten genen en de 
aanwezigheid van PDGF receptoren geeft aan dat de geproduceerde PDGF kan 
funktioneren als een autocriene groeifaktor en zo een rol kan spelen in de maligne 
transformatie van mesotheelcellen. 
Het onderzoek dat in dit proefschrift wordt beschreven heeft de kennis vergroot 
over de eigenschappen van maligne mesothelioomcellen. Het geTsoleerde panel van 
maligne mesothelioomcellijnen zal een bruikbaar instrument zijn voor de ontwikkeling 
van nieuwe diagnostische technieken. Bovendien zullen gekweekte normale en maligne 
mesotheelcellen een nuttig model zijn voor onderzoek naar de regulatie van de 
expressie van genen die coderen voor PDGF ketens en PDGF receptoren. 
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ABBREVIATIONS 
bcr breakpoint cluster region 
eDNA complementary deoxyribonucleic acid 
CEA carcinoembryonic antigen 
cpm counts per minute 
c-sis cellular homologue of SSV 
der derivative 
del deletion 
dup duplication 
dm double minute 
DM direct method 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EGF epidermal growth factor 
EM electron microscopy 
EMA epithelial membrane antigen 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GTG G banding by trypsin giemsa 
HC hydrocortisone 
HMFG human milk fat globule 
HSR homogeneously staining region 
isochromosome 
IFP intermediate filament protein 
inv inversion 
ISCN international system for cytogenetic nomenclature 
kb kilo base 
kD kilo dalton 
MAbs. monoclonal antibodies 
mar marker 
Me- mesothelioma 
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Mero-
MM 
mRNA 
p 
PAS-d 
PBS 
PDGF 
q 
QFQ 
RFA 
RNA 
S.C. 
sse 
ssv 
t 
TEM 
ter 
TGF 
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mesothelioma Rotterdam (cell line) 
malignant mesothelioma 
messenger ribonucleic acid 
short arm chromosome 
periodic acid Schiff-diastase 
phosphate buffered saline 
platelet-derived growth factor 
long arm chromosome 
Q banding by fluorescence after quinacrine 
R banding by fluorescence after acridine orange 
ribonucleic acid 
subcutaneous 
standard saline citrate 
simian sarcoma virus 
translocation 
transmission electron microscopy 
terminal segment of chromosome arm 
transforming growth factor 


